Engineered cascade components and cascade complexes

ABSTRACT

The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.16/420,061, filed 22 May 2019, now allowed, which is a continuation ofU.S. patent application Ser. No. 16/262,773, filed 30 Jan. 2019, nowU.S. Pat. No. 10,329,547, which is a continuation of U.S. patentapplication Ser. No. 16/104,875, filed 17 Aug. 2018, now U.S. Pat. No.10,227,576, which claims the benefit of U.S. Provisional PatentApplication Ser. No. 62/684,735, filed 13 Jun. 2018, now expired, thecontents of which are herein incorporated by reference in theirentirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

Not applicable.

SEQUENCE LISTING

The present application contains a Sequence Listing that has beensubmitted electronically in ASCII format and is hereby incorporated byreference in its entirety. The ASCII copy, created on 7 Oct. 2019 isnamed CBI032-13_ST25.txt and is 2.2 MB in size.

TECHNICAL FIELD

The present disclosure relates generally to engineered Class 1 Type ICRISPR-Cas (Cascade) systems that comprise multi-protein effectorcomplexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunitproteins and nucleic acid guides, polynucleotides encoding Type ICRISPR-Cas subunit proteins, and guide polynucleotides. The disclosurealso relates to compositions and methods for making and using theengineered Type I CRISPR-Cas systems of the present invention.

BACKGROUND

Clustered regularly interspaced short palindromic repeats (CRISPR) andCRISPR-associated proteins (Cas) constitute CRISPR-Cas systems. TheCRISPR-Cas systems provide adaptive immunity against foreignpolynucleotides in bacteria and archaea (see, e.g., Barrangou, R., etal., Science 315:1709-1712 (2007); Makarova, K. S., et al., NatureReviews Microbiology 9:467-477 (2011); Garneau, J. E., et al., Nature468:67-71 (2010); Sapranauskas, R., et al., Nucleic Acids Research39:9275-9282 (2011); Koonin, E. V., et al., Curr. Opin. Microbiol.37:67-78 (2017)). Various CRISPR-Cas systems in their native hosts arecapable of DNA targeting (Class 1 Type I; Class 2 Type II and Type V),RNA targeting (Class 2 Type VI), and joint DNA and RNA targeting (Class1 Type III) (see, e.g., Makarova, K. S., et al., Nat. Rev. Microbiol.13(11):722-736 (2015); Shmakov, S., et al., Nat. Rev. Microbiol.15:169-182 (2017); Abudayyeh, O. O., et al., Science 353:1-17 (2016)).

The classification of CRISPR-Cas systems has had many iterations.Koonin, E. V., et al., (Curr. Opin. Microbiol. 37:67-78 (2017)) proposeda classification system that takes into consideration the signature casgenes specific for individual types and subtypes of CRISPR-Cas systems.The classification also considered sequence similarity between multipleshared Cas proteins, the phylogeny of the best conserved Cas protein,gene organization, and the structure of the CRISPR array. This approachprovided a classification scheme that divides CRISPR-Cas systems intotwo distinct classes: Class 1 comprising a multiprotein effector complex(Type I (CRISPR-associated complex for antiviral defense (“Cascade”)effector complex), Type III (Cmr/Csm effector complex), and Type IV);and Class 2 comprising a single effector protein (Type II (Cas9), Type V(Cas12a, previously referred to as Cpfl), and Type VI (Cas13a,previously referred to as C2c2)). In the Class 1 systems, Type I is themost common and diverse, Type III is more common in archaea thanbacteria, and Type IV is least common.

The Type I systems comprise the signature Cas3 protein. The Cas3 proteinhas helicase and DNase domains responsible for DNA target sequencecleavage. To date, seven subtypes of the Type I system have beenidentified (i.e., Type I-A, I-B, I-C, I-D, I-E, I-F (and variants forI-F (e.g., I-Fv1, I-Fv2), and I-U) that have a variable number of casgenes. Type I cas genes include, but are not limited to, the following:cas7, cas5, cas8, cse2, csa5, cas3, cast, cas4, cas1, and cash. Examplesof organisms having Type I systems are as follows: I-A, Archaeoglobusfuldgidus; I-B, Clostridium kluyveri; I-C, Bacillus halodurans; I-U,Geobacter sulfurreducens; I-D, Cyanothece sp. 8802; I-E, Escherichiacoli K12; I-F, Yersinia pseudo-tuberculosis; I-F variant, Shewanellaputrefaciens CN-32 (Koonin, E. V., et al., Curr. Opin. Microbiol.37:67-78 (2017)).

Type I systems typically encode proteins that combine with a CRISPR RNA(crRNA or “guide RNA”) to form a Cascade complex. These complexescomprise multiple proteins and a CRISPR RNA (crRNA), which aretranscribed from this CRISPR locus. In Type I systems, primaryprocessing of a pre-crRNA is catalyzed by Cash. This typically resultsin a crRNA with a 5′ handle of 8 nucleotides, a spacer region, and a 3′handle; both 5′ and 3′ handles are derived from the repeat sequence. Insome systems, the 3′ handle forms a stem-loop structure; in othersystems, secondary processing of the 3′ end of crRNA is catalyzed byribonuclease(s) (van der Oost, J., et al., Nature Reviews Microbiology12:479-492 (2014)).

The Cascade effector complexes of the Type I CRISPR-Cas systems comprisea backbone having paralogous Repeat-Associated Mysterious Proteins(RAMPs; e.g., Cas7 and Cas5 proteins) containing the RNA RecognitionMotif (RRM) fold and additional “large” and “small” subunit proteins(see, e.g., Koonin, E. V., et al., Curr. Opin. Microbiol. 37:67-78, FIG.2 (2017)). These Cascade effector complexes typically have a Cas5subunit protein and several Cas7 subunit proteins. Such Cascade effectorcomplexes also comprise the guide RNA. The Cascade effector complexescomprise the various subunit proteins arranged in an asymmetric fashionalong the length of the guide RNA. The Cas5 subunit protein and thelarge subunit protein (Cas8 protein) are positioned at one end of thecomplex, enveloping the 5′ end of the guide RNA. Several copies of thesmall subunit protein interact with the guide RNA backbone, which isbound to multiple copies of the Cas7 subunit protein. The Cas6 subunitprotein, another RAMP protein, is associated with the Cascade effectorcomplex primarily through association with the 3′ handle (repeat region)of the crRNA. The Cas6 subunit protein usually functions as therepeat-specific RNase involved in pre-crRNA processing; however, in TypeI-C systems, Cas5 functions as the repeat-specific RNase and there is noCas6.

The primary sequences of the CRISPR-Cas Type I Cascade subunit proteinshave little sequence identity; however, the presence of homologous RAMPmodules and the overall structural similarity of the multiproteineffector complexes supports a common origin of these effector complexes(Koonin, E. V., et al., Curr. Opin. Microbiol. 37:67-78 (2017)).

The adaptive immunity mechanism of action in the Type I CRISPR-Cassystems involves essentially three phases: adaptation, expression, andinterference. In the adaptation phase, a foreign DNA or RNA infects thehost and proteins encoded by various cas genes bind regions of theinfecting DNA or RNA. Such regions are called protospacers. Aprotospacer adjacent motif (PAM) is a short nucleotide sequence (e.g., 2to 6 base pair DNA sequence) that is adjacent to the protospacer. PAMsequences are typically recognized by a Cas1 subunit protein/Cas2subunit protein complex, wherein the active PAM-sensing site isassociated with the Cas1 subunit proteins (Jackson, S. A., et al.,Science 356:356(6333) (2017)).

In the expression phase, the CRISPR array comprising multiplespacer-repeat elements is transcribed as a single transcript. Individualspacer repeat elements are processed by an endonuclease (e.g., Type I, aCas6 protein; and Type I-C, a Cas5 protein) into individual crRNAs. Cassubunit proteins are expressed and associate with the crRNA to form aCascade effector complex.

The Cascade effector complex scans foreign polynucleotides infecting thehost to identify DNA complementary to the spacer. In Type I systems,interference occurs when the effector complex identifies a sequencecomplementary to the spacer that is adjacent a PAM; and the Cas3 proteinis recruited to the DNA-bound Cascade effector complex to cleave andprogressively digest the foreign polynucleotide.

Makarova, K. S., et al., (Cell 168:946 (2017)) provide a summary ofgenes, homologs, Cascade complexes, and mechanisms of action for Type ICRISPR-Cas systems.

Although CRISPR-Cas systems have been used for genome editing, thereremains a need to improve editing efficiency and editing fidelity ofthese systems.

SUMMARY OF THE INVENTION

The present invention generally relates to compositions comprisingengineered Type I CRISPR-Cas effector complexes, modified guidepolynucleotides, and combinations thereof.

One embodiment of the present invention is a composition comprising:

a first engineered Type I CRISPR-Cas effector complex comprising,

a first Cse2 subunit protein, a first Cas5 subunit protein, a first Cas6subunit protein, and a first Cas7 subunit protein,

a first fusion protein comprising a first Cas8 subunit protein and afirst FokI, wherein the N-terminus of the first Cas8 subunit protein orthe C-terminus of the first Cas8 subunit protein is covalently connectedby a first linker polypeptide to the C-terminus or N-terminus,respectively, of the first FokI, and wherein the first linkerpolypeptide has a length of between 10 amino acids to 40 amino acids,and

a first guide polynucleotide comprising a first spacer capable ofbinding a first nucleic acid target sequence; and

a second engineered Type I CRISPR-Cas effector complex comprising,

a second Cse2 subunit protein, a second Cas5 subunit protein, a secondCas6 subunit protein, and a second Cas7 subunit protein,

a second fusion protein comprising a second Cas8 subunit protein and asecond FokI, wherein the N-terminus of the second Cas8 subunit proteinor the C-terminus of the second Cas8 protein is covalently connected bya second linker polypeptide to the C-terminus or N-terminus,respectively, of the second FokI, and wherein the second linkerpolypeptide has a length of between 10 amino acids to 40 amino acids,and

a second guide polynucleotide comprising a second spacer capable ofbinding a second nucleic acid target sequence, wherein a protospaceradjacent motif (PAM) of the second nucleic acid target sequence and aPAM of the first nucleic acid target sequence have an interspacerdistance between 20 base pairs (bp) to 42 bp.

In some embodiments, the length of the first linker polypeptide and/orthe second linker polypeptide is a length of between about 15 aminoacids and about 30 amino acids, or between about 17 amino acids andabout 20 amino acids. In one embodiment, the length of the first linkerpolypeptide and the second linker polypeptide are the same.

Interspacer distances between the second nucleic acid target sequenceand the first nucleic acid target sequence include, but are not limitedto, between about 22 bp to about 40 bp, between about 26 bp to about 36bp, between about 29 bp to about 35 bp, or between about 30 bp to about34 bp.

The first FokI and the second FokI can be monomeric subunits that arecapable of associating to form a homodimer, or distinct subunits thatare capable of associating to form a heterodimer.

In some embodiments, the N-terminus of the first Cas8 subunit protein iscovalently connected by the first linker polypeptide to the C-terminusof the first FokI, the C-terminus of the first Cas8 subunit protein iscovalently connected by a first linker polypeptide to the N-terminus ofthe first FokI, the N-terminus of the second Cas8 subunit protein iscovalently connected by the second linker polypeptide to the C-terminusof the second FokI, the C-terminus of the second Cas8 subunit protein iscovalently connected by a second linker polypeptide to the N-terminus ofthe second FokI, and combinations thereof. The first Cas8 subunitprotein and the second Cas8 subunit protein can each comprise a Cas8subunit protein having a different sequence or both the first and thesecond Cas8 subunit protein can comprise identical amino acid sequences.

Similarly, the first Cse2 subunit protein and the second Cse2 subunitprotein can each comprise different or identical Cse2 subunit proteinamino acid sequences, the first Cas5 subunit protein and the second Cas5subunit protein can each comprise different or identical Cas5 subunitprotein amino acid sequences, the first Cas6 subunit protein and thesecond Cas6 subunit protein can each comprise different or identicalCas6 subunit protein amino acid sequences, the first Cas7 subunitprotein and the second Cas7 subunit protein can each comprise differentor identical Cas7 subunit protein amino acid sequences, and combinationsthereof.

In a preferred embodiment, the guide polynucleotides comprise RNA.

Additional embodiments of the present invention will be readily apparentto those of ordinary skill in the art in view of the disclosures herein.

BRIEF DESCRIPTION OF THE FIGURES

The Figures are not proportionally rendered, nor are they to scale. Thelocations of indicators are approximate.

FIG. 1A present a generalized illustration of a Type I CRISPR-Caseffector complex. FIG. 1B presents a generalized illustration of a TypeI CRISPR-Cas crRNA.

FIG. 2A, FIG. 2B, and FIG. 2C present illustrative examples of twoengineered Type I CRISPR-Cas effector complexes with fusion domainsbound to neighboring spacer sequences.

FIG. 3 presents information related to SEQ ID NO:1 to SEQ ID NO:351.

FIG. 4A and FIG. 4B present examples of circularly permuted proteins.

FIG. 5A, FIG. 5B, FIG. 6A, FIG. 6B, FIG. 7A, FIG. 7B, FIG. 7C, FIG. 8A,FIG. 8B, FIG. 9, FIG. 10, FIG. 11A, and FIG. 11B illustrate a variety ofexamples of engineered Type I CRISPR-Cas effector complexes of thepresent invention.

FIG. 12A and FIG. 12B illustrate examples of substrate channels.

FIG. 13A, FIG. 13B, and FIG. 13C present a generalized illustration ofsite-directed recruitment of a functional protein domain fused to aCascade subunit protein by a dCas9:NATNA complex.

FIG. 14A, FIG. 14B, FIG. 15A, FIG. 15B, and FIG. 15C illustrate examplesof engineered Type I CRISPR-Cas effector complexes of the presentinvention.

FIG. 16A, FIG. 16B, FIG. 16C, FIG. 17A, FIG. 17B, FIG. 17C, FIG. 18A,FIG. 18B, FIG. 18C, FIG. 19A, FIG. 19B, FIG. 19C, FIG. 19D, FIG. 20A,FIG. 20B, FIG. 21A, and FIG. 21B present examples of engineered Type ICRISPR-Cas effector complexes of the present invention and methods ofuse thereof.

FIG. 22A, FIG. 22B, FIG. 22C, FIG. 22D, FIG. 23A, FIG. 23B, FIG. 23C,and FIG. 23D illustrate embodiments of the present invention that use aCas3 protein comprising active endonuclease activity.

FIG. 24A, FIG. 24B, FIG. 24C, FIG. 24D, FIG. 24E, FIG. 25, FIG. 26, FIG.27, and FIG. 28 present schematic diagrams of a variety of Cascadecomponent expression systems.

FIG. 29, FIG. 30, FIG. 31, FIG. 32A, FIG. 32B, FIG. 33, FIG. 34A, FIG.34B, and FIG. 35 present data related to genome editing of theengineered Cascade systems of the present invention.

INCORPORATION BY REFERENCE

All patents, publications, and patent applications cited in the presentSpecification are herein incorporated by reference as if each individualpatent, publication, or patent application was specifically andindividually indicated to be incorporated by reference in its entiretyfor all purposes.

DETAILED DESCRIPTION OF THE INVENTION

It is to be understood that the terminology used herein is for thepurpose of describing particular embodiments only, and is not intendedto be limiting. As used in the present Specification and the Claims, thesingular forms “a,” “an,” and “the” include plural referents unless thecontext clearly dictates otherwise. Thus, for example, reference to “apolynucleotide” includes one or more polynucleotides, and reference to“a vector” includes one or more vectors.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which the invention pertains. Although other methods andmaterials similar, or equivalent, to those described herein can beuseful in the present invention, preferred materials and methods aredescribed herein.

In view of the teachings of the present Specification and the Examples,one of ordinary skill in the art can apply conventional techniques ofimmunology, biochemistry, chemistry, molecular biology, microbiology,cell biology, genomics, and recombinant polynucleotides, as taught, forexample, by the following standard texts: Cellular and MolecularImmunology, Ninth Edition, A. K. Abbas., et al., Elsevier (2017), ISBN978-0323479783; Cancer Immunotherapy Principles and Practice, FirstEdition, L. H. Butterfield, et al., Demos Medical (2017), ISBN978-1620700976; Janeway's Immunobiology, Ninth Edition, Kenneth Murphy,Garland Science (2016), ISBN 978-0815345053; Clinical Immunology andSerology: A Laboratory Perspective, Fourth Edition, C. DorresteynStevens, et al., F. A. Davis Company (2016), ISBN 978-0803644663;Antibodies: A Laboratory Manual, Second edition, E. A. Greenfield, ColdSpring Harbor Laboratory Press (2014), ISBN 978-1-936113-81-1; Cultureof Animal Cells: A Manual of Basic Technique and SpecializedApplications, Seventh Edition, R. I. Freshney, Wiley-Blackwell (2016),ISBN 978-1118873656; Transgenic Animal Technology, Third Edition: ALaboratory Handbook, C. A. Pinkert, Elsevier (2014), ISBN978-0124104907; The Laboratory Mouse, Second Edition, H. Hedrich,Academic Press (2012), ISBN 978-0123820082; Manipulating the MouseEmbryo: A Laboratory Manual, Fourth Edition, R. Behringer, et al., ColdSpring Harbor Laboratory Press (2013), ISBN 978-1936113019; PCR 2: APractical Approach, M. J. McPherson, et al., IRL Press (1995), ISBN978-0199634248; Methods in Molecular Biology (Series), J. M. Walker,ISSN 1064-3745, Humana Press; RNA: A Laboratory Manual, D. C. Rio, etal., Cold Spring Harbor Laboratory Press (2010), ISBN 978-0879698911;Methods in Enzymology (Series), Academic Press; Molecular Cloning: ALaboratory Manual (Fourth Edition), M. R. Green, et al., Cold SpringHarbor Laboratory Press (2012), ISBN 978-1605500560; BioconjugateTechniques, Third Edition, G. T. Hermanson, Academic Press (2013), ISBN978-0123822390; Methods in Plant Biochemistry and Molecular Biology, W.V. Dashek, CRC Press (1997), ISBN 978-0849394805; Plant Cell CultureProtocols (Methods in Molecular Biology), V. M. Loyola-Vargas, et al.,Humana Press (2012), ISBN 978-1617798177; Plant TransformationTechnologies, C. N. Stewart, et al., Wiley-Blackwell (2011), ISBN978-0813821955; Recombinant Proteins from Plants (Methods inBiotechnology), C. Cunningham, et al., Humana Press (2010), ISBN978-1617370212; Plant Genomics: Methods and Protocols (Methods inMolecular Biology), W. Busch, Humana Press (2017), ISBN 978-1493970018;Plant Biotechnology: Methods in Tissue Culture and Gene Transfer, R.Keshavachandran, et al., Orient Blackswan (2008), ISBN 978-8173716164.

Clustered regularly interspaced short palindromic repeats (CRISPR) andrelated CRISPR-associated proteins (Cas proteins) constitute CRISPR-Cassystems (see, e.g., Barrangou, R., et al., Science 315:1709-1712(2007)).

As used herein, “Cas protein,” “CRISPR-Cas protein,” and “CRISPR-Cassubunit protein,” and “Cas subunit protein,” unless otherwiseidentified, all refer to Class 1 Type I CRISPR-Cas proteins. Typically,for use in aspects of the present invention, Cas subunit proteins arecapable of interacting with one or more cognate polynucleotides (mosttypically, a crRNA) to form a Type I effector complex (most typically, aribonucleoprotein complex). Genes encoding Cas subunit proteins arelisted in Table 1.

TABLE 1 Type I CRISPR-Cas Proteins Universal Reported familystoichiometry Role name* Alternative designation (when present) RNA 5′cap, PAM Cas5 CasD, Cas5e, Csc1, Csy2, 1 recognition, duplex Csf3,Cas1822 unwinding PAM recognition, Cas8 Large subunit, CasA, Cse1, 1duplex unwinding, Cas8a, Cas8b, Cas8c, Cas8e, Cas3 recruitment Cas8f,Csy1 R-loop Cse2 Small subunit, CasB, Cas11 2 stabilization BackboneCas7 CasC, Cse4, Csc2, Csy3, Csf2, 3-6 Cas1821, Cst2/DevR RNA 3′ capCas6 CasE, Cse3, Cas6e, Cas6f, Csy4 1 DNA cleavage Cas3 Cas3′, Cas3″ 1*As defined by Makarova, K. S., et al., Nat. Rev. Microbiol. 13(11):722-736 (2015); Koonin, E. V., et al., Curr Opin Microbiol. 37: 67-78(2017).

The terms “Type I CRISPR-Cas effector complex,” “Cascade complex,” “TypeI CRISPR-Cas nucleoprotein complex,” and “Type I complexes” are usedinterchangeably herein. The terms “Cascade RNP complex” and “Type Iribonucleoprotein (RNP) complex” refer to a Cascade complex specificallycomprising a crRNA (versus a more generic guide polynucleotide, asdescribed below). An example of a wild-type Type I CRISPR-Cas effectorcomplex is illustrated in FIG. 1A. FIG. 1A is adapted from Makarova, K.S., et al., (Cell 168:946 (2017); and Makarova, K., et al., Naturereviews Microbiology 13(11):722-736 (2015)). doi:10.1038/nrmicro3569.).FIG. 1A illustrates six Cas7 proteins, a Cas5 protein, a Cas8 protein,two Cse2 proteins, a Cas6 protein, and a crRNA associated as a Cascadecomplex. The complex is capable of binding a nucleic acid targetsequence. After association of a wild-type Cas3 with the complex, theCascade complex is capable of cleavage of a nucleic acid targetsequence. As noted in Table 1, the total number of some Cas subunitproteins can vary in Cascade complexes.

“Cas3” and “Cas3 protein” are used interchangeably herein to refer toType I CRISPR-Cas3 proteins, modifications, and variants thereof. TheType I CRISPR-Cas effector complexes bind foreign DNA complementary tothe crRNA guide and recruit Cas3, a trans-acting nuclease-helicaserequired for target degradation. Cas3 proteins have motifscharacteristic of helicases from superfamily 2 and contain a DEAD/DEAHbox region and a conserved C-terminal domain. Cas3 proteins and variantsthereof are known in the art (see, e.g., Westra, E. R., et al., MolCell. 46(5): 595-605 (2012); Sinkunas, T., et al., EMBO J.30(7):1335-1342 (2011); Beloglazova, N., et al., EMBO J. 30:4616-4627(2011); Mulepati, S., et al., J. Biol. Chem. 286:31896-31903 (2011)). Asused herein, dCas3* is a mutated Cas3 protein that does not have anynuclease activity and/or helicase activity.

The term “nuclease” as used herein refers to an enzyme capable ofcleaving the phosphodiester bonds, such as those connecting twonucleotides, as found in double-stranded (ds) nucleic acids (e.g.,dsDNA, genomic DNA (gDNA), dsRNA), single-stranded (ss) nucleic acids(e.g., ssDNA, RNA) or hybrid dsRNA/DNA. An “endonuclease” typically caneffect ss-(nicks) or ds-breaks in its target molecules. One example of aDNA endonuclease is a FokI enzyme. “FokI endonuclease” and “FokI” areused interchangeably herein and refer to a FokI enzyme, FokI homologs,enzymatically active domain(s) of FokI enzymes, and variants of FokIenzymes. FokI dimerization is typically required for DNA cleavage.Dimers of FokI can comprise two monomeric subunits that associate toform a homodimer or two distinct monomeric subunits that associate toform a heterodimer (see, e.g., Bitinaite, J., et al., Proceedings of theNational Academy of Sciences 95(18):10570-10575 (1998); Ramalingam, S.,et al., Journal of Molecular Biology, 405(3):630-641 (2011)). Oneexample of a FokI variant is the Sharkey variant described by Guo, etal. (Guo, J., et al., J. Mol. Biol. 400:96-107 (2010)). Additional DNAand RNA nucleases are known in the art.

“CRISPR RNA,” “crRNA,” and “guide RNA,” as used herein, refer to one ormore RNAs with which Cas subunit proteins are capable of interacting toform a Type I effector complex that guides the complex to preferentiallybind a nucleic acid target sequence in a polynucleotide (relative to apolynucleotide that does not comprise the nucleic acid target sequence).“Guide” and “guide polynucleotide” as used herein refer to thepolynucleotide component of Type I effector complexes and can compriseribonucleotide bases (e.g., RNA), deoxyribonucleotide bases (e.g., DNA),combinations of ribonucleotide bases and deoxyribonucleotide bases,nucleotides, nucleotide analogs, modified nucleotides, and the like, aswell as synthetic, naturally occurring, and non-naturally occurringmodified backbone residues or linkages, for example, as describedherein. An example of a Type I CRISPR-Cas crRNA associated with anucleic acid target sequence through the crRNA spacer is illustrated inFIG. 1B. FIG. 1B is adapted from Hochstrasser, M. L., et al., MolecularCell 63(5):840-851 (2016). In FIG. 1B, the PAM associated with thenucleic acid target sequence and the 5′ and 3′ strands of adouble-stranded nucleic acid are illustrated (FIG. 1B, vertical linesrepresent hydrogen bonds). A guide polynucleotide typically comprises a5′ handle region (FIG. 1B, 5′ Handle Region), a spacer region (FIG. 1B,Spacer) comprising a seed region, and a 3′ hairpin comprising twohydrogen-bonded repeat regions (FIG. 1B, 3′ Hairpin; horizontal linesrepresent hydrogen bonds). FIG. 1B illustrates the Cascade complexspacer bound to the nucleic acid target sequences (FIG. 1B, verticallines represent hydrogen bonds). FIG. 1B also illustrates theprotospacer region (FIG. 1B, protospacer). The spacer can comprise aregion of the crRNA between about 6 to about 56 nucleotides, wherein thespacer is complementary to a nucleic acid target sequence in apolynucleotide. The spacer length can be modified to fine-tune Cascadeactivity in Type I-E CRISPR-Cas systems. Cascade complexes canincorporate an extra Cas7 subunit with every 6 nucleotides added to thecrRNA spacer and an extra Cse2 subunit with every 12 nucleotides addedto the spacer (Luo, M. L., et al., Nucleic Acids Research.44(15):7385-7394 (2016)). The spacer typically comprises a region ofbetween about 32 to about 36 nucleotides.

The terms “spacer,” “spacer sequence,” and “nucleic acid target bindingsequence” are used interchangeably herein.

As used herein, a “stem element” or “stem structure” refers to twostrands of nucleic acids that are known or predicted to form adouble-stranded region (the “stem element”). A “stem-loop element” or“stem-loop structure” refers to a stem structure wherein 3′-endsequences of one strand are covalently bonded to 5′-end sequences of thesecond strand by a nucleotide sequence of typically single-strandednucleotides (“a stem-loop element nucleotide sequence”). In someembodiments, the loop element comprises a loop element nucleotidesequence of between about 3 and about 20 nucleotides in length,preferably between about 4 and about 10 nucleotides in length. Inpreferred embodiments, a loop element nucleotide sequence is asingle-stranded nucleotide sequence of unpaired nucleic acid bases thatdo not interact through hydrogen bond formation to create a stem elementwithin the loop element nucleotide sequence. The term “hairpin element”is also used herein to refer to stem-loop structures. Such structuresare well known in the art. The base pairing may be exact; however, as isknown in the art, a stem element does not require exact base pairing.Thus, the stem element may include one or more base mismatches ornon-paired bases. An example of a stem-loop structure in a guidepolynucleotide is illustrated in FIG. 1B.

A “linker element nucleotide sequence,” “linker nucleotide sequence,”and “linker polynucleotide” are used interchangeably herein and refer toeither a single-stranded nucleic acid sequence or a double-strandednucleic acid sequence of one or more nucleotides covalently attached toa first nucleic acid sequence (e.g., 5′-linker nucleotide sequence-firstnucleic acid sequence-3′). In some embodiments, a linker nucleotidesequence connects two separate nucleic acid sequences to form a singlepolynucleotide (e.g., 5′-first nucleic acid sequence-linker nucleotidesequence-second nucleic acid sequence-3′). Other examples of linkernucleotide sequences include, but are not limited to, 5′-first nucleicacid sequence-linker nucleotide sequence-3′ and 5′-linker nucleotidesequence-first first nucleic acid sequence-linker nucleotidesequence-3′. In some embodiments, the linker element nucleotide sequencecan be a single-stranded nucleotide sequence of unpaired nucleic acidbases that do not interact with each other through hydrogen bondformation to create a secondary structure (e.g., a stem-loop structure)within the linker element nucleotide sequence. In some embodiments, twolinker element nucleotide sequences can interact with each other throughhydrogen bonding between the two linker element nucleotide sequences. Insome embodiments, a linker polynucleotide encodes a “linkerpolypeptide.” Such a linker polynucleotide typically connects the 3′ endof a first polynucleotide encoding a first polypeptide to the 5′ end ofa second polynucleotide encoding a second polypeptide to form a singlepolynucleotide that encodes a fusion protein comprising N-the firstpolypeptide-the linker polypeptide-the second polypeptide-C. In someembodiments of the present invention, more than two polypeptidesequences can be connected in tandem by linker polypeptides (e.g., N-afirst polypeptide-a first linker polypeptide-a second polypeptide-asecond linker polypeptide-a third polypeptide-C). Linker polypeptide,“linker polypeptide sequence,” “amino acid linker sequence,” and “linkersequence” are used interchangeably herein.

As used herein, a “connecting nucleotide sequence” refers to asingle-stranded nucleic acid sequence linker sequence that covalentlyconnects a first nucleic acid sequence and a second nucleic acidsequence.

As used herein, the terms “interspacer,” “interspacer region,” and“interspacer distance” are used interchangeably and refer to thedistance between a PAM of a first nucleic acid target sequence (e.g., afirst DNA target sequence) and a PAM of a second nucleic acid targetsequence (e.g., a second DNA target sequence) typically in a PAM-inorientation, wherein a first Type I CRISPR-Cas effector complexcomprises a first spacer capable of binding the first nucleic acidtarget sequence, and a second Type I CRISPR-Cas effector complexcomprises a second spacer capable of binding the second nucleic acidtarget sequence. FIG. 2A, FIG. 2B, and FIG. 2C present illustrativeexamples of two Type I CRISPR-Cas effector complexes (“Cascade1”comprising “crRNA1” and “Cascade2” comprising “crRNA2”) comprisingfusion proteins (“FP1” and “FP2”; e.g., FokI) connected with eachCascade complex through linker polynucleotides (“Linker1” and“Linker2”), wherein the CRISPR-Cas effector complexes are bound toneighboring nucleic acid target sequences on double-stranded DNA(“dsDNA”). PAM sequences associated with each nucleic acid targetsequence are indicated (“PAM1,” open box, and “PAM2,” open box)). FIG.2A illustrates an interspacer (shown as a double-arrowheaded line)between two target sites in a PAM-in (PAM-in/PAM-in) configuration. FIG.2B illustrates an interspacer (shown as a double-arrowheaded line)between two target sites in a PAM-in/PAM-out configuration. FIG. 2Cillustrates an interspacer between two target sites in the PAM-out(PAM-out/PAM-out) configuration. FIG. 2A, FIG. 2B, and FIG. 2C alsoillustrate the separation of the two strands of the dsDNA. A Cascadecomplex recognizes a dsDNA target sequence adjacent a PAM. PAM sequencesare recognized by Cse1. Base pairing between the crRNA and complementarytarget DNA strand results in an R-loop with the displacednon-complementary target DNA strand (Beloglazova, N., et al., NucleicAcids Research 43(1):530-543 (2015)).

As used herein, the term “cognate” typically refers to a group of Cassubunit proteins (e.g., Cse2, Cas5, Cash, Cas7, and Cas8) and one ormore guide polynucleotides (e.g., a Type I CRISPR-Cas RNA) that arecapable of forming a nucleoprotein complex capable of site-directedbinding to a nucleic acid target sequence complementary to a spacerpresent in one of the one or more guide polynucleotides.

The terms “wild-type,” “naturally occurring,” and “unmodified” are usedherein to mean the typical (or most common) form, appearance, phenotype,or strain existing in nature; for example, the typical form of cells,organisms, polynucleotides, proteins, macromolecular complexes, genes,RNAs, DNAs, or genomes as they occur in, and can be isolated from, asource in nature. The wild-type form, appearance, phenotype, or strainserve as the original parent before an intentional modification. Thus,mutant, variant, engineered, recombinant, and modified forms are notwild-type forms.

As used herein, the terms “engineered,” “genetically engineered,”“recombinant,” “modified,” “non-naturally occurring,” “non-natural,” and“non-native” are interchangeable and indicate intentional humanmanipulation.

“Covalent bond,” “covalently attached,” “covalently bound,” “covalentlylinked,” “covalently connected,” and “molecular bond” are usedinterchangeably herein and refer to a chemical bond that involves thesharing of electron pairs between atoms. Examples of covalent bondsinclude, but are not limited to, phosphodiester bonds, phosphorothioatebonds, disulfide bonds and peptide bonds (—CO—NH—).

“Non-covalent bond,” “non-covalently attached,” “non-covalently bound,”“non-covalently linked,” “non-covalent interaction,” and “non-covalentlyconnected” are used interchangeably herein and refer to any relativelyweak chemical bond that does not involve sharing of a pair of electrons.Multiple non-covalent bonds often stabilize the conformation ofmacromolecules and mediate specific interactions between molecules.Examples of non-covalent bonds include, but are not limited to, hydrogenbonding, ionic interactions (e.g., Na⁺Cl⁻), van der Waals interactions,and hydrophobic bonds.

As used herein, “hydrogen bonding,” “hydrogen-base pairing,” and“hydrogen bonded” are used interchangeably and refer to canonicalhydrogen bonding and non-canonical hydrogen bonding including, but notlimited to, “Watson-Crick-hydrogen-bonded base pairs”(W-C-hydrogen-bonded base pairs or W-C hydrogen bonding);“Hoogsteen-hydrogen-bonded base pairs” (Hoogsteen hydrogen bonding); and“wobble-hydrogen-bonded base pairs” (wobble hydrogen bonding). W-Chydrogen bonding, including reverse W-C hydrogen bonding, refers topurine-pyrimidine base pairing, e.g., adenine:thymine, guanine:cytosine,and uracil:adenine. Hoogsteen hydrogen bonding, including reverseHoogsteen hydrogen bonding, refers to a variation of base pairing innucleic acids wherein two nucleobases, one on each strand, are heldtogether by hydrogen bonds in the major groove. This non-W-C hydrogenbonding can allow a third strand to wind around a duplex and formtriple-stranded helices. Wobble hydrogen bonding, including reversewobble hydrogen bonding, refers to a pairing between two nucleotides inRNA molecules that does not follow Watson-Crick base pair rules. Thereare four major wobble base pairs: guanine:uracil, inosine(hypoxanthine):uracil, inosine-adenine, and inosine-cytosine. Rules forcanonical hydrogen bonding and non-canonical hydrogen bonding are knownto those of ordinary skill in the art (see, e.g., The RNA World, ThirdEdition (Cold Spring Harbor Monograph Series), R. F. Gesteland, ColdSpring Harbor Laboratory Press (2005), ISBN 978-0879697396; The RNAWorld, Second Edition (Cold Spring Harbor Monograph Series), R. F.Gesteland, et al., Cold Spring Harbor Laboratory Press (1999), ISBN978-0879695613; The RNA World (Cold Spring Harbor Monograph Series), R.F. Gesteland, et al., Cold Spring Harbor Laboratory Press (1993), ISBN978-0879694562 (see, e.g., Appendix 1: Structures of Base PairsInvolving at Least Two Hydrogen Bonds, I. Tinoco); Principles of NucleicAcid Structure, W. Saenger, Springer International Publishing AG (1988),ISBN 978-0-387-90761-1; Principles of Nucleic Acid Structure, FirstEdition, S. Neidle, Academic Press (2007), ISBN 978-01236950791).

“Connect,” “connected,” and “connecting” are used interchangeably hereinand refer to a covalent bond or a non-covalent bond between twomacromolecules (e.g., polynucleotides, proteins, and the like).

As used herein, the terms “nucleic acid sequence,” “nucleotidesequence,” and “oligonucleotide” are interchangeable and refer to apolymeric form of nucleotides. As used herein, the term “polynucleotide”refers to a polymeric form of nucleotides that has one 5′ end and one 3′end, and can comprise one or more nucleic acid sequences. A “circularpolynucleotide” refers to a polynucleotide having a covalent bondbetween its 5′ end and 3′ end, thus forming the circular polynucleotide.The nucleotides may be deoxyribonucleotides (DNA), ribonucleotides(RNA), analogs thereof, or combinations thereof, and may be of anylength. Polynucleotides may perform any function and may have varioussecondary and tertiary structures. The terms encompass known analogs ofnatural nucleotides and nucleotides that are modified in the base,sugar, and/or phosphate moieties. Analogs of a particular nucleotidehave the same base-pairing specificity (e.g., an analog of A base pairswith T). A polynucleotide may comprise one modified nucleotide ormultiple modified nucleotides. Examples of modified nucleotides include,but are not limited to, fluorinated nucleotides, methylated nucleotides,and nucleotide analogs. Nucleotide structure may be modified before orafter a polymer is assembled. Following polymerization, polynucleotidesmay be additionally modified via, for example, conjugation with alabeling component or target binding component. A nucleotide sequencemay incorporate non-nucleotide components. Also encompassed are nucleicacids comprising modified backbone residues or linkages, that aresynthetic, naturally occurring, and/or non-naturally occurring, and havesimilar binding properties as a reference polynucleotide (e.g., DNA orRNA). Examples of such analogs include, but are not limited to,phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methylphosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs),Locked Nucleic Acid (LNA™) (Exiqon, Inc., Woburn, Mass.) nucleosides,glycol nucleic acid, bridged nucleic acids, and morpholino structures.

Peptide-nucleic acids (PNAs) are synthetic homologs of nucleic acidswherein the polynucleotide phosphate-sugar backbone is replaced by aflexible pseudo-peptide polymer, and nucleobases are linked to thepolymer. PNAs have the capacity to hybridize with high affinity andspecificity to complementary sequences of RNA and DNA.

In phosphorothioate nucleic acids, the phosphorothioate (PS) bondsubstitutes a sulfur atom for a non-bridging oxygen in thepolynucleotide phosphate backbone. This modification makes theinternucleotide linkage resistant to nuclease degradation. In someembodiments, phosphorothioate bonds are introduced between the last 3 to5 nucleotides at the 5′-end or 3′-end sequences of a polynucleotidesequence to inhibit exonuclease degradation. Placement ofphosphorothioate bonds throughout an entire oligonucleotide helps reducedegradation by endonucleases, as well.

Threose nucleic acid (TNA) is an artificial genetic polymer. Thebackbone structure of TNA comprises repeating threose sugars linked byphosphodiester bonds. TNA polymers are resistant to nucleasedegradation. TNA can self-assemble by base-pair hydrogen bonding intoduplex structures.

Linkage inversions can be introduced into polynucleotides through use of“reversed phosphoramidites” (see, e.g.,www.ucalgary.ca/dnalab/synthesis/-modifications/linkages). A 3′-3′linkage at a terminus of a polynucleotide stabilizes the polynucleotideto exonuclease degradation by creating an oligonucleotide having two5′-OH termini but lacking a 3′-OH terminus. Typically, suchpolynucleotides have phosphoramidite groups on the 5′-OH position and adimethoxytrityl (DMT) protecting group on the 3′-OH position. Normally,the DMT protecting group is on the 5′-OH and the phosphoramidite is onthe 3′-OH.

Polynucleotide sequences are displayed herein in the conventional 5′ to3′ orientation unless otherwise indicated.

As used herein, “sequence identity” generally refers to the percentidentity of nucleotide bases or amino acids comparing a firstpolynucleotide or polypeptide to a second polynucleotide or polypeptideusing algorithms having various weighting parameters. Sequence identitybetween two polynucleotides or two polypeptides can be determined usingsequence alignment by various methods and computer programs (e.g.,BLAST, CS-BLAST, PSI-BLAST, FASTA, HMMER, L-ALIGN, and the like)available through the worldwide web at sites including, but not limitedto, GENBANK (www.ncbi.nlm.nih.gov/genbank/) and EMBL-EBI(www.ebi.ac.uk). Sequence identity between two polynucleotides or twopolypeptide sequences is generally calculated using the standard defaultparameters of the various methods or computer programs. A high degree ofsequence identity, as used herein, between two polynucleotides or twopolypeptides is typically between about 90% identity and 100% identity,for example, about 90% identity or higher, preferably about 95% identityor higher, more preferably about 98% identity or higher. A moderatedegree of sequence identity, as used herein, between two polynucleotidesor two polypeptides is typically between about 80% identity to about 85%identity, for example, about 80% identity or higher, preferably about85% identity. A low degree of sequence identity, as used herein, betweentwo polynucleotides or two polypeptides is typically between about 50%identity and 75% identity, for example, about 50% identity, preferablyabout 60% identity, more preferably about 75% identity. For example, aCas protein (e.g., Type I-E Cse2, Cas5, Cas6, Cas7, and/or Cas8)comprising amino acid substitutions can have a low degree of sequenceidentity, a moderate degree of sequence identity, or a high degree ofsequence identity over its length to a reference Cas protein (e.g.,wild-type Type I-E Cse2, Cas5, Cas6, Cas7, and/or Cas8, respectively).As another example, a guide polynucleotide can have a low degree ofsequence identity, a moderate degree of sequence identity, or a highdegree of sequence identity over its length compared with a referencewild-type guide polynucleotide that complexes with the reference Casproteins (e.g., a guide polynucleotide that forms a complex with a TypeI-E Cse2, Cas5, Cas6, Cas7, and/or Cas8).

As used herein, “hybridization” “hybridize,” or “hybridizing” is theprocess of combining two complementary single-stranded DNA or RNAmolecules so as to form a single double-stranded molecule (DNA/DNA,DNA/RNA, RNA/RNA) through hydrogen base pairing. Hybridizationstringency is typically determined by the hybridization temperature andthe salt concentration of the hybridization buffer; e.g., hightemperature and low salt provide high stringency hybridizationconditions. Examples of salt concentration ranges and temperature rangesfor different hybridization conditions are as follows: high stringency,approximately 0.01M to approximately 0.05M salt, hybridizationtemperature 5′C to 10° C. below T_(m); moderate stringency,approximately 0.16M to approximately 0.33M salt, hybridizationtemperature 20° C. to 29° C. below T_(m); and low stringency,approximately 0.33M to approximately 0.82M salt, hybridizationtemperature 40° C. to 48° C. below T_(m). T_(m) of duplex nucleic acidsequences is calculated by standard methods well known in the art (see,e.g., Maniatis, T., et al., Molecular Cloning: A Laboratory Manual, ColdSpring Harbor Laboratory Press: New York (1982); Casey, J., et al.,Nucleic Acids Research 4:1539-1552 (1977); Bodkin, D. K., et al.,Journal of Virological Methods 10(1):45-52 (1985); Wallace, R. B., etal., Nucleic Acids Research 9(4):879-894 (1981)). Algorithm predictiontools to estimate T_(m) are also widely available. High stringencyconditions for hybridization typically refer to conditions under which apolynucleotide complementary to a target sequence predominantlyhybridizes with the target sequence and substantially does not hybridizeto non-target sequences. Typically, hybridization conditions are ofmoderate stringency, preferably high stringency.

As used herein, “complementarity” refers to the ability of a nucleicacid sequence to form hydrogen bond(s) with another nucleic acidsequence (e.g., through canonical Watson-Crick base pairing). A percentcomplementarity indicates the percentage of residues in a nucleic acidsequence that can form hydrogen bonds with a second nucleic acidsequence. If two nucleic acid sequences have 100% complementarity, thetwo sequences are perfectly complementary, i.e., all of the contiguousresidues of a first polynucleotide hydrogen bond with the same number ofcontiguous residues in a second polynucleotide.

As used herein, “binding” refers to a non-covalent interaction betweenmacromolecules (e.g., between a protein and a polynucleotide, between apolynucleotide and a polynucleotide, between a protein and a protein,and the like). Such non-covalent interaction is also referred to as“associating” or “interacting” (e.g., if a first macromolecule interactswith a second macromolecule, the first macromolecule binds to secondmacromolecule in a non-covalent manner). Some portions of a bindinginteraction may be sequence-specific (the terms “sequence-specificbinding,” “sequence-specifically bind,” “site-specific binding,” and“site specifically binds” are used interchangeably herein).Sequence-specific binding, as used herein, typically refers to one ormore guide polynucleotides capable of forming a complex with Type ICRISPR-Cas subunit proteins (e.g., Cse2, Cas5, Cash, Cas7, and Cas8) tocause the protein to bind a nucleic acid sequence (e.g., a DNA sequence)comprising a nucleic acid target sequence (e.g., a DNA target sequence)preferentially relative to a second nucleic acid sequence (e.g., asecond DNA sequence) without the nucleic acid target binding sequence(e.g., the DNA target binding sequence). All components of a bindinginteraction do not need to be sequence-specific, such as contacts of aprotein with phosphate residues in a DNA backbone. Binding interactionscan be characterized by a dissociation constant (Kd). “Binding affinity”refers to the strength of the binding interaction. An increased bindingaffinity is correlated with a lower Kd.

As used herein, effector complexes are said to “target” a polynucleotideif such a complex binds or cleaves a polynucleotide in the nucleic acidtarget sequence within the polynucleotide.

As used herein, a “double-strand break” (DSB) refers to both strands ofa double-stranded segment of DNA being severed. In some instances, ifsuch a break occurs, one strand can be said to have a “sticky end”wherein nucleotides are exposed and not hydrogen bonded to nucleotideson the other strand. In other instances, a “blunt end” can occur whereinboth strands remain fully base paired with each other.

“Donor polynucleotide,” “donor oligonucleotide,” and “donor template”are used interchangeably herein and can be a double-strandedpolynucleotide (e.g., DNA), a single-stranded polynucleotide (e.g., DNAor RNA), or a combination thereof. Donor polynucleotides can comprisehomology arms flanking the insertion sequence (e.g., DSBs in the DNA).The homology arms on each side can vary in length (e.g., 1-50 bases,50-100 bases, 100-200 bases, 200-300 bases, 300-500 bases, 500-1000bases). Homology arms can be symmetric or asymmetric in length.Parameters for the design and construction of donor polynucleotides arewell known in the art (see, e.g., Ran, F., et al., Nature Protocols8(11):2281-2308 (2013); Smithies, O., et al., Nature 317:230-234 (1985);Thomas, K., et al., Cell 44:419-428 (1986); Wu, S., et al., NatureProtocols 3:1056-1076 (2008); Singer, B., et al., Cell 31:25-33 (1982);Shen, P., et al., Genetics 112:441-457 (1986); Watt, V., et al.,Proceedings of the National Academy of Sciences of the United States ofAmerica 82:4768-4772 (1985); Sugawara, N., et al., Journal of MolecularCell Biology 12(2):563-575 (1992); Rubnitz, J., et al., Journal ofMolecular Cell Biology 4(11):2253-2258 (1984); Ayares, D., et al.,Proceedings of the National Academy of Sciences of the United States ofAmerica 83(14):5199-5203 (1986); Liskay, R., et al., Genetics115(1):161-167 (1987)).

As used herein, “homology-directed repair” (HDR) refers to DNA repairthat takes place in cells, for example, during repair of a DSB ingenomic DNA. HDR requires nucleotide sequence homology and uses a donoror template polynucleotide to repair the sequence wherein the DSB (e.g.,within a DNA target sequence) occurred. The donor polynucleotidegenerally has the requisite sequence homology with the sequence flankingthe DSB so that the donor polynucleotide can serve as a suitabletemplate for repair. HDR results in the transfer of genetic informationfrom, for example, the donor polynucleotide to the DNA target sequence.HDR may result in alteration of the DNA target sequence (e.g.,insertion, deletion, or mutation) if the donor polynucleotide sequencediffers from the DNA target sequence and part or all of the donorpolynucleotide is incorporated into the DNA target sequence. In someembodiments, an entire donor polynucleotide, a portion of the donorpolynucleotide, or a copy of the donor polynucleotide is integrated atthe site of the DNA target sequence. For example, a donor polynucleotidecan be used for repair of the break in the DNA target sequence, whereinthe repair results in the transfer of genetic information from the donorpolynucleotide at the site or in close proximity of the break in theDNA. Accordingly, new genetic information may be inserted or copied at aDNA target sequence.

A “genomic region” is a segment of a chromosome in the genome of a hostcell that is present on either side of the nucleic acid target sequencesite or, alternatively, also includes a portion of the nucleic acidtarget sequence site. The homology arms of the donor polynucleotide havesufficient homology to undergo homologous recombination with thecorresponding genomic regions. In some embodiments, the homology arms ofthe donor polynucleotide share significant sequence homology to thegenomic region immediately flanking the nucleic acid target sequencesite; it is recognized that the homology arms can be designed to havesufficient homology to genomic regions farther from the nucleic acidtarget sequence site.

As used herein, “non-homologous end joining” (NHEJ) refers to the repairof a DSB in DNA by direct ligation of one terminus of the break to theother terminus of the break without a requirement for a donorpolynucleotide. NHEJ is a DNA repair pathway available to cells torepair DNA without the use of a repair template. NHEJ in the absence ofa donor polynucleotide often results in nucleotides being randomlyinserted or deleted at the site of the DSB.

“Microhomology-mediated end joining” (MMEJ) is pathway for repairing aDSB in genomic DNA. MMEJ involves deletions flanking a DSB and alignmentof microhomologous sequences internal to the break site before joining.MMEJ is genetically defined and requires the activity of, for example,CtIP, Poly(ADP-Ribose) Polymerase 1 (PARP1), DNA polymerase theta (Polθ), DNA Ligase 1 (Lig 1), or DNA Ligase 3 (Lig 3). Additional geneticcomponents are known in the art (see, e.g., Sfeir, A., et al., Trends inBiochemical Sciences 40:701-714 (2015)).

As used herein, “DNA repair” encompasses any process whereby cellularmachinery repairs damage to a DNA molecule contained in the cell. Thedamage repaired can include ss-breaks or DSBs. At least three mechanismsexist to repair DSBs: HDR, NHEJ, and MMEJ. “DNA repair” is also usedherein to refer to DNA repair resulting from human manipulation, whereina target locus is modified, e.g., by inserting, deleting, orsubstituting nucleotides, all of which represent forms of genomeediting.

As used herein, “recombination” refers to a process of exchange ofgenetic information between two polynucleotides.

As used herein, the terms “regulatory sequences,” “regulatory elements,”and “control elements” are interchangeable and refer to polynucleotidesequences that are upstream (5′ non-coding sequences), within, ordownstream (3′ non-translated sequences) of a polynucleotide target tobe expressed. Regulatory sequences influence, for example, the timing oftranscription, amount or level of transcription, RNA processing orstability, and/or translation of the related structural nucleotidesequence. Regulatory sequences may include activator binding sequences,enhancers, introns, polyadenylation recognition sequences, promoters,transcription start sites, repressor binding sequences, stem-loopstructures, translational initiation sequences, internal ribosome entrysites (IRES), translation leader sequences, transcription terminationsequences (e.g., polyadenylation signals and poly-U sequences),translation termination sequences, primer binding sites, and the like.

Regulatory elements include those that direct constitutive, inducible,and repressible expression of a nucleotide sequence in many types ofhost cells and those that direct expression of the nucleotide sequenceonly in certain host cells (e.g., tissue-specific regulatory sequences).In some embodiments, a vector comprises one or more pol III promoters,one or more pol II promoters, one or more pol I promoters, orcombinations thereof. Examples of pol III promoters include, but are notlimited to, U6 and H1 promoters. Examples of pol II promoters include,but are not limited to, the retroviral Rous sarcoma virus (RSV) LTRpromoter (optionally with the RSV enhancer), the cytomegalovirus (CMV)promoter (optionally with the CMV enhancer; see, e.g., Boshart, M., etal., Cell 41:521-530 (1985)), the SV40 promoter, the dihydrofolatereductase promoter, the (β-actin promoter, the phosphoglycerol kinase(PGK) promoter, and the EF1α promoter. It will be appreciated by thoseskilled in the art that the design of an expression vector may depend onsuch factors as the choice of the host cell to be transformed, the levelof expression desired, and the like. A vector can be introduced intohost cells to thereby produce transcripts, proteins, or peptides,including fusion proteins or peptides, encoded by nucleic acid sequencesas described herein.

“Gene,” as used herein, refers to a polynucleotide sequence comprisingexon(s) and related regulatory sequences. A gene may further compriseintron(s) and/or untranslated region(s) (UTR(s)).

As used herein, the term “operably linked” refers to polynucleotidesequences or amino acid sequences placed into a functional relationshipwith one another. For example, regulatory sequences (e.g., a promoter orenhancer) are “operably linked” to a polynucleotide encoding a geneproduct if the regulatory sequences regulate or contribute to themodulation of the transcription of the polynucleotide. Operably linkedregulatory elements are typically contiguous with the coding sequence.However, enhancers can function if separated from a promoter by up toseveral kilobases or more. Accordingly, some regulatory elements may beoperably linked to a polynucleotide sequence but not contiguous with thepolynucleotide sequence. Similarly, translational regulatory elementscontribute to the modulation of protein expression from apolynucleotide.

As used herein, “expression” refers to transcription of a polynucleotidefrom a DNA template, resulting in, for example, a messenger RNA (mRNA)or other RNA transcript (e.g., non-coding, such as structural orscaffolding RNAs). The term further refers to the process through whichtranscribed mRNA is translated into peptides, polypeptides, or proteins.Transcripts and encoded polypeptides may be referred to collectively as“gene product(s).” Expression may include splicing the mRNA in aeukaryotic cell, if the polynucleotide is derived from genomic DNA.

As used herein, the term “modulate” refers to a change in the quantity,degree or amount of a function. For example, a Type I CRISPRnucleoprotein complex, as disclosed herein, may modulate the activity ofa promoter sequence by binding to a nucleic acid target sequence at ornear the promoter or a transcriptional start site or regulator site.Depending on the action occurring after binding, the Type I CRISPRnucleoprotein complex can induce, enhance, suppress, or inhibittranscription of a gene operatively linked to the promoter sequence.Thus, “modulation” of gene expression includes both gene activation andgene repression.

Modulation can be assayed by determining any characteristic directly orindirectly affected by the expression of the target gene. Suchcharacteristics include, for example, changes in RNA or protein levels,protein activity, product levels, expression of the gene, or activitylevel of reporter genes. Accordingly, the terms “modulating expression,”“inhibiting expression,” and “activating expression” of a gene can referto the ability of a Type I CRISPR nucleoprotein complex to change,activate, or inhibit transcription of a gene.

“Vector” and “plasmid,” as used herein, refer to a polynucleotidevehicle to introduce genetic material into a cell. Vectors can be linearor circular. Vectors can contain a replication sequence capable ofeffecting replication of the vector in a suitable host cell (e.g., anorigin of replication). Upon transformation of a suitable host, thevector can replicate and function independently of the host genome orintegrate into the host genome. Vector design depends, among otherthings, on the intended use and host cell for the vector, and the designof a vector of the invention for a particular use and host cell iswithin the level of skill in the art. The four major types of vectorsare plasmids, viral vectors, cosmids, and artificial chromosomes.Typically, vectors comprise an origin of replication, a multicloningsite, and/or a selectable marker. An expression vector typicallycomprises an expression cassette.

As used herein, “expression cassette” refers to a polynucleotideconstruct generated using recombinant methods or by synthetic means andcomprising regulatory sequences operably linked to a selectedpolynucleotide to facilitate expression of the selected polynucleotidein a host cell. For example, the regulatory sequences can facilitatetranscription of the selected polynucleotide in a host cell, ortranscription and translation of the selected polynucleotide in a hostcell. An expression cassette can, for example, be integrated in thegenome of a host cell or be present in a vector to form an expressionvector.

As used herein, a “targeting vector” is a recombinant DNA constructtypically comprising tailored DNA arms, homologous to genomic DNA, thatflank elements of a target gene or nucleic acid target sequence (e.g., aDSB). A targeting vector comprises a donor polynucleotide. Elements ofthe target gene can be modified in a number of ways, including deletionsand/or insertions. A defective target gene can be replaced by afunctional target gene, or in the alternative a functional gene can beknocked out. Optionally, the donor polynucleotide of a targeting vectorcomprises a selection cassette comprising a selectable marker that isintroduced into the target gene. Targeting regions adjacent or within atarget gene can be used to affect regulation of gene expression.

As used herein, the term “between” is inclusive of end values in a givenrange (e.g., between 1 and 50 nucleotides in length includes 1nucleotide and 50 nucleotides; between 5 amino acids and 50 amino acidsin length includes 5 amino acids and 50 amino acids).

As used herein, the term “amino acid” (aa) refers to natural andsynthetic (unnatural) amino acids, including amino acid analogs,modified amino acids, peptidomimetics, glycine, and D or L opticalisomers.

As used herein, the terms “peptide,” “polypeptide,” “protein,” and“subunit protein” are interchangeable and refer to polymers of aminoacids. A polypeptide may be of any length. It may be branched or linear,it may be interrupted by non-amino acids, and it may comprise modifiedamino acids. The terms also refer to an amino acid polymer that has beenmodified through, for example, acetylation, disulfide bond formation,glycosylation, lipidation, phosphorylation, pegylation, biotinylation,cross-linking, and/or conjugation (e.g., with a labeling component orligand). Polypeptide sequences are displayed herein in the conventionalN-terminal to C-terminal orientation, unless otherwise indicated.

Polypeptides and polynucleotides can be made using routine techniques inthe field of molecular biology (see, e.g., standard texts discussedabove). Furthermore, essentially any polypeptide or polynucleotide isavailable from commercial sources.

The terms “fusion protein” and “chimeric protein,” as used herein, referto a single protein created by joining two or more proteins, proteindomains, or protein fragments or circular permuted polypeptides that donot naturally occur together in a single protein. In some embodiments, alinker polynucleotide can be used to connect a first protein, proteindomains, or protein fragments, or circular permuted polypeptides to asecond protein, protein domains, or protein fragments or circularpermuted polypeptides. For example, a fusion protein can comprise a TypeI CRISPR-Cas protein (e.g., Cas8, Cas3) and a functional domain fromanother protein (e.g., FokI; see, e.g., U.S. Pat. No. 9,885,026, issued6 Feb. 2018). The modification to include such domains in fusionproteins may confer additional activity on engineered Type I CRISPR-Casproteins. Such activities can include nuclease activity,methyltransferase activity, demethylase activity, DNA repair activity,DNA damage activity, deamination activity, dismutase activity,alkylation activity, depurination activity, oxidation activity,pyrimidine dimer forming activity, integrase activity, transposaseactivity, recombinase activity, polymerase activity, ligase activity,helicase activity, photolyase activity, glycosylase activity,acetyltransferase activity, deacetylase activity, kinase activity,phosphatase activity, ubiquitin ligase activity, deubiquitinatingactivity, adenylation activity, deadenylation activity, SUMOylatingactivity, deSUMOylating activity, ribosylation activity, deribosylationactivity, and/or myristoylation activity or demyristoylation activitythat modifies a polypeptide associated with nucleic acid target sequence(e.g., a histone).

In some embodiments, a fusion protein can comprise epitope tags (e.g.,histidine tags, HA tags, FLAG® (Sigma Aldrich, St. Louis, Mo.) tags, Myctags, nuclear localization signal (NLS) tags, SunTag), reporter proteinsequences (e.g., glutathione-S-transferase, beta-galactosidase,luciferase, green fluorescent protein, cyan fluorescent protein, yellowfluorescent protein), and/or nucleic acid sequence binding domains(e.g., a DNA binding domain or an RNA binding domain).

A fusion protein can also comprise activator domains (e.g., heat shocktranscription factors, NFKB activators) or repressor domains (e.g., aKRAB domain). As described by Lupo, A., et al., Current Genomics14(4):268-278 (2013), the KRAB domain is a potent transcriptionalrepression module and is located in the amino-terminal sequence of mostC2H2 zinc finger proteins (see, e.g., Margolin, J., et al., Proceedingsof the National Academy of Sciences of the United States of America91:4509-4513 (1994); Witzgall, R., et al., Proceedings of the NationalAcademy of Sciences of the United States of America 91:4514-4518(1994)). The KRAB domain typically binds to co-repressor proteins and/ortranscription factors via protein-protein interactions, causingtranscriptional repression of genes to which KRAB zinc finger proteins(KRAB-ZFPs) bind (see, e.g., Friedman J. R., et al., Genes & Development10:2067-2678 (1996)). In some embodiments, linker nucleic acid sequencesare used to join the two or more proteins, protein domains, or proteinfragments.

As used herein “CASCADEa” (Cascade activation) is a CRISPR method orsystem wherein the method or system activates the expression of a genewithin the locus of the target nucleic acid sequence. For therecruitment of endogenous transcription factors, one or more subunitproteins in a Cascade complex and/or the guide polynucleotide istypically fused to an effector domain (e.g., VP16 or VP64). In someembodiments, the guide polynucleotide can be fused 5′ or 3′ to anucleotide effector domain such as an MS2 binding RNA that also recruitstranscription factors. Fusions comprising one or more Cascade subunitproteins and the guide polynucleotide can be combined.

As used herein “CASCADE” (Cascade inhibition) is a CRISPR method orsystem wherein the CRISPR method or system downregulates the expressionof a gene within the locus of the target nucleic acid sequence. For therecruitment of endogenous repression factors, one or more subunitproteins in a Cascade complex and/or the guide polynucleotide istypically fused to an effector domain (e.g., KRAB). In some embodiments,the guide polynucleotide can be fused 5′ or 3′ to a nucleotide effectordomain that also recruits transcription factors. Fusions comprising oneor more Cascade subunit proteins and the guide polynucleotide can becombined.

A “moiety,” as used herein, refers to a portion of a molecule. A moietycan be a functional group or describe a portion of a molecule withmultiple functional groups (e.g., that share common structural aspects).The terms “moiety” and “functional group” are typically usedinterchangeably; however, a “functional group” can more specificallyrefer to a portion of a molecule that comprises some common chemicalbehavior.

The term “affinity tag,” as used herein, typically refers to one or moremoieties that increases the binding affinity of one macromolecule foranother, for example, to facilitate formation of an engineered Type ICRISPR-Cas nucleoprotein complex. In some embodiments, an affinity tagcan be used to increase the binding affinity of one Cas subunit proteinfor another Cas subunit protein (e.g., a first Cas7 protein for a secondCas7 protein). In some embodiments, an affinity tag can be used toincrease the binding affinity of one or more Cas subunit proteins for acognate guide polynucleotide. Some embodiments of the present inventionintroduce one or more affinity tags to the N-terminal of a Cas subunitprotein sequence, to the C-terminal of a Cas subunit protein sequence,to a position located between the N-terminal and C-terminal of a Cassubunit protein sequence, or to combinations thereof. In someembodiments of the present invention, one or more guide polynucleotidecomprises an affinity tag that increases binding affinity of the guidepolynucleotide with one or more Cas subunit proteins. A wide variety ofaffinity tags are disclosed in U.S. Published Patent Application No.2014-0315985, published 23 Oct. 2014. Ligands and ligand-bindingmoieties are paired affinity tags.

As used herein, a “cross-link” is a bond that links one polymer chain(e.g., a polynucleotide or polypeptide) to another. Such bonds can becovalent bonds or ionic bonds. In some embodiments, one polynucleotidecan be bound to another polynucleotide by cross linking thepolynucleotides. In other embodiments, a polynucleotide can be crosslinked to a polypeptide. In additional embodiments, a polypeptide can becross linked to a polypeptide.

The term “cross-linking moiety,” as used herein, typically refers to amoiety suitable to provide cross linking between two macromolecules. Across-linking moiety is another example of an affinity tag.

As used herein, a “host cell” generally refers to a biological cell. Acell is the basic structural, functional, and/or biological unit of anorganism. A cell can originate from any organism having one or morecells. Examples of host cells include, but are not limited to, aprokaryotic cell, eukaryotic cell, a bacterial cell, an archaeal cell, acell of a single-cell eukaryotic organism, a cell of a eukaryoticorganism, a protozoal cell, a cell from a plant (e.g., cells from plantcrops (such as soy, tomatoes, sugar beets, pumpkin, hay, cannabis,tobacco, plantains, yams, sweet potatoes, cassava, potatoes, wheat,sorghum, soybean, rice, corn, maize, oil-producing Brassica (e.g.,oil-producing rapeseed and canola), cotton, sugar cane, sunflower,millet, and alfalfa), fruits, vegetables, grains, seeds, floweringplants, conifers, gymnosperms, ferns, clubmosses, hornworts, liverworts,mosses), an algal cell, (e.g., Botryococcus braunii, Chlamydomonasreinhardtii, Nannochloropsis gaditana, Chlorella pyrenoidosa, Sargassumpatens C. agardh, and the like), seaweeds (e.g., kelp), a fungal cell(e.g., a yeast cell or a cell from a mushroom), an animal cell, a cellfrom an invertebrate animal (e.g., fruit fly, cnidarian, echinoderm,nematode, and the like), a cell from a vertebrate animal (e.g., fish,amphibian, reptile, bird, or mammal), a cell from a mammal (e.g., a pig,a cow, a goat, a sheep, a rodent, a rat, a mouse, a non-human primate, ahuman, and the like). Furthermore, a cell can be a stem cell or aprogenitor cell. In some embodiments, a host cell is a non-human cell.In some embodiments, a host cell is a human cell outside of a humanbody, wherein in particular embodiments the human cell is not introducedinto a human body.

As used herein, “stem cell” refers to a cell that has the capacity forself-renewal, i.e., the ability to go through numerous cycles of celldivision while maintaining the undifferentiated state. Stem cells can betotipotent, pluripotent, multipotent, oligopotent, or unipotent. Stemcells can be embryonic, fetal, amniotic, adult, or induced pluripotentstem cells.

As used herein, “induced pluripotent stem cell” refers to a type ofpluripotent stem cell that is artificially derived from anon-pluripotent cell, typically a somatic cell. In some embodiments, thesomatic cell is a human somatic cell. Examples of somatic cells include,but are not limited to, dermal fibroblasts, bone marrow-derivedmesenchymal cells, cardiac muscle cells, keratinocytes, liver cells,stomach cells, neural stem cells, lung cells, kidney cells, spleencells, and pancreatic cells. Additional examples of somatic cellsinclude cells of the immune system, including but not limited to, Bcells, dendritic cells, granulocytes, innate lymphoid cells,megakaryocytes, monocytes/macrophages, myeloid-derived suppressor cells,natural killer (NK) cells, T cells, thymocytes, and hematopoietic stemcells.

“Plant,” as used herein, refers to whole plants, plant organs, planttissues, germplasm, seeds, plant cells, and progeny of the same. Plantcells include, without limitation, cells from seeds, suspensioncultures, embryos, meristematic regions, callus tissue, leaves, roots,shoots, gametophytes, sporophytes, pollen, and microspores. Plant partsinclude differentiated and undifferentiated tissues including, but notlimited to, roots, stems, shoots, leaves, pollens, seeds, tumor tissue,and various forms of cells and culture (e.g., single cells, protoplasts,embryos, and callus tissue). The plant tissue may be in plant or in aplant organ, tissue, or cell culture. “Plant organ” refers to planttissue or a group of tissues that constitute a morphologically andfunctionally distinct part of a plant.

“Subject,” as used herein, refers to any member of the phylum Chordata,including, without limitation, humans and other primates, includingnon-human primates such as rhesus macaques, chimpanzees, and othermonkey and ape species; farm animals, such as cattle, sheep, pigs,goats, and horses; domestic mammals, such as dogs and cats; laboratoryanimals, including rabbits, mice, rats, and guinea pigs; birds,including domestic, wild, and game birds, such as chickens, turkeys andother gallinaceous birds, ducks, and geese; and the like. The term doesnot denote a particular age or gender. Thus, the term includes adult,young, and newborn individuals as well as male and female. In someembodiments, a host cell is derived from a subject (e.g., stem cells,progenitor cells, or tissue-specific cells). In some embodiments, thesubject is a non-human subject.

As used herein, “transgenic organism” refers to an organism thatcontains genetic material into which DNA from an unrelated organism hasbeen artificially introduced. The term includes the progeny (anygeneration) of a transgenic organism, provided that the progeny has thegenetic modification. In some embodiments, the transgenic organism is anon-human transgenic organism.

As used herein, “isolated” can refer to a molecule (e.g., apolynucleotide or a polypeptide) that, by human intervention, existsapart from its native environment and is therefore not a product ofnature. An isolated polynucleotide or polypeptide can exist in apurified form and/or can exist in a non-native environment such as, forexample, in a recombinant cell.

As used herein, a “substrate channel” refers to the direct transfer of areactant from one enzymatic reaction to another enzymatic reactionwithout first diffusing into the bulk environment (Wheeldon, I., et al.,Nat. Chem. 8(4):299-309 (2016)). Intermediates of these enzymatic stepsare not in equilibrium with the bulk solution, which enables theincreased efficiencies and yields in enzymatic processes. Frequently,enzymes in naturally occurring metabolic processes have evolved means ofco-localization and assembly into controlled aggregates.

As used herein, “substrate channel element” refers to a component of ametabolic pathway. In some embodiments, a substrate channel element isan enzyme that catalyzes a chemical reaction.

As used herein, “substrate channel complex” refers to multiple substratechannel elements that are co-localized together via some means.

As used herein, an “RNA scaffold” refers to an RNA molecule thatpeptides can use as a substrate for binding.

In a first aspect, the present invention relates to engineeredpolynucleotides encoding Cascade components including, but not limitedto, Cascade subunit proteins and Cascade guide polynucleotides.

In one embodiment, the present invention relates to engineeredpolynucleotides encoding Cascade components that are derived fromCascade Type I-E systems. Exemplary polynucleotide constructs comprisingCascade proteins and Cascade crRNAs are presented in Example 1. Example1, Table 10, and SEQ ID NO:1 through SEQ ID NO:20 (FIG. 3) presentpolynucleotide DNA sequences of genes encoding the five subunit proteinsof Type I-E Cascade, specifically from E. coli strain K-12 MG1655, aswell as the amino acid sequences of the resulting protein components.The polynucleotide sequences were derived from E. coli genomic DNA andwere codon optimized specifically for expression in E. coli, and/orcodon optimized specifically for expression in eukaryotic cells (e.g.,human cells). When this polynucleotide is transcribed into a precursorcrRNA and processed by the Cascade RNA endonuclease, a mature crRNA isproduced that functions as a guide RNA to target complementary DNAsequences in the genome. The minimal CRISPR array comprises two repeatsequences (underlined in the CRISPR array sequences presented inExample 1) flanking an exemplary spacer sequence, which represents theguide portion of the crRNA. RNA processing by the Cascade endonucleasegenerates a crRNA with repeat sequences on both the 5′ and 3′ ends,flanking the guide sequence. One of ordinary skill in the art, in viewof the teachings of the present Specification and the Examples, canselect appropriate spacer sequences to target binding of a Cascadecomplex to a chosen target sequence (e.g., in genomic DNA).

Polynucleotide sequences encoding Cascade components from additionalbacterial or archaeal species can be identified and designed followingthe guidance of the present Specification and using bioinformatics toolssuch as BLAST and PSI-BLAST to locate, as an example, homologs ofCascade subunit genes from E. coli strain K-12 MG1655, and theninspecting the flanking genomic neighborhood of the Cascade gene tolocate and identify genes of the remaining Cascade subunit proteins(see, e.g., Example 14, Example 15). Because Cascade genes co-occur asconserved operons, they are typically arranged in a consistent order,within the same Type I subtype, facilitating their identification andselection for follow-up analysis and experimentation. As an example,additional Type I-E systems can be identified by locating Cas8 homologs,identifying promising bacterial species for homologous Cascade testing,and then obtaining or designing polynucleotide sequences encoding theCas8 and other protein components of the Cascade from those homologousCRISPR-Cas systems.

Polynucleotide DNA sequences of genes encoding the five subunit proteinsof Cascade from twelve species (these species are listed in Table 2)with Cascade complexes homologous to those derived from E. coli strainK-12 MG1655, and the amino acid sequences of the resulting proteincomponents, as well as exemplary minimal CRISPR arrays, are presented asSEQ ID NO:22 through SEQ ID NO:213 (FIG. 3). The polynucleotidesequences for the proteins were derived from the genomic DNA of the hostbacterium, and were codon optimized specifically for expression in E.coli, and/or codon optimized specifically for expression in eukaryoticcells (e.g., human cells). The polynucleotide DNA sequences encodingcorresponding minimal CRISPR arrays were based on repeat sequencesderived from the 12 species and can be used to generate mature crRNAthat function as guide RNAs. In Table 2, the minimal CRISPR arraycomprises two repeat sequences (lower case, underlined) flanking anexemplary “spacer” sequence, which represents the guide portion of thecrRNA. RNA processing by the endonuclease Cascade subunit generates acrRNA with repeat sequences on both the 5′ and 3′ ends, flanking theguide sequence.

TABLE 2 Minimal CRISPR Arrays SEQ ID NO: Species Minimal CRISPR repeatSEQ ID I-E_Oceanicola sp. HL-35 ctgttccccgcacacgcggggatgaaccgGGTTCTNO: 37 TCGATCTGCGCATCCATGATGCCGC Cctgttccccgcacacgcggggatgaaccg SEQ IDI-E_Pseudomonas sp. S-6-2 gtgttccccgcacctgcggggatgaaccGGGCCG NO: 53GGGCGTTTGCGCTGTCAGGGGCGT CCCgtgttccccgcacctgcggggatgaaccg SEQ IDI-E_Salmonella enterica sub sp. gtgttccccgcgccagcggggataaaccgCAGCTTNO: 69 enterica serovar Muenster strain TAGCATCGGTCGACAGCCCATCTGGCgtgttccccgcgccagcggggataaaccg SEQ ID I-E_Atlantibacter hermanniigtgttccccgcgccagcggggataaaccgTTTTAA NO: 85 NBRC 105704AACAGGATGTGGCCCGCCTGGTGC TGgtgttccccgcgccagcggggataaaccg SEQ IDI-E_Geothermobacter sp. EPR- ctgttccccgcacccgcggggatgaaccgGTCATC NO: 101M TATTTTTAATGGACGATATTTTTCA Actgttccccgcacccgcggggatgaaccg SEQ IDI-E_Methylocaldum sp. 14B ctgttccccacgtacgtggggatgaaccgACGGCG NO: 117TAATGGTAATTGTTAGCCGACAAG TTctgttccccacgtacgtggggatgaaccg SEQ IDI-E_Methanocella arvoryzae aaagtccccacaggcgtgggggtgaaccgTGATC NO: 133MRE50 AGTAACCCGGTCACCATTAAACAG ATTaaagtccccacaggcgtgggggtgaaccg SEQ IDI-E_Lachnospiraceae bacterium gtattccccacgcacgtggrggtaaatcCGCTGAGNO: 149 KH1T2 TTTAATTACGCAGCGGAAGCCGGA GCGgtattccccacgcacgtgggggtaaatcSEQ ID I-E_Klebsiella pneumoniae gtatccccacacgcgtgggggtgtttcCGGCTCTTNO: 165 strain VRCO0172 TTTTATCTCCTTCATCCTTCGCTATgtcttccccacacgcgtgggggtgtttc SEQ ID I-E_Pseudomonas aeruginosagtgttccccacatgcgtggggatgaaccgGGCACC NO: 181 DHS01ATCGGCGCCATTGACCGCGCGCTG AAGgtgttccccacatgcgtggggatgaaccg SEQ IDI-E_Streptococcus thermophilus gtttttcccgcacacgcgggggtgatccTATACCTNO: 197 strain ND07 ATATCAATGGCCTCCCACGCATAAGCgtttttcccgcacacgcgggggtgatcc SEQ ID I-E_Streptomyces sp. S4gtcggccccgcacccgcggggatgctccAATGGC NO: 213 CGAGGACGACGGCGATCTGGCCACGGACgtcggccccgcacccgcggggatgctcc

In another embodiment, the present invention relates to engineeredpolynucleotide sequences encoding Cascade components from additionalbacterial or archaeal species, within other Type I subtypes; including,but not limited, to Types I-B, I-C, I-F, and variants of I-F, which canbe identified and designed following the guidance of the presentSpecification and by using bioinformatics tools such as BLAST andPSI-BLAST to locate homologs of Cascade genes from hallmark systemstypifying each subtype (see, e.g., Makarova, K. S., et al., Nat. Rev.Microbiol. 13(11):722-736 (2015); Koonin, E. V., et al., Curr OpinMicrobiol. 37:67-78 (2017)). After identifying desirable homologs, theflanking genomic neighborhoods of the Cascade gene can be inspected tolocate and identify genes of the remaining Cascade subunit proteins asdisclosed herein. As an example, additional Type I-F systems can beidentified by locating Cas8 homologs (and additional Type I-F variant 2systems can be identified by locating Cas5 homologs) and identifyingpromising bacterial species for homologous Cascade testing, and thenobtaining or designing polynucleotide sequences encoding the Cas8, Cas5,and other protein components of the Cascade from those homologousCRISPR-Cas systems.

Polynucleotide DNA sequences of genes encoding the three, four, or fivesubunit proteins of Cascade from Types I-B, I-C, I-F, and I-F variant 2from twelve additional homologous Cascade complexes, and the amino acidsequences of the resulting protein components, as well as exemplaryminimal CRISPR arrays, are presented as SEQ ID NO:214 through SEQ IDNO:351 (FIG. 3). The polynucleotide sequences for the subunit proteinswere derived from the genomic DNA of the host bacterium, and were codonoptimized specifically for expression in E. coli, and/or codon optimizedspecifically for expression in eukaryotic cells (e.g., human cells). Thepolynucleotide DNA sequences encoding corresponding minimal CRISPRarrays were based on repeat sequences derived from the twelve speciesand can be used to generate mature crRNA that function as guide RNAs. InTable 3 the minimal CRISPR array comprises two repeat sequences (lowercase, underlined) flanking an exemplary “spacer” sequence, whichrepresents the guide portion of the crRNA. RNA processing by theendonuclease Cascade subunit generates a crRNA with repeat sequences onboth the 5′ and 3′ ends, flanking the guide sequence.

TABLE 3 Minimal CRISPR Arrays SEQ ID NO: Species Minimal CRISPR repeatSEQ ID I-B_Fusobacterium nucleatumatgaactgtaaacttgaaaagttttgaaatGTTGACAA NO: 226 subsp. animalis 3_1_33ATATTCAGATAATTTTTCAAAATCTT TTatgaactgtaaacttgaaaagttttgaaat SEQ IDI-B_Campylobacter fetus subsp. gtttgctaatgacaatatttgtgttaaaacAAGCGTAGNO: 239 testudinum Sp3 CACCAAAAGAAGCGTATGAAAGCATAGgtttgctaatgacaatatttgtgttaaaac SEQ ID I-B_Odoribacter splanchnicuscttttaattgaactaaggtagaattgaaacTAGGAATA NO: 252 DSM 20712AACCGTACCCAACCACGTAGCCATA TACGcttttaattgaactaaggtagaattgaaac SEQ IDI-C_Bacillus halodurans C-125 gtcgcactcttcatgggtgcgtggattgaaatCCTTTGNO: 262 ACGGAGAGGGGAACAGGAAATTAG AGAAGgtcgcactcttcatgggtgcgtggattgaaatSEQ ID I-C_Desulfovibrio vulgaris gtcgccccccacgcgggggcgtggattgaaacCAGTCNO: 272 RCH1 plasmid pDEVAL01 TCGTTACCCTGTCGCGGAGGGCGTCGATgtcgccccccacgcgggggcgtggattgaaac SEQ ID I-C_GeobacillusgttgcacccggctattaagccgggtgaggattgaaacTA NO: 282 thermocatenulatus strainTATCACACAGCTTCTTAGTATCATCG KCTC 3921 ACAACACGTgttgcacccggctattaagccgggtgaggattgaaac SEQ ID I-F_Vibrio cholerae strain L15gttcactgccgtacaggcagcttagaaaAATATGCA NO: 295 GGGGTTTGAAACGCTCGATGTTATgttcactgccgtacaggcagcttagaaa SEQ ID I-F_Klebsiella oxytoca straingttcactgccgtacaggcagcttagaaaAAAAACTG NO: 308 ICU1-2bAGCGGCCGCAGAATGAAGTTGTAAgt tcactgccgtacaggcagcttagaaa SEQ IDI-F_Pseudomonas aeruginosa gttcactgccgtgtaggcagctaagaaaACCACCCG NO: 321UCBPP-PA14 CTACCACCGGCAGCCGCACCGGCCgtt cactgccgtgtaggcagctaagaaa SEQ IDI-Fv2_Shewanella putrefaciens gttcaccgccgcacaggcggcttagaaaTCAACCANO: 331 CN-32 AATCATAAATTGCGCGACCACATTGg ttcaccgccgcacaggcggcttagaaaSEQ ID I-Fv2_Acinetobacter sp. gttcactgccatataggcagcttagaaaATCGTTTTTNO: 341 869535 TCATACGAGATTCGAAACGGACAgttc actgccatataggcagcttagaaaSEQ ID I-Fv2_Vibrio cholerae HE48 gttcactgccgcacaggcagcttagaaaTAACCGGANO: 351 GGCGTACACTCGATAGAGGCAGCGgt tcactgccgcacaggcagcttagaaa

Example 19 describes the design and testing of multiple Cascade complexhomologs, each comprising a Cas subunit protein-FokI fusion protein, toevaluate the efficiency of genome editing for each Cascade complex.

In a second aspect, the present invention relates to modified Cascadesubunit proteins. Cascade subunit proteins suitable for modificationinclude, but are not limited to, Cascade subunit proteins of the speciesdescribed herein.

In one embodiment, the present invention relates to engineered circularpermutations of Cascade subunit proteins. Such circular permutations ofa Cascade subunit protein result in a protein structure having differentconnectivity of the original linear sequence of amino acids of theCascade subunit protein, but having an overall similar three-dimensionalshape (see, e.g., Bliven, S., et al., PLoS Comput. Biol. 8(3):e1002445(2012)). Circular permutations of Cascade subunit proteins can have anumber of advantages. For example, a circular permutation of a Cas7subunit protein can create a new N-terminus and a new C-terminusdesigned to be positioned for connection with an additional polypeptidesequence to form a fusion protein or linker region without disturbingthe Cas7 protein fold or the Cascade complex assembly. Three examples ofcircular permutations of Cas7 (circularly permuted Cas7, cpCas7) areillustrated in FIG. 4A and FIG. 4B. In FIG. 4A and FIG. 4B, threeportions of the protein are shown: a N-terminal portion of the nativeprotein (vertical stripes), a central portion of the native protein(grey shading), and a C-terminal portion of the native protein (noshading). FIG. 4A illustrates relocation of a N-terminal portion of thenative protein to the C-terminal position of the cpCas7, wherein theN-terminal portion of the native protein is now at the N-terminal end ofthe cpCas7 and is connected to the central portion of the native proteinby a linker polypeptide. FIG. 4B illustrates relocation of a C-terminalportion of the native protein to the N-terminal position of the cpCas7,wherein the C-terminal portion of the native protein is now at theN-terminal end of the cpCas7 and is connected to the central portion ofthe native protein by a linker polypeptide.

The data in Example 10 show that purification of Cascade complexescomprising circularly-permuted Cas7 subunit protein variants demonstratethat circularly-permuted Type I-E CRISPR-Cas subunit proteins can besuccessfully used to form Cascade complexes having essentially the samecomposition (based on molecular weight) as Cascade complexes comprisingwild-type proteins.

In another embodiment, the present invention relates to Cascade subunitproteins fused to additional polypeptide sequences to create fusionproteins, as well as polynucleotides encoding such fusion proteins.Additional polypeptide sequences can include, but are not limited to,proteins, protein domains, protein fragments, and functional domains.Examples of such additional polypeptide sequences include, but are notlimited to, sequences derived from transcription activator or repressordomains, and nucleotide deaminases (e.g., a cytidine deaminase or anadenine deaminase such as described in Komor et. al., Nature 553:420-424(2016); Koblan et. al., Nat Biotechnol. 2018 May 29-doi:10.1038/nbt.4172). Additional functional domains for fusion proteins arepresented herein.

An additional polypeptide sequence can be fused to any of the Cascadesubunit proteins wherein the additional polypeptide sequence is encodedby an additional polynucleotide sequence that is typically appended toeither the 5′ or 3′ end of a polynucleotide comprising the codingsequence of a Cascade subunit protein. In some embodiments, additionalpolynucleotide sequences that encode amino acid linkers connect aCascade subunit protein to the additional polypeptide sequences ofinterest. In some embodiments, the polynucleotide sequences for thefusion protein partner and the linker sequence can be derived fromnaturally occurring genomic DNA sequences or may be codon optimized forbacterial expression in E. coli or eukaryotic expression in mammaliancells (e.g., human cells). Examples of fusions proteins comprisingaffinity tags (e.g., His6, Strep-tag® II (IBA GMBH LLC, Göttingen,Germany)), nuclear localization signal or sequence (NLS), maltosebinding protein, and FokI are presented in Example 1. Exemplary aminoacid linker sequences are also disclosed in Example 1.

Example 11 describes Cascade subunit protein-FokI fusions, as well asCascade subunit protein fusions to cytidine deaminases, endonucleases,restriction enzymes, a nuclease/helicase, or domains thereof. Example 11describes Cascade subunit protein fusions with other Cascade subunitproteins, as well as Cascade subunit protein fusions with other Cascadesubunit fusion proteins and an enzymatic protein domain. In someembodiments, a Type I CRISPR subunit protein can be evaluated in silicofor the ability to be used to generate protein fusions at theN-terminus, C-terminus, or positions between the N-terminus and theC-terminus. In some embodiments, a Type I CRISPR subunit protein can belinked to one or more fusion domains at the N-terminus, C-terminus, orpositions between the N-terminus and the C-terminus using one or morepolypeptide linkers. Examples of polypeptide linkers are set forth inExamples 1, 11, 18, and 19.

FIG. 5A and FIG. 5B illustrate Cascade complexes comprising a Cas8subunit protein fused to an additional protein sequence (e.g., a FokI).FIG. 5A shows an example of the additional protein sequence (“FP”)connected with the C-terminus of a Cas8 subunit protein using a linkerpolypeptide. FIG. 5B shows an example of the additional protein sequence(“FP”) connected with the N-terminus of a Cas8 subunit protein using alinker polypeptide. Example 11A describes in silico design, cloning,expression, and purification of a Type I-E Cas8 fused N-terminally witha FokI nuclease domain.

FIG. 6A and FIG. 6B illustrate additional examples of Cascade complexescomprising a Cascade subunit protein fused to an additional proteinsequence. FIG. 6A shows an example of a detectable moiety (e.g., a greenfluorescent protein, GFP) fused to each of six Cas7 subunit proteins,each via a linker polypeptide. Such a Cascade complex can be useful fordetection of binding of the complex to a nucleic acid target sequence byproviding significant signal amplification as a result of the presenceof the multiple detectable moieties associated with the Cascade complex.FIG. 6B shows an example of an additional protein sequence (“FP”)connected with Cas6 subunit protein using a linker polypeptide.

Examples of fusion proteins containing E. coli Type I-E Cascade subunitproteins include, but are not limited to, the following: the samesubunit (e.g., Cse2_linker_Cse2), circularly permuted subunits (e.g.,cpCas7_linker_cpCas7_linker_cpCas7_linker_cpCas7_linker_cpCas7_linker_cpCas7),a Type I-E Cascade protein fused to a nuclease (e.g., FokI_linker_Cas8,Cas3_linker_Cas8, Cas6_linker FokI, S1Nuclease_linker_Cse2_linker_Cse2),a Type I-E Cascade protein fused to a cytidine deaminase (e.g.,Cas8_linker_AID, Cse2_linker_Cse2_linker APOBEC3G), and a Type I-ECascade protein fused one or more other Type I-E Cascade proteins (e.g.,Cas6_linker_cpCas7_linker_cpCas7__linker_cpCas7_linker_cpCas7_linker_cpCas7_linker_cpCas7,cpCas7_linker_cpCas7_linker_cpCas7_linker_cpCas7_linker_cpCas7_linker_cpCas7_linker_Cas5,Cas6_linker_cpCas7_linker_cpCas7_linker_cpCas7_linker_cpCas7_linker_cpCas7_linker_cpCas7_linker_Cas5).

FIG. 7A, FIG. 7B, and FIG. 7C present illustrations of modified Type ICRISPR-Cas effector complexes that contain cpCas7 (compare FIG. 4A)).FIG. 7A presents a Cascade complex comprising six individual cpCas7subunit proteins. FIG. 7B presents a Cascade complex comprising sixfused cpCas7 subunit proteins, wherein the C-terminus of a cpCas7subunit protein is connected with the N-terminus of an adjacent cpCas7subunit protein using a linker polypeptide. FIG. 7C presents anembodiment wherein the Cascade complex comprises six fused cpCas7subunit proteins (a “backbone”), wherein the C-terminus of the firstcpCas7 subunit protein is connected with the N-terminus of the secondcpCas7 subunit protein using a linker polypeptide, the C-terminus of thesecond cpCas7 subunit protein is connected with the N-terminus of adifferent protein sequence (“FP”) (e.g., a cytidine deaminase) using alinker polypeptide and the C-terminus of this protein coding sequence isconnected with the N-terminus of the third cpCas7 using a linkerpolypeptide. One advantage of such a fused backbone of cpCas7 subunitproteins is that an additional protein sequence can be introduced at aspecific location along the backbone to provide access of the additionalprotein sequence to different locations along the length of the nucleicacid target sequence to which the guide directs binding of the Cascadecomplex.

FIG. 8A and FIG. 8B illustrate further embodiments of modified Type ICRISPR-Cas effector complexes comprising fusion proteins. FIG. 8A showsa Cascade complex comprising a Cse2-Cse2 fusion protein. In silicodesign, cloning, expression, purification, and electrophoretic mobilityshift assays are described in Example 11B and Example 11C Cascadecomplexes comprising Cse2-Cse2 fusion proteins. FIG. 8B shows a Cascadecomplex comprising a Cse2-Cse2 fusion protein connected with anadditional protein sequence (“FP”). Example 11D describes in silicodesign, cloning, expression, and purification of a Cse2-Cse2 proteinfused to a cytidine deaminase.

In some embodiments, one or more nuclear localization signals can beadded at the engineered N-terminus or C-terminus of a Cascade proteinsubunit (e.g., a Cas8-FokI fusion protein, a cpCas7 protein, or aCse2-Cse2 fusion protein).

In some embodiments of fusion polypeptides, linker polypeptides connecttwo or more protein coding sequences. The length of exemplary linkerpolypeptides are described in the Examples. Typically, linker lengthsinclude, but are not limited to, between about 10 amino acids to about40 amino acids, between about 15 amino acids and about 30 amino acids,and between about 17 amino acids and about 20 amino acids. The aminoacid composition of linker polypeptides typically comprises amino acidsthat are polar, small, and/or charged (e.g., Gly, Ala, Leu, Val, Gln,Ser, Thr, Pro, Glu, Asp, Lys, Arg, His, Asn, Cys, Tyr). Following theguidance of the present Specification, the linker polypeptide isdesigned to provide appropriate spacing and positioning of thefunctional domain and the Cascade protein within the fusion protein(Chichili, C., et al., Protein Science 22(2):153-167 (2013); Chen, X.,et al., 65(10):1357-1369 (2013); George, R., et al., ProteinEngineering, Design and Selection 15:(11):871-879 (2002)). Additionalexamples of linker polypeptides useful in the practice of the presentinvention are linker polypeptides identified that connect codingsequences of Cascade proteins to each other in organisms comprisingCascade systems (e.g., the linker polypeptide that connects Cas8 to Cas3in Streptomyces griseus as described by Westra, E. R., et al., Mol Cell.46(5): 595-605 (2012)).

Fusion protein coding DNA sequences can be codon optimized forexpression in a selected organism such as bacteria, archae, plants,fungi, or mammalian cells. Codon-optimizing programs are widelyavailable. such as on the Integrated DNA Technologies website(www.idtdna.com/CodonOpt), or through Genscript® services (Genscript,Piscataway, N.J.). To facilitate cloning into the recipient expressionvector, additional sequences overlapping with the vector compatible forSLIC cloning (Li, M., et al., Methods Mol. Biol. 852:51-59 (2012)) canbe appended at the 5′ and 3′ ends of the DNA sequence.

In other embodiments, Cascade subunit proteins can be fused totranscription activation and/or repression domains. In some embodiments,a fusion protein can comprise activator domains (e.g., heat shocktranscription factors, NFKB activators, VP16, and VP64 (Eguchi, A. et.al., PNAS 113(51):E8257-E8266 (2016); Perez-Pinera, P. et. al., NatureMethods 10(10):973-6 (2013); Gilbert, L. A., et. al. Cell 159(3):647-61(2014)) or repressor domains (e.g., a KRAB domain). In some embodiments,linker nucleic acid sequences are used to join the two or more codingsequences for proteins, protein domains, or protein fragments.

Cascade complexes comprising Type I CRISPR-Cas subunit proteins fused totranscription activators can be used to activate the expression of thegene. The target locus can contain a transcriptional start site (TSS)that typically harbors one or more binding site for the transcriptionalactivation machinery (factors) of a cell. FIG. 9 illustrates a Cascadecomplex comprising six fusion proteins comprising a cpCas7 connected viaa linker polypeptide to the transcriptional activator VP64. Suchmodification of a Cascade complex converts the complex into a flexibletool for transcriptional activation of a gene (CASCADEa), whereintargeting a selected gene is achieved by selection of a guide sequencethat directs binding of the Cascade complex to one or more regulatoryelements (e.g., a TSS) of the selected gene. Example 12 describes thedesign of a E. coli Type I-E cp-Cas7 protein fused to a VP64 activationdomain to confer transcriptional activation activity to the Cascadecomplex.

In addition, Cascade complexes comprising Type I CRISPR-Cas subunitproteins fused to transcription repressors can be used to repress theexpression of the gene. The target locus can comprise transcriptionalregulatory elements. In one embodiment, a Cascade subunit protein can beconnected to a KRAB domain via a linker polypeptide. A Cascade complexcomprising the Cascade subunit protein/KRAB domain fusion can convertthe complex into a flexible tool for transcriptional repression of agene (CASCADEi), wherein targeting a selected gene is achieved byselection of a guide sequence that directs binding of the Cascadecomplex to one or more regulatory elements of the selected gene.

In additional embodiments, Cascade subunit proteins can be fused toaffinity tags.

In other embodiments of the present invention, Type I CRISPR-Cas guidepolynucleotides can be modified by insertion of a selectedpolynucleotide element or modification of a nucleotides at selectedpositions within the guide polynucleotides (e.g., substitution of a DNAmoiety for a RNA moiety). Such embodiments include, but are not limitedto, Type I CRISPR-Cas guide polynucleotides 5′, 3′ or internally fusedto one or more nucleotide effector domain (e.g., an MS2 or MS2-P65-HSF1binding RNA or Aptamer that recruits transcription factors). FIG. 10illustrates a Type I CRISPR guide polynucleotide comprising an RNAaptamer introduced into the 3′ hairpin of the guide.

The length of Type I CRISPR-Cas guides can also be modified, typicallyby lengthening or shortening the Cas7 subunit protein and Cse2 subunitprotein binding region. FIG. 11A illustrates a Cascade complex withthree Cas7 subunits, one Cse2 subunit and a shortened crRNA. FIG. 11Billustrates a Cascade complex with nine Cas7 subunits, three Cse2subunit and a lengthened crRNA.

Example 16 describes the generation and testing of modifications of TypeI CRISPR-Cas guide crRNAs and the suitability of the modified guides foruse in constructing engineered Type I CRISPR-Cas effector complexes.

In a third aspect, the present invention relates to nucleic acidsequences encoding one or more engineered Cascade components, as well asexpression cassettes, vectors, and recombinant cells comprising nucleicacid sequences encoding one or more engineered Cascade components. Someembodiments of the third aspect of the invention include one or morepolypeptide encoding all the components of a selected Cascade system(e.g., Cse2, Cas5, Cash, Cas7, and Cas8 proteins, and one or morecognate guides), wherein the components are capable of forming aneffector complex. Typically, when more than one cognate guide isexpressed, the guides have different spacer sequences to direct bindingto different nucleic acid target sequences. Such embodiments include,but are not limited to, expression cassettes, vectors, and recombinantcells.

In one embodiment, the present invention relates to one or moreexpression cassettes comprising one or more nucleic acid sequencesencoding one or more engineered Cascade components. Expression cassettestypically comprise a regulatory sequence involved in one or more of thefollowing: regulation of transcription, post-transcriptional regulation,or regulation of translation. Expression cassettes can be introducedinto a wide variety of organisms including, but not limited to,bacterial cells, yeast cells, plant cells, and mammalian cells(including human cells). Expression cassettes typically comprisefunctional regulatory sequences corresponding to the organism(s) intowhich they are being introduced.

A further embodiment of the present invention relates to vectors,including expression vectors, comprising one or more nucleic acidsequences encoding one or more one or more engineered Cascadecomponents. Vectors can also include sequences encoding selectable orscreenable markers. Furthermore, nuclear targeting sequences can also beadded, for example, to Cascade subunit proteins. Vectors can alsoinclude polynucleotides encoding protein tags (e.g., poly-His tags,hemagglutinin tags, fluorescent protein tags, and bioluminescent tags).The coding sequences for such protein tags can be fused to, for example,one or more nucleic acid sequences encoding a Cascade subunit protein.

General methods for construction of expression vectors are known in theart. Expression vectors for host cells are commercially available. Thereare several commercial software products designed to facilitateselection of appropriate vectors and construction thereof, such asinsect cell vectors for insect cell transformation and gene expressionin insect cells, bacterial plasmids for bacterial transformation andgene expression in bacterial cells, yeast plasmids for celltransformation and gene expression in yeast and other fungi, mammalianvectors for mammalian cell transformation and gene expression inmammalian cells or mammals, and viral vectors (including lentivirus,retrovirus, adenovirus, herpes simplex virus I or II, parvovirus,reticuloendotheliosis virus, and adeno-associated virus (AAV) vectors)for cell transformation and gene expression and methods to easily allowcloning of such polynucleotides. Illustrative plant transformationvectors include those derived from a Ti plasmid of Agrobacteriumtumefaciens (Lee, L. Y., et al., Plant Physiology 146(2):325-332(2008)). Also useful and known in the art are Agrobacterium rhizogenesplasmids. For example, SNAPGENE™ (GSL Biotech LLC, Chicago, Ill.;snapgene.com/resources/plasmid_files/your_time_is_valuable/) provides anextensive list of vectors, individual vector sequences, and vector maps,as well as commercial sources for many of the vectors.

In order to express and purify recombinant Cascade in a bacterialexpression system, vectors can be designed that encode Cascade subunitproteins, as well as a minimal CRISPR arrays comprising guide sequencesof interest. Accordingly, one aspect of the present invention includessuch expression systems. In one embodiment, the Cascade complex isexpressed off of three distinct plasmid vectors, which collectivelyencode the following components: a Cas8 protein; Cse2, Cas7, Cas5, andCas6 proteins; and a CRISPR crRNA. In some embodiments, the expressionplasmid encoding Cas8 comprises the natural, genomic DNA gene sequenceand, in other embodiments, the expression plasmid can encode Cas8 thatis codon optimized for expression in a chosen cell type. Similarly, theexpression plasmid encoding Cse2, Cas7, Cas5, and Cas6 can contain thenatural, genomic DNA gene sequences or can contain gene sequences thathave been codon optimized for expression in a chosen cell type. In someembodiments, the entire Cascade subunit protein coding operon can beplaced downstream of a single transcriptional promoter, such that thedifferent proteins are all translated from a single polycistronictranscript. In additional embodiments, the gene encoding the Cascadesubunit proteins can be separated from each other, with interveningtranscriptional terminators and promoters.

The expression plasmid encoding the crRNA may contain as few as tworepeats flanking a single spacer sequence, downstream of an appropriatetranscriptional promoter, or may contain many repeats flanking multiplespacer sequences, of either the same exact guide sequence or multipledistinct guide sequences. Coordinated expression of the CRISPR and theCascade subunits, in particular the Cas6 subunit, lead to processing oflong precursor crRNAs into the mature length crRNA, each one of whichcomprises fragments of a single repeat on the 5′ and 3′ ends of thecrRNA, and a single spacer sequence in the middle.

An alternative strategy to express the complete Cascade complex in E.coli uses two plasmids: one plasmid that encodes the entireCas8-Cse2-Cas7-Cas5-Cas6 operon on a single expression plasmid and oneencoding the CRISPR crRNA. In this case, the 5′ end of the Cse2 gene,which normally overlaps with the 3′ end of the Cas8 gene, is separatedspatially from the 3′ end of the Cas8 gene, in order to append apolynucleotide sequence encoding an affinity tag and/or proteaserecognition sequence.

Example 2 describes two types of bacterial expression plasmid systemsfor the Cascade proteins: the first type comprises two plasmids, a firstplasmid encoding the Cas8 protein and a second encoding the 4 subunitproteins of the CasBCDE complex (cse2-cas7-cas5-cas6 operon); and thesecond type comprises an expression plasmid encoding all 5 subunitproteins of the Cascade complex (cas8-cse2-cas7-cas5-cash operon).Cognate CRISPR arrays are also described.

In order to facilitate purification of Cascade complexes, an affinitytag can be appended onto the Cse2 subunit, such as an N-terminalStrep-II tag or a hexahistidine (His6) tag. Furthermore, an amino acidsequence recognized by a protease, such as TEV protease or the HRV3Cprotease can be inserted between the affinity tag and the nativeN-terminus of the Cse2 subunit, such that biochemical cleavage of thesequence with the protease after initial purification liberates theaffinity tag from the final recombinant Cascade complex. The affinitytag may also be placed on other subunits, or left on the Cse2 subunitand combined with additional affinity tags on other subunits. Examplesof Cascade subunit proteins comprising affinity tags are set forth inExample 1, Example 2, and Example 3.

For Type I-E Cascade systems, a strain of E. coli can be transformedwith plasmids encoding the CRISPR crRNA as well as theCse2-Cas7-Cas5-Cas6 genes, protein expression induced, and a Cascadecomplex that is lacking the Cas8 subunit can be produced. This Cascadecomplex typically is referred to as a Cas8-minus Cascade complex, oralternatively as a CasBCDE complex (Jore, M., et al., Nat. Struct. Mol.Biol. 18(5):529-536 (2011)). This purified complex can be biochemicallycombined with separately purified Cas8 to reconstitute full Cascade(Sashital, D. G., et al., Mol. Cell 46(5):606-615 (2012)).

Table 4 presents exemplary sequences of bacterial expression plasmidsencoding the minimal CRISPR array, Cas8, Cse2-Cas7-Cas5-Cas6 constructs,and Cas8-Cse2-Cas7-Cas5-Cas6 constructs, containing different tags anddesigns. Plasmids that encode Cascade complexes and Cascade complexesfrom homologous Type I systems can be designed similarly as theexemplary expression plasmid sequences for the Type I-E found in E. coliK-12 MG1655 following the guidance of the present Specification. Table 4additionally contains sequences of expression plasmids expressingCas8-Cse2-Cas7-Cas5-Cas6 as well as FokI fusions to either the Cas8 geneor the Cas6 gene, for the production of nuclease-Cascade fusions forgene editing experiments.

TABLE 4 Vectors for Production of Cascade Effector Complexes Effectorcomplex SEQ ID NO: Description species of origin Type of sequence SEQ IDNO: 352 minimal CRISPR array I-E_Escherichia Spacer sequence targets J3coli K-12 MG1655 SEQ ID NO: 353 minimal CRISPR array I-E_EscherichiaSpacer sequence targets coli K-12 MG1655 CCR5.1 SEQ ID NO: 354 minimalCRISPR array I-E_Escherichia Dual-guide spacer sequence (J3/L3) coliK-12 MG1655 targets J3 and L3 SEQ ID NO: 355 minimal CRISPR arrayI-E_Escherichia Dual-guide spacer sequence (Hsa07) coli K-12 MG1655targets Hsa07 SEQ ID NO: 356 His6-MBP-TEV-Cas8 I-E_Escherichia Derivedfrom genomic coli K-12 MG1655 DNA, with appended tags SEQ ID NO: 357StrepII-HRV3C- I-E_Escherichia Derived from genomic Cse2_Cas7_Cas5_Cas6coli K-12 MG1655 DNA, with appended tags SEQ ID NO: 358 Cas8_His6-HRV3C-I-E_Escherichia Derived from genomic Cse2_Cas7_Cas5_Cas6 coli K-12MG1655 DNA, with appended tags SEQ ID NO: 359 FokI-30aa-Cas8_His6-I-E_Escherichia Derived from genomic HRV3C- coli K-12 MG1655 DNA, withappended tags Cse2_Cas7_Cas5_Cas6 SEQ ID NO: 360 FokI-30aa-Cas8_His6-I-E_Escherichia Derived from genomic HRV3C- coli K-12 MG1655 DNA, withappended tags Cse2_Cas7_Cas5_NLS- Cas6 SEQ ID NO: 361FokI-30aa-Cas8_His6- I-E_Escherichia Derived from genomicHRV3C-Cse2_Cas7- coli K-12 MG1655 DNA, with appended tags NLS_Cas5_Cas6SEQ ID NO: 362 Cas8_His6-HRV3C- I-E_Escherichia Derived from genomicCse2_Cas7_Cas5_Cas6- coli K-12 MG1655 DNA, with appended tags 20aa-FokI

Table 5 contains the sequences of single polypromoter bacterialexpression plasmids encoding all 5 subunit proteins together with thecrRNA from a single bacterial expression plasmid. In this design, eachgene is separated from the other genes it flanks upstream and downstreamwith a transcriptional promoter and terminator. Additional sequences canbe introduced that encode an affinity tag and/or protease recognitiontag, as well as a fusion to a nuclease protein, in order to generate aCascade-nuclease fusion for gene editing.

TABLE 5 Vectors for Production of Cascade Effector Complexes Effectorcomplex SEQ ID NO: Description species of origin Type of sequence SEQ IDNO: 363 Polypromoter, I-E_Escherichia Derived from genomicCas5_Cas3_Cse2_Cas7_Cas6_Cas8_CRISPR(J3) coli K-12 MG1655 DNA, withappended tags SEQ ID NO: 364 Polypromoter, I-E_Escherichia Derived fromgenomic Cas5_Cas3_Cse2_Cas7_CRISPR(J3)_Cas6_Cas8 coli K-12 MG1655 DNA,with appended tags SEQ ID NO: 365 Polypromoter(EcoCO), I-E_EscherichiaE. coli codon-optimized CRISPR(J3/L3)_Cse2_Cas7_Cas5_Cas8_Cas6 coli K-12MG1655 DNA gene sequences SEQ ID NO: 366 Polypromoter(EcoCO),I-E_Escherichia E. coli codon-optimizedCRISPR(J3/L3)_Cse2_Cas7_Cas5_Cas8_FokI-30aa-Cas6 coli K-12 MG1655 DNAgene sequences SEQ ID NO: 367 Polypromoter(EcoCO), I-E_Escherichia E.coli codon-optimized CRISPR(J3/L3)_Cse2_Cas7_Cas5_Cas6_FokI-30aa-Cas8coli K-12 MG1655 DNA gene sequences

Additional bacterial expression plasmids can be designed encodinghomologous Cascade complexes from other Type I subtypes and otherbacterial or archaeal organisms based on the design criteria herein.Such expression plasmids can be designed with genomic DNA sequences forthe Cascade genes, or they can be designed with gene sequences that havebeen codon optimized for expression in E. coli or other bacterialstrains.

In order to express Cascade or effectors fusions to Cascade in mammaliancells, such as human cells, eukaryotic expression plasmid vectors weredesigned to enable expression of the relevant proteins and RNAcomponents by eukaryotic transcription and translation machinery. In oneembodiment, Cascade can be generated in mammalian cells by encoding eachof the protein components on a separate expression vector driven by aeukaryotic promoter (e.g., a cytomegalovirus (CMV) promoter), andencoding the crRNA on a separate expression vector driving by a RNAPolymerase III promoter (e.g., the human U6 promoter). The CRISPR RNAcan be encoded with a minimal CRISPR array containing at least tworepeats flanking one or more spacer sequences that function as the guideportion of the mature crRNA. The construct generating CRISPR RNA can bedesigned with additional sequences flanking the outermost repeats in theminimal array. Processing of the precursor CRISPR RNA is enabled by theRNA processing subunit of the Cascade complex (Cas6 subunit protein),which can be expressed from a separate plasmid.

Table 6 contains the sequences of individual eukaryotic expressionplasmids for each protein of the E. coli Type I-E Cascade complex. Cas8subunit can be fused to additional effector nuclease domains, such asthe FokI nuclease (Example 1 and Example 3). Table 6 also contains thesequences of expression plasmids for the crRNA component of Cascade,encoding two separate dual-guide crRNAs, whereby three repeat sequencesflank two spacer spacers. Each of the protein-coding genes can beappended to polynucleotide sequences that append nuclear localizationsignals (NLS), affinity tags, and linker sequences connecting thosetags. Other fusions to any of the Cascade subunit proteins can beencoded by additional polynucleotide sequences that typically areappended to either the 5′ or 3′ coding sequence, including additionalpolynucleotide sequences that encode amino acid linkers connecting tothe Cascade subunit protein to additional polypeptide sequences ofinterest. Examples of candidate fusions proteins are described herein.

TABLE 6 Vectors for Production of Cascade Effector Complexes Effectorcomplex SEQ ID NO: Description species of origin Type of sequence SEQ IDNO: 368 Cas8, HsCO I-E_Escherichia Homo sapiens coli K-12 MG1655codon-optimized DNA gene sequence SEQ ID NO: 369 NLS-Cas8, HsCOI-E_Escherichia Homo sapiens coli K-12 MG1655 codon-optimized DNA genesequence SEQ ID NO: 370 NLS-HA-FokI-30aa- I-E_Escherichia Homo sapiensCas8, HsCO coli K-12 MG1655 codon-optimized DNA gene sequence SEQ ID NO:371 NLS-Cse2, HsCO I-E_Escherichia Homo sapiens coli K-12 MG1655codon-optimized DNA gene sequence SEQ ID NO: 372 NLS-Cas7, HsCOI-E_Escherichia Homo sapiens coli K-12 MG1655 codon-optimized DNA genesequence SEQ ID NO: 373 Cas5, HsCO I-E_Escherichia Homo sapiens coliK-12 MG1655 codon-optimized DNA gene sequence SEQ ID NO: 374 NLS-Cas5,HsCO I-E_Escherichia Homo sapiens coli K-12 MG1655 codon-optimized DNAgene sequence SEQ ID NO: 375 Cas6, HsCO I-E_Escherichia Homo sapienscoli K-12 MG1655 codon-optimized DNA gene sequence SEQ ID NO: 376NLS-Cas6, HsCO I-E_Escherichia Homo sapiens coli K-12MG1655codon-optimized DNA gene sequence SEQ ID NO: 377 NLS-V5-FokI-30aa-I-E_Escherichia Homo sapiens Cas8, HsCO coli K-12 MG1655 codon-optimizedDNA gene sequence SEQ ID NO: 378 Cas3-NLS, HsCO I-E_Escherichia Homosapiens coli K-12 MG1655 codon-optimized DNA gene sequence SEQ ID NO:379 CRISPR(Hsa07) I-E_Escherichia Homo sapiens coli K-12 MG1655codon-optimized DNA gene sequence

In order to express components of the Cascade complex on fewerexpression vectors, polycistronic expression vectors can be constructed,whereby a single promoter (e.g., CMV promoter) drives expression ofmultiple coding sequence simultaneously that are separated by a Thoseaasigna virus 2A sequence. 2A viral peptide sequences induce ribosomalskipping, thus enabling multiple protein-coding genes to be concatenatedwithin a single polycistronic construct for expression in eukaryoticcells. Thus, polycistronic vectors can be designed that encode 4 or 5subunits of the Cascade complex on a single transcript driven by asingle promoter. Table 7 contains the sequences of eukaryoticpolycistronic expression plasmids that can be combined with a CRISPR RNAexpression plasmid to produce functional Cascade in mammalian cells.

TABLE 7 Vectors for Production of Cascade Effector Complexes Effectorcomplex SEQ ID NO: Description species of origin Type of sequence SEQ IDNO: 380 Polycistronic(HsCO), NLS- I-E_Escherichia Homo sapiensCas7_NLS-Cse2_NLS- coli K-12 MG1655 codon-optimized Cas5_NLS-Cas6 DNAgene sequence SEQ ID NO: 381 Polycistronic(HsCO), NLS- I-E_EscherichiaHomo sapiens Cas7_NLS-Cse2_NLS- coli K-12 MG1655 codon-optimizedCas5_NLS-Cas6_NLS-Cas8 DNA gene sequence SEQ ID NO: 382Polycistronic(HsCO), NLS- I-E_Escherichia Homo sapiensCas7_NLS-Cse2_NLS- coli K-12 MG1655 codon-optimizedCas5_NLS-Cas6_NLS-FokI- DNA gene sequence 30aa-Cas8 SEQ ID NO: 383Polycistronic(HsCO), NLS- I-E_Escherichia Homo sapiensCas7_NLS-Cse2_NLS- coli K-12 MG1655 codon-optimizedCas5_NLS-Cas6_NLS-FokI- DNA gene sequence 30aa-Cas8, no epitope tags SEQID NO: 384 Polycistronic(HsCO), NLS- I-E_Escherichia Homo sapiensCas7_NLS-Cse2_NLS- coli K-12 MG1655 codon-optimized Cas5_NLS-FokI-30aa-DNA gene sequence Cas6_NLS-Cas8, no epitope tags

In some embodiments, the CRISPR RNA is encoded within the 3′untranslated region (UTR) of a protein-coding gene, whose expression isdriven by a RNA Polymerase II promoter (e.g., CMV promoter) to produce atranscript. In such embodiments, the minimal CRISPR array is designed toexist downstream of a protein coding gene such as Cash, Cas7, or areporter gene (e.g., an enhanced green fluorescent protein, eGFP), andis separated from the protein coding sequence by a MALAT1 triplexsequence that has previously been shown to confer stability to theupstream transcript. The minimal CRISPR array is processed by the RNAprocessing subunit of Cascade (typically expressed using a differentplasmid), an endonuclease that cleaves the minimal CRISPR array, and abreak is introduced into the transcript, and the triplex sequenceprotects the 3′ end of the upstream protein-coding gene from prematureexonucleolytic degradation. Table 8 contains sequences of threepolynucleotide sequences, whereby the CRISPR array is cloned downstreamof either Cash, Cas7, or eGFP, and expression of the entire fusionsequence is driven by a CMV promoter.

TABLE 8 Vectors for Production of Minimal CRISPR Arrays Effector complexSEQ ID NO: Description species of origin Type of sequence SEQ ID NO: 385eGFP_MALAT1- I-E_Escherichia Homo sapiens triplex_CRISPR coli K-12MG1655 codon-optimized (Hsa07) DNA gene sequence SEQ ID NO: 386 NLS-I-E_Escherichia Homo sapiens Cas7_MALAT1- coli K-12 MG1655codon-optimized triplex_CRISPR DNA gene sequence (Hsa07) SEQ ID NO: 387NLS- I-E_Escherichia Homo sapiens Cas6_MALAT1- coli K-12 MG1655codon-optimized triplex_CRISPR DNA gene sequence (Hsa07)

In some embodiments, the CRISPR RNA array is encoded on the same vectoras the polycistronic construct driving expression of the 5 Cascadesubunits; the combination of these two elements generates an all-in-onevector that produces all functional subunits (both protein and RNA) ofthe Cascade complex, together with any nuclease or effector domainsfused to one of the Cascade subunits. Table 9 contains tworepresentative sequences of these all-in-one polynucleotide sequencesthat encode all the respective components to produce functionalFokI-Cascade RNPs in mammalian cells.

TABLE 9 Vectors for Production of Cascade Effector Complexes Effectorcomplex SEQ ID NO: Description species of origin Type of sequence SEQ IDNO: 388 hU6_CRISPR(Hsa07)_F, I-E_Escherichia Homo sapiensCMV_NLS-Cas7_NLS-Cse2_NLS- coli K-12 MG1655 codon-optimizedCas5_NLS-Cas6_NLS-FokI-30aa- DNA gene sequence Cas8 SEQ ID NO: 389hU6_CRISPR(Hsa07)_R, I-E_Escherichia Homo sapiensCMV_NLS-Cas7_NLS-Cse2_NLS- coli K-12 MG1655 codon-optimizedCas5_NLS-Cas6_NLS-FokI-30aa- DNA gene sequence Cas8

Example 3 describes expression systems using separate plasmidsexpressing each Cascade subunit protein and minimal CRISPR array,expression systems wherein multiple Cascade subunit protein codingsequences are expressed from a single promoter, and an expression systemwherein a single plasmid Cascade expression system was constructed toexpress the entire Cas8-Cse2-Cas7-Cas5-Cash operon and a minimal CRISPRarray for use in mammalian cells.

One of ordinary skill in the art following the guidance of the presentSpecification can design additional mammalian expression vectorsencoding other Cascade complexes analogously to the examples providedthe E. coli Type I-E Cascade complex.

In a fourth aspect, the present invention relates to production ofengineered Type I CRISPR-Cas effector complexes by introduction ofplasmids encoding one or more components of the engineered Type ICRISPR-Cas effector complexes into host cells. Transformed host cells(or recombinant cells) or the progeny of cells that have beentransformed or transfected using recombinant DNA techniques can compriseone or more nucleic acid sequences encoding one or more component of anengineered Type I CRISPR-Cas effector complex. Methods of introducingpolynucleotides (e.g., an expression vector) into host cells are knownin the art and are typically selected based on the kind of host cell.Such methods include, for example, viral or bacteriophage infection,transfection, conjugation, electroporation, calcium phosphateprecipitation, polyethyleneimine-mediated transfection, DEAE-dextranmediated transfection, protoplast fusion, lipofection, liposome-mediatedtransfection, particle gun technology, microprojectile bombardment,direct microinjection, and nanoparticle-mediated delivery. In oneembodiment of the present invention, polynucleotides encoding componentsof engineered Type I CRISPR-Cas effector complexes are introduced intobacterial cells (e.g., E. coli).

Example 4 describes a method for introduction and expression of Cas8protein coding sequences, as well as coding sequences for components ofengineered Type I CRISPR-Cas effector complexes for bacterial productionof such complexes using E. coli expression systems.

A variety of exemplary host cells disclosed herein can be used toproduce recombinant cells using an engineered Cascade effector complex.Such host cells include, but are not limited to, a plant cell, a yeastcell, a bacterial cell, an insect cell, an algal cell, and a mammaliancell.

For ease of discussion, “transfection” is used below to refer to anymethod of introducing polynucleotides into a host cell.

In some embodiments, a host cell is transiently or non-transientlytransfected with nucleic acid sequences encoding one or more componentof a Type I CRISPR-Cas effector complex. In some embodiments, a cell istransfected as it naturally occurs in a subject. In some embodiments, acell that is transfected is first removed from a subject, e.g., aprimary cell or progenitor cell. In some embodiments, the primary cellor progenitor cell is cultured and/or is returned after ex vivotransfection to the same subject or to a different subject.

Example 9 illustrates the design and delivery of E. coli Type I-ECascade complexes comprising FokI fusion proteins to facilitate genomeediting in human cells. The Example describes the delivery of plasmidvectors expressing Cascade complex components into eukaryotic cells.

In a fifth aspect, the present invention relates to the purification ofengineered Type I CRISPR-Cas effector complexes from cells and uses ofsuch complexes. Engineered Type I CRISPR-Cas effector complexes areproduced in a host cell. The engineered Type I CRISPR-Cas effectorcomplexes (in this case Cascade ribonucleoprotein (RNP) complexes) arepurified from cell lysates.

Example 5 describes purification of E. coli Type I-E Cascade RNPcomplexes produced by overexpression in bacteria as described in Example4. The method uses immobilized metal affinity chromatography followed bysize exclusion chromatography. The Example also describes methods thatcan be used to assess the quality of purified Cascade RNP products.Examples are presented illustrating the purification of Cas8, Cas7,Cas6, Cas5, and Cse2 Cascade RNP complexes, Cascade complexes comprisingCas7, Cas6, Cas5, and Cse2 proteins, and FokI-Cas8 fusion proteins.

The purified, engineered Type I CRISPR-Cas effector complexes can alsobe used directly in biochemical assays (e.g., binding and/or cleavageassays). Example 6 describes production of dsDNA target sequences foruse in in vitro DNA binding or cleavage assays. The Example describesthree methods to produce target sequences, including annealing ofsynthetic ssDNA oligonucleotides, PCR amplification of selected nucleicacid target sequences from genomic DNA, as well as cloning of nucleicacid target sequences into bacterial plasmids. The dsDNA targetsequences were used in Cascade binding or cleavage assays.

The site-specific binding of and/or cutting by one or more engineeredType I CRISPR-Cas effector complexes can be confirmed, if necessary,using an electrophoretic mobility shift assay (see, e.g., Garner, M., etal., Nucleic Acids Research 9(13):3047-3060 (1981); Fried, M., et al.,Nucleic Acids Research 9(23):6505-6525 (1981); Fried, M.,Electrophoresis 10:366-376 (1989); Gagnon, K., et al., Methods MolecularBiology 703:275-2791 (2011); Fillebeen, C., et al., J. Vis. Exp. (94),e52230, doi:10.3791/52230 (2014)), or the biochemical cleavage assaydescribed in Example 7.

The data presented in Example 7 demonstrate that engineered Type ICRISPR-Cas effector complexes can exhibited nearly quantitative DNAcleavage, as evidenced by conversion of a supercoiled, circular plasmidsubstrate into a cleaved, linear form.

In another embodiment, the complexes are introduced directly into acell, as an alternative to expressing one or more nucleic acid sequencesencoding one or more components of engineered Type I CRISPR-Cas effectorcomplexes in a cell. The purified, engineered Type I CRISPR-Cas effectorcomplexes can be directly introduced into cells. Methods to introducethe components into a cell include electroporation, lipofection,particle gun technology, and microprojectile bombardment.

Example 8 illustrates the design and delivery of E. coli Type I-ECascade complexes comprising Cas subunit protein-FokI fusion proteins tohuman cells. The data in the Example demonstrate delivery ofpre-assembled Cascade RNPs into target cells and effective genomeediting in human cells.

In some embodiments, the engineered Type I CRISPR-Cas effector complexesdescribed herein can be used to generate non-human transgenic organismsby site specifically introducing a selected polynucleotide sequence(e.g., a portion of a donor polynucleotide) at a DNA target locus in thegenome to generate a modification of the genomic DNA. The transgenicorganism can be an animal or a plant.

A transgenic animal is typically generated by introducing engineeredType I CRISPR-Cas effector complexes into a zygote cell. A basictechnique, described with reference to making transgenic mice (see,e.g., Cho, A., et al., “Generation of Transgenic Mice,” CurrentProtocols in Cell Biology, CHAPTER.Unit-19.11 (2009)) involves fivebasic steps: first, preparation of a system, as described herein,including a suitable donor polynucleotide; second, harvesting of donorzygotes; third, microinjection of the system into the mouse zygote;fourth, implantation of microinjected zygotes into pseudo-pregnantrecipient mice; and fifth, performing genotyping and analysis of themodification of the genomic DNA established in founder mice. The foundermice will pass the genetic modification to any progeny. The founder miceare typically heterozygous for the transgene. Mating between these micewill produce mice that are homozygous for the transgene 25% of the time.

Methods for generating transgenic plants are also well known and can beapplied using engineered 1 Type I CRISPR-Cas effector complexes. Agenerated transgenic plant, for example using Agrobacterium-mediatedtransformation, typically contains one transgene inserted into onechromosome. It is possible to produce a transgenic plant that ishomozygous with respect to a transgene by sexually mating (i.e.,selfing) an independent segregant transgenic plant containing a singletransgene to itself. Typical zygosity assays include, but are notlimited to, single nucleotide polymorphism assays and thermalamplification assays that distinguish between homozygotes andheterozygotes.

In a sixth aspect, the present invention relates to use of engineeredType I CRISPR-Cas effector complexes to create substrate channels. Insome embodiments, fusion proteins comprising substrate channel elementsand Cas7 subunit proteins are constructed. These Cas7 fusion proteinsare then assembled into an engineered Type I CRISPR-Cas effector complex(e.g., comprising Cse2, Cas5, Cas6, Cas7-substrate channel elementfusions, and Cas8). In some embodiments, the crRNA of the engineeredType I CRISPR-Cas effector complex can be extended to accommodateadditional Cas7 subunits (Luo, M., et al., Nucleic Acids Research44:7385-7394 (2016)). Different substrate elements can be fused to Cas7and then mixed at the desired stoichiometry. When these various Cas7subunits assemble into a complete Type I CRISPR-Cas effector complex,co-localization of substrate elements can improve the efficacy ofsubstrate channeling.

In some embodiments, an RNA scaffold is constructed such that multipleCas7-substrate channel element fusions can bind to it in the absence ofother Type I CRISPR-Cas effector complex components.

Substrate channel elements can be fused to the N-terminus of Cas7 and/orthe C-terminus of Cas7. In addition, circular permutations of Cas7 canbe fused to substrate channel elements.

FIG. 12A and FIG. 12B presents illustrations of substrate channelsconsisting of three consecutive enzymes in a pathway. Substrate channelsfacilitate the passing of intermediary metabolic products directly tothe active site of the consecutive enzyme in the metabolic pathway chainwithout release into the extra channel space. FIG. 12A illustrates atypical arrangement of an engineered substrate channel. Enzymes E1, E2,and E3 are linked covalently or non-covalently to a scaffold protein(S1, S2, S3) matrix. The substrate is then processed to the productwithout release to the extra channel space. FIG. 12B illustrates oneembodiment of the present invention comprising a modified Type ICRISPR-Cas effector complex that carries Enzymes E1, E2, and E3 asfusion proteins to Cas7 subunit proteins, thus creating a substratechannel. cpCas7 proteins and backbones formed of cpCas7 proteins canalso be useful in the practice of this aspect of the present invention.

In other embodiments, substrate channel elements can be fused to Cas6.The Cas6 subunit of Cascade complexes recognizes specific RNA hairpinstructures. An RNA scaffold can be constructed that is composed ofmultiple Cas6 RNA hairpin structures concatenated together. Cas6peptides from different Cascade complexes have different recognitionsequences. Accordingly, RNA scaffolds can be constructed from multipleorthogonal Cas6 RNA hairpins. By fusing different substrate channelelements to orthogonal Cas6 peptides, substrate channel complexes can beassembled in specific stoichiometry.

Substrate channel elements can be fused to the N-terminus of Cas6 and/orthe C-terminus of Cas6. In addition, circular permutations of Cas6 canbe fused to substrate channel elements.

In some embodiments, a heterologous metabolic pathway of interest can beexpressed in a model organism, such as E. coli. When genes areheterologously expressed, the genes can be codon optimized to expressthe genes more efficiently.

In one embodiment, the metabolic pathway of interest is the mevalonatepathway from Saccharomyces cerevisiae. Substrate channel elements ofthis pathway include, but are not limited to, acetoacetyl-CoA-thioase(AtoB), hydroxy-methylglutaryl-CoA synthase (HMGS), andhydroxy-methylglutaryl-CoA reductase (HMGR).

In another embodiment, the metabolic pathway of interest is the glycerolsynthesis pathway from S. cerevisiae. Substrate channel elements of thispathway include, but are not limited to, glycerol-3-phosphatedehydrogenase (GPD1) and glycerol-3-phosphate phosphatase (GPP2).

In yet another embodiment, the metabolic pathway of interest is thestarch hydrolysis pathway from Clostridium stercorarium. Substratechannel elements of this pathway include, but are not limited to, CelYand CelZ.

In an additional embodiment, the metabolic pathway of interest is theglucose phosphotransferase pathway from E. coli. Substrate channelelements of this pathway include, but are not limited to,trehalose-6-phosphate synthetase (TPS) and trehalose-6-phosphatephosphatase (TPP).

In a seventh aspect, the present invention relates to site-directedrecruitment of functional domains fused to Cascade subunit proteins bycomplexes comprising a Class 2 Type II Cas9 protein and a nucleicacid-targeting nucleic acid (NATNA; see e.g., U.S. Pat. No. 9,260,752,issued 16 Feb. 2016; U.S. Pat. No. 9,580,727, issued 28 Feb. 2017; U.S.Pat. No. 9,677,090, issued 13 Jun. 2017; U.S. Pat. No. 9,771,600, issued26 Sep. 2017; U.S. Pat. No. 9,816,093, issued 14 Nov. 2017). Functionaldomains are disclosed herein and include, but are not limited to,protein domains having enzymatic function, capable of transcriptionalactivation, or capable of transcriptional repression. Example 13describes a method of modifying a Class 2 Type II CRISPR sgRNA, crRNA,tracrRNA, or crRNA and tracrRNA sequences with a Class 1 Type I CRISPRrepeat stem sequence, allowing for the recruitment of one or moreCascade subunit proteins to a Type II CRISPR Cas protein/guide RNAcomplex binding site.

FIG. 13A, FIG. 13B, and FIG. 13C present a generalized illustration ofthe site-directed recruitment of a functional protein domain fused to aCascade subunit protein by a dCas9:NATNA complex to a target site. AClass 2 Type II CRISPR NATNA (FIG. 13A, 102) comprising a spacersequence (FIG. 13A, 101) is covalently linked through a linker nucleicacid sequence (FIG. 13A, 103) to a Class 1 Type I CRISPR repeat stemsequence (FIG. 13A, 104). The Type II CRISRP NATNA covalently linked tothe Type I CRISPR repeat stem sequence (FIG. 13A, 105) is capable ofbinding to a Type II dCas9 (FIG. 13A, 106) and a Type I Cascade subunitprotein (e.g., Cas6; FIG. 13A, 107) which is fused though a linkersequence (FIG. 13A, 108) to a functional protein domain (e.g., anenzymatic domain, a transcriptional activation or repression domain;FIG. 13A, 109) to form an RNP complex. This RNP complex (FIG. 13B, 110)is capable of targeting a double-stranded DNA (FIG. 13B, 111) comprisinga target sequence (FIG. 13B, 112) complementary to the Type II CRISPRNATNA spacer sequence (FIG. 13A, 101). Target recognition by the RNPcomplex results in hybridization (FIG. 13B, 113) between the spacersequence (FIG. 13A, 101) and the target sequence (FIG. 13B, 112).Localization of the Cascade subunit-functional domain fusion protein tothe DNA allows for modification of the DNA by the functional proteindomain or transcriptional regulation of an adjacent gene (FIG. 13C,114).

In an eighth aspect, the present invention relates to compositionscomprising engineered Type I CRISPR-Cas effector complexes, modifiedguide polynucleotides, and combinations thereof. In some embodiments,the engineered Type I CRISPR-Cas effector complex comprises anassociated Cas3 fusion protein.

An embodiment of this aspect of the present invention relates to acomposition comprising two engineered Type I CRISPR-Cas effectorcomplexes each comprising a spacer and a fusion protein comprising a Cassubunit and an endonuclease (e.g., a FokI; see e.g., the Cascadecomplexes of FIG. 2A, FIG. 2B, and FIG. 2C), wherein at least twoparameters are varied to modulate genome editing efficiency. Suchparameters include:

the length of a linker polypeptide used to produce the fusion proteincomprising a Cas subunit protein and the endonuclease (e.g., FokI); and

the length of the interspacer distance between the nucleic acid targetsequences to which the spacers are capable of binding.

Guidance is provided herein regarding the amino acid composition andsequence linker polypeptides.

One embodiment of this aspect of the present invention is a compositioncomprising:

a first engineered Type I CRISPR-Cas effector complex comprising,

a first Cse2 subunit protein, a first Cas5 subunit protein, a first Cas6subunit protein, and a first Cas7 subunit protein,

a first fusion protein comprising a first Cas8 subunit protein and afirst FokI, wherein the N-terminus of the first Cas8 subunit protein orthe C-terminus of the first Cas8 subunit protein is covalently connectedby a first linker polypeptide to the C-terminus or N-terminus,respectively, of the first FokI, and wherein the first linkerpolypeptide has a length of between 10 amino acids to 40 amino acids,and

a first guide polynucleotide comprising a first spacer capable ofbinding a first nucleic acid target sequence; and

a second engineered Type I CRISPR-Cas effector complex comprising,

a second Cse2 subunit protein, a second Cas5 subunit protein, a secondCas6 subunit protein, and a second Cas7 subunit protein,

a second fusion protein comprising a second Cas8 subunit protein and asecond FokI, wherein the N-terminus of the second Cas8 subunit proteinor the C-terminus of the second Cas8 protein is covalently connected bya second linker polypeptide to the C-terminus or N-terminus,respectively, of the second FokI, and wherein the second linkerpolypeptide has a length of between 10 amino acids to 40 amino acids,and

a second guide polynucleotide comprising a second spacer capable ofbinding a second nucleic acid target sequence, wherein a protospaceradjacent motif (PAM) of the second nucleic acid target sequence and aPAM of the first nucleic acid target sequence have an interspacerdistance between 20 bp 42 bp.

Examples of such a first engineered Type I CRISPR-Cas effector complexbound to a first nucleic acid target sequence and a second engineeredType I CRISPR-Cas effector complex bound to a second nucleic acid targetsequence are illustrated in FIG. 2A, FIG. 2B, and FIG. 2C.

In some embodiments, the length of the first linker polypeptide and/orthe second linker polypeptide is a length of between about 15 aminoacids and about 30 amino acids, or between about 17 amino acids andabout 20 amino acids. In one embodiment, the length of the first linkerpolypeptide and the second linker polypeptide are the same.

The first Cas8 subunit protein and the second Cas8 subunit protein caneach comprise identical amino acid sequences of the Cas8 subunitprotein.

Similarly, the first Cse2 subunit protein and the second Cse2 subunitprotein can each comprise identical amino acid sequences of the Cse2subunit protein, the first Cas5 subunit protein and the second Cas5subunit protein can each comprise identical amino acid sequences of theCas5 subunit protein, the first Cas6 subunit protein and the second Cas6subunit protein can each comprise identical amino acid sequences of theCas6 subunit protein, the first Cas7 subunit protein and the second Cas7subunit protein can each comprise identical amino acid sequences of theCas7 subunit protein, and combinations thereof.

Typically, the N-terminus of the first Cas8 subunit protein iscovalently connected by the first linker polypeptide to the C-terminusof the first FokI, the C-terminus of the first Cas8 subunit protein iscovalently connected by a first linker polypeptide to the N-terminus ofthe first FokI, the N-terminus of the second Cas8 subunit protein iscovalently connected by the second linker polypeptide to the C-terminusof the second FokI, the C-terminus of the second Cas8 subunit protein iscovalently connected by a second linker polypeptide to the N-terminus ofthe second FokI, and combinations thereof.

Embodiments of this aspect of the present invention include embodimentswherein the length between the second nucleic acid target sequence andthe first nucleic acid target sequence is an interspacer distancebetween about 22 bp to about 40 bp, between about 26 bp to about 36 bp,between about 29 bp to about 35 bp, or between about 30 bp to about 34bp.

The first FokI and the second FokI can be monomeric subunits that arecapable of associating to form a homodimer, or distinct subunits thatare capable of associating to form a heterodimer.

In a preferred embodiment, the guide polynucleotides comprise RNA.

In some embodiments, genomic DNA comprises the PAM of the second nucleicacid target sequence and the PAM of the first nucleic acid targetsequence.

In some embodiments, the engineered Type I CRISPR-Cas effector complexesare based on Type I CRISPR-Cas effector complexes of one or moreorganisms selected from the group consisting of Salmonella enterica,Geothermobacter sp. EPR-M, Methanocella arvoryzae MRE50, Streptococcusthermophilus (strain ND07)), S. thermophilus, Pseudomonas sp. S-6-2 andE. coli. In preferred embodiments, the engineered Type I CRISPR-Caseffector complexes are based on Type I CRISPR-Cas effector complexes ofS. thermophilus, Pseudomonas sp. S-6-2, and/or E. coli.

The data presented in Example 18 and Example 20 demonstrate that varyingthe length of the linker polypeptide used to produce the fusion proteincomprising the Cas subunit protein and the FokI and/or varying thelength of the interspacer distance between the nucleic acid targetsequences to which the spacers are capable of binding facilitatemodulation of genome editing efficiency in cells.

In yet another embodiment, the present invention relates to anengineered Type I CRISPR-Cas effector complex comprising a first fusionprotein that comprises a Cascade subunit protein (e.g., a Cas8 subunitprotein) and a first functional domain (e.g., FokI), and a second fusionprotein that comprises a dCas3* protein and a second functional domain(e.g., FokI). The engineered Type I CRISPR-Cas effector complexcomprising the first functional domain (e.g., FokI) (FIG. 14A,Cas8-linker1-FP1 fusion) can bind DNA and can then recruit thedCas3*-second functional domain (e.g., FokI) fusion protein (FIG. 14A,dCas3*-linker2-FP2). In the case where the first functional domain (FIG.14A, Cas8-linker1-FP1 fusion) and the second functional domain (FIG.14A, dCas3*-linker2-FP2) comprise subunits of a dimeric protein, thedCas3*-second functional domain (e.g., FokI) fusion protein binds theengineered Type I CRISPR-Cas effector complex comprising the firstfunctional domain (e.g., FokI) facilitating dimerization of the firstfunctional domain and the second functional domain (FIG. 14A). FIG. 15Aillustrates the binding to dsDNA of an engineered Type I CRISPR-Caseffector complex (FIG. 15A, Cascade) comprising the first functionaldomain (FIG. 15A, FD1) connected to a Cas subunit protein (FIG. 15A,striped box) via a linker polypeptide (FIG. 15A, Linker 1) and a dCas3*connected to a second functional domain (FIG. 15A, FD2) via a linkerpolypeptide (FIG. 15A, Linker 2) associated with the Cascade complex;thus bringing FD1 and FD2 into proximity and facilitating theinteraction of FD1 and FD2. Binding of the Cascade complex involves asingle PAM sequence (FIG. 15A, PAM, open box). In the case of thefunctional domain being a dimeric endonuclease (e.g., FokI), theproximity of FD1 and FD2 facilitates formation of a functional dimer.

One advantage of this embodiment of the present invention is a singleCascade complex (recognizing a single PAM sequence) can be used tocleave a double-stranded nucleic acid target sequence, versus using twoFokI-Cascade complexes (FIG. 15A compare FIG. 2A, FIG. 2B, and FIG. 2C).Using two FokI-Cascade complexes requires two PAM sequences in theproper orientation (FIG. 2A, FIG. 2B, and FIG. 2C), which can limitselection of proximal nucleic acid target sequences.

The length and/or composition of the linker polypeptide used to producethe fusion protein comprising a Cas subunit protein and an endonuclease(e.g., FokI), as well as the length and/or composition of the linkerpolypeptide used to produce the fusion protein comprising adCas3*protein and an endonuclease can be varied to modulate genomeediting efficiency. Example 21 describes the design and testing ofmultiple Cas3-FokI linker compositions and lengths and FokI-Cas8 linkercompositions and lengths for modulation of genome editing efficiency.

Another embodiment of this aspect of the invention comprises anengineered Type I CRISPR-Cas effector complex and a fusion proteincomprising a dCas3*protein and a functional domain (e.g., cytidinedeaminase) connected by a linker polypeptide (FIG. 14B, dCas3*, Linker,and FP). The engineered Type I CRISPR-Cas effector complex can bind DNAand recruit the dCas3*-functional domain (e.g., cytidine deaminase)fusion protein. This embodiment can facilitate site-specific targetingof a nucleic acid target sequence for modification by, or interactionwith, a functional domain. In the case of cytidine deaminase, anengineered Type I CRISPR-Cas effector complex and a fusion protein thatcomprises a dCas3* protein and cytidine deaminase can be used forsite-specific base editing in a nucleic acid target sequence. FIG. 15Billustrates an example of an engineered Type I CRISPR-Cas effectorcomplex (FIG. 15B, Cascade) comprising a fusion protein comprising adCas3* protein (FIG. 15B, dCas3*) connected with a functional domain(FIG. 15B, FD) via a linker polypeptide (FIG. 15B, Linker), wherein thecomplex is bound to dsDNA. In FIG. 15B, contact of the functional domainwith dsDNA is facilitated. FIG. 15C illustrates another example of anengineered Type I CRISPR-Cas effector complex (FIG. 15C, Cascade)comprising a fusion protein comprising a dCas3* protein (FIG. 15C,dCas3*) connected with a functional domain (FIG. 15C, FD) via a linkerpolypeptide (FIG. 15C, Linker), wherein the complex is bound to dsDNA.In FIG. 15C, contact of the functional domain with ssDNA is facilitated.

Some embodiments of the invention can use an engineered Type ICRISPR-Cas effector complex and mutant form of Cas3 lacking ATPaseand/or helicase activity (e.g., the Cas3 can be a nickase). Theengineered Type I CRISPR-Cas effector complexes can bind DNA and thenrecruit the ATPase or helicase mutant form of Cas3. This embodiment canfacilitate site-specific cleavage of genomic DNA by a mutant form ofCas3.

Additional functional domains and proteins that can be used to constructfusion proteins with Type I CRISPR-Cas subunit proteins are described inthe present Specification and Examples. Linker polypeptide compositionsand lengths for Cas3-linker polypeptide-functional domain fusionproteins can be evaluated following the guidance of Example 21 and thepresent Specification to evaluate effects on the performance of thefunctional domain.

In a ninth aspect, the present invention relates to methods of usingengineered Type I CRISPR-Cas effector complexes.

In one embodiment, the present invention includes a method of binding anucleic acid target sequence in a polynucleotide (e.g., dsDNA)comprising providing one or more engineered Type I CRISPR-Cas effectorcomplexes for introduction into a cell or a biochemical reaction andintroducing the engineered Type I CRISPR-Cas effector complex(es) intothe cell or biochemical reaction, thereby facilitating contact of theengineered Type I CRISPR-Cas effector complex(es) with thepolynucleotide. In one embodiment, a first engineered Type I CRISPR-Caseffector complex comprises a guide complementary to a first nucleic acidtarget sequence in the polynucleotide and a second engineered Type ICRISPR-Cas effector complex comprises a guide complementary to a secondnucleic acid target sequence in the polynucleotide. In anotherembodiment, an engineered Type I CRISPR-Cas effector complex comprises aguide complementary to a nucleic acid target sequence in thepolynucleotide and further comprises a dCas3*fusion protein capable ofassociating with the complex. Contact of the complex(es) with thepolynucleotide results in binding of the engineered Type I CRISPR-Caseffector complex(es) to the nucleic acid target sequence(s) in thepolynucleotide. In one embodiment, a first engineered 1 Type ICRISPR-Cas effector complex binds to a first nucleic acid targetsequence and a second engineered Type I CRISPR-Cas effector complexbinds to a second nucleic acid target sequence in the polynucleotide. Inanother embodiment, an engineered Type I CRISPR-Cas effector complexbinds to a nucleic acid target sequence in the polynucleotide, and theeffector complex comprises a dCas3*fusion protein associated with thecomplex.

Such methods of binding a nucleic acid target sequence can be carriedout in vitro (e.g., in a biochemical reaction or in cultured cells; insome embodiments, the cultured cells are human cultured cells thatremain in culture and are not introduced into a human); in vivo (e.g.,in cells of a living organism, with the proviso that, in someembodiments, the organism is a non-human organism); or ex vivo (e.g.,cells removed from a subject, with the proviso that, in someembodiments, the subject is a non-human subject).

A variety of methods are known in the art to evaluate and/or quantitateinteractions between nucleic acid sequences and polypeptides including,but not limited to, the following: immunoprecipitation (ChIP) assays,DNA electrophoretic mobility shift assays (EMSA), DNA pull-down assays,and microplate capture and detection assays. Commercial kits, materials,and reagents are available to practice many of these methods and, forexample, can be obtained from the following suppliers: Thermo Scientific(Wilmington, Del.), Signosis (Santa Clara, Calif.), Bio-Rad (Hercules,Calif.), and Promega (Madison, Wis.). A common approach to detectinteractions between a polypeptide and a nucleic acid sequence is EMSA(see, e.g., Hellman L. M., et al., Nature Protocols 2(8):1849-1861(2007)).

In another embodiment, the present invention includes a method ofcutting a nucleic acid target sequence in a polynucleotide (e.g., asingle-strand cut in dsDNA or double-strand cut in dsDNA) comprisingproviding one or more engineered Type I CRISPR-Cas effector complexesfor introduction into a cell or biochemical reaction, and introducingthe engineered Type I CRISPR-Cas effector complex(es) into the cell orbiochemical reaction, thereby facilitating contact of the engineeredType I CRISPR-Cas effector complex(es) with the polynucleotide. In oneembodiment, a first engineered Type I CRISPR-Cas effector complexcomprising a guide complementary to a first nucleic acid target sequencein the polynucleotide and a first nuclease domain (e.g., FokI) (FIG.16A, Cascade1), and a second engineered Type I CRISPR-Cas effectorcomplex comprising a guide complementary to a second nucleic acid targetsequence in the polynucleotide and a second nuclease domain (e.g., FokI)(FIG. 16A, Cascade 2) are introduced into the cell or biochemicalreaction. In another embodiment, an engineered Type I CRISPR-Caseffector complex comprising a guide complementary to a nucleic acidtarget sequence in the polynucleotide and a first nuclease domain (e.g.,FokI) (FIG. 17A, Cascade), and a dCas3*-second nuclease domain (e.g.,FokI) fusion protein (FIG. 17A, dCas3) capable of associating with thecomplex are introduced into the cell or biochemical reaction. Thecontacting results in cutting of the nucleic acid target sequence(s) inthe polynucleotide (e.g., a dsDNA) by the engineered Type I CRISPR-Caseffector complex(es). In one embodiment, the first engineered 1 Type ICRISPR-Cas effector complex binds to the first nucleic acid targetsequence in dsDNA (FIG. 16B, Cascade1) and cleaves the first strand of adsDNA (FIG. 16C, Cascade1), and the second engineered Type I CRISPR-Caseffector complex binds to the second nucleic acid target sequence indsDNA (FIG. 16B, Cascade2) and cleaves the second strand of a dsDNA(FIG. 16C, Cascade2). In another embodiment, the engineered Type ICRISPR-Cas effector complex binds to a nucleic acid target sequence indsDNA (FIG. 17B, Cascade) and cleaves the first strand of a dsDNA (FIG.17C, Cascade), and the dCas3*fusion protein associates with the complex(FIG. 17B, dCas3*) and cleaves the second strand of the dsDNA (FIG. 17C,dCas3*).

In an additional embodiment of the method of cutting a nucleic acidtarget sequence in a polynucleotide, a donor polynucleotide can also beintroduced into a cell to facilitate incorporation of at least a portionof the donor polynucleotide into genomic DNA of the cell. FIG. 18Aillustrates an example of both strands of a dsDNA being cleaved by afirst engineered Type I CRISPR-Cas effector complex comprising a guidecomplementary to a first nucleic acid target sequence in thepolynucleotide and a first nuclease domain (e.g., FokI) (FIG. 18A,Cascade1), and a second engineered Type I CRISPR-Cas effector complexcomprising a guide complementary to a second nucleic acid targetsequence in the polynucleotide and a second nuclease domain (e.g., FokI)(FIG. 18A, Cascade 2). FIG. 18B illustrates a donor polynucleotidecomprising homology arms complementary to DNA sequences adjacent thedouble-strand cut site (FIG. 18B, Donor, dashed lines). FIG. 18Cillustrates incorporation of a portion of the donor polynucleotide (FIG.18C dashed lines) at the double-strand cut site. Incorporation of thedonor polynucleotide is mediated by cellular DNA repair mechanisms(e.g., homology-directed repair).

In other embodiments, an engineered Type I CRISPR-Cas effector complexcomprising a guide complementary to a first nucleic acid target sequencein a polynucleotide and a first nuclease domain can be paired with asecond component comprising a second nuclease domain, wherein the secondcomponent is capable of binding to a second nucleic acid target sequencein the polynucleotide. Examples of such second components include, atranscription activator-like effector nuclease (TALEN) comprising thesecond nuclease domain, a zinc finger comprising the second nucleasedomain, or a dCas9/NATNA complex comprising the second nuclease domain.

In some embodiments, the nucleic acid target sequence is dsDNA (e.g.,genomic) DNA. In some embodiments, the nucleic acid target sequence isdouble-stranded and one or both of the strands is cut. Such methods ofcutting a nucleic acid target sequence can be carried out in vitro, invivo, or ex vivo.

In yet another embodiment, the present invention includes a method ofmodifying one or more nucleic acid target sequences in a polynucleotide(e.g., DNA) in a cell or biochemical reaction comprising providing oneor more engineered Type I CRISPR-Cas effector complexes (e.g.,comprising a Cas subunit protein-cytidine deaminase fusion protein) forintroduction into the cell or the biochemical reaction, and introducingthe engineered Type I CRISPR-Cas effector complex(es) into the cell orbiochemical reaction, thereby facilitating contact of the engineeredType I CRISPR-Cas effector complex(es) with the polynucleotide resultingin binding of the engineered Type I CRISPR-Cas effector complex(es) tothe nucleic acid target sequence(s) in the polynucleotide thatfacilitates modification of the nucleic acid target sequence(s) (e.g.,C-to-T, G-to-A, A-to-G, and T-to-C). FIG. 19A to FIG. 19D illustrate anexample of using a Cascade complex comprising a Cas subunitprotein-linker polypeptide-cytidine deaminase fusion protein (Cascade/CDcomplex) to modify a target nucleotide in genomic DNA of a cell. TheCascade/CD complex (FIG. 19A) is introduced into the cell. TheCascade/CD complex comprises a guide complementary to a DNA targetsequence adjacent a target cytosine (FIG. 19B, FIG. 19C). The Cascade/CDcomplex binds the DNA target sequence (FIG. 19B) and the cytidinedeaminase converts the cytosine to a uracil (FIG. 19C). Cellular repairmechanisms can then repair the uracil to a thymidine, and change themismatched guanidine to adenine (FIG. 19D).

In yet another embodiment, the present invention includes methods ofmodulating in vitro or in vivo transcription, for example, transcriptionof a gene comprising regulatory element sequences. Such methods compriseproviding one or more engineered Type I CRISPR-Cas effector complexes(e.g., comprising a Cas subunit protein-transcription factor fusionprotein) for introduction into the cell or the biochemical reaction, andintroducing the engineered Type I CRISPR-Cas effector complex(es) intothe cell or biochemical reaction, thereby facilitating contact of theengineered Type I CRISPR-Cas effector complex(es) with the regulatoryelement sequences resulting in binding of the engineered Type ICRISPR-Cas effector complex(es) to the regulatory element sequencesthereby facilitating modulating in vitro or in vivo transcription of thegene comprising the regulatory element sequences.

FIG. 20A and FIG. 20B present general illustrations of examples for thetranscriptional activation of a generic gene (“GENE1”). FIG. 20Aprovides an overview of transcriptional regulation of an endogenous genein a eukaryotic cell. In FIG. 20A, the two dark parallel lines representdouble-stranded DNA, the location of Gene 1 (FIG. 20A, GENE 1) isindicated, as well as the transcriptional start site (FIG. 20A, TSS)associated with Gene 1. In the first panel of FIG. 20A, a transcriptionfactor (FIG. 20A, TF) that is needed for the transcriptional activationof Gene 1 and polymerase II (FIG. 20A, Pol II) are illustrated as notyet associated with Gene1-TSS. The second panel illustrates associationof the TF with its cognate TSS. The TF then recruits a transcriptionactivation protein (TP) that then recruits RNA Polymerase II (Pol II).Typically, in eukaryotes the TF factor and the TP form a complexcomprising multiple proteins and possibly other molecules. The thirdpanel illustrates the resulting transcription of Gene 1 by Pol II. Thistype of transcriptional activation is typically dependent on TF(s) thatare specific to the expression of a gene(s). FIG. 20B presents anillustration of one embodiment of the present invention, wherein aCascade complex is modified with a protein or factor (FIG. 20B,CASCADEa) that attracts one or more components in the cells responsiblefor transcriptional activation (Transcriptional Activation factor; FIG.20B, TA). An example of one such protein or factor is the protein vp64.CASCADEa comprises a guide that is capable of binding at or near the TSS(FIG. 20B, TSS). In FIG. 20B, the two dark parallel lines representdouble-stranded DNA, the location of Gene 1 (FIG. 20B, GENE 1) isindicated, as well as the transcriptional start site (TSS) associatedwith Gene 1. In the first panel of FIG. 20B, CASCADEa and polymerase II(FIG. 20B, Pol II) are illustrated as not yet associated with Gene1-TSS.The second panel illustrates association of CASCADEa with its target,the TSS. The CASCADEa then recruits a transcription activation protein(FIG. 20B, TA) that then recruits RNA Polymerase II (FIG. 20B, Pol II).The third panel illustrates the resulting transcription of Gene 1 by PolII. One advantage of this embodiment of the present invention is thattranscriptional activation of a gene is not dependent on endogenoustranscription factors that bind to the TSS of the gene, rather the TSSof a gene can be targeted by selection of an appropriate Cascade guide.

FIG. 21A and FIG. 21B present a general illustration of an example forthe transcriptional repression of a generic gene (FIG. 21 A, GENE 1)using a Cascade complex comprising a Cas subunit protein-KRAB domainfusion and a guide (FIG. 21A, CASCADEi) complementary to regulatorysequences (FIG. 21A, promoter) associated with GENE 1. Binding ofCASCADEi to the regulatory sequences (FIG. 21B) results intranscriptional repression of GENE 1.

In yet another aspect, the present invention relates to using Type ICRISPR systems and Cas3 to delete nucleic acid target sequences in a 3′to 5′ manner. This method can be used to make long range deletions of aspecific length and can be useful for creation of gene knockouts.

In one embodiment, a region of a target polynucleotide (e.g., genomicDNA) can be deleted using a combination of a Cascade complex comprisinga guide complementary to a first nucleic acid target sequence in thetarget polynucleotide and a dCas9/NATNA complex wherein the NATNAcomprises a spacer sequence complementary to a second nucleic acidtarget sequence in the target polynucleotide. The first and secondnucleic acid target sequences are selected to flank the nucleic acidtarget sequence targeted for deletion. A Cas3 protein comprising anactive endonuclease activity associates with the Cascade complex andthen progressively deletes a single strand of the dsDNA comprising thenucleic acid target sequence targeted for deletion. When the Cas3protein collides with the dCas9/NATNA complex, the Cas3 nucleaseactivity can be stopped at the second nucleic acid target sequence bythe dCas9/NATNA complex. FIG. 22A to FIG. 22D illustrate an example of aCas3 deletion of a nucleic acid target sequence. FIG. 22A shows a dsDNAcomprising nucleic acid target sequence 1 (FIG. 22A, NATS1) and nucleicacid target sequence 2 (FIG. 22A, NATS2) that flank the nucleic acidtarget sequence targeted for deletion. FIG. 22A shows the Cascadecomplex comprising a guide complementary to NATS1 (FIG. 22A, Cascade),the Cas3 protein (FIG. 22A, Cas3), and the dCas9/NATNA complexcomprising a spacer complementary to NATS2 (FIG. 22A, dCas9). FIG. 22Bshows binding of the Cascade complex to NATS1, association of the Cas3protein with the Cascade complex, and binding of the dCas9/NATNA complexto NATS2. FIG. 22C illustrates the progressive deletion by Cas3 of asingle strand of the nucleic acid target sequence targeted for deletion.FIG. 22D shows the dissociation of the Cas3 protein from the dsDNA atthe position of the dCas9/NATNA complex bound to NATS2.

In another embodiment, a region of a target polynucleotide (e.g.,genomic DNA) can be deleted using a combination of a first Cascadecomplex comprising a guide complementary to a first nucleic acid targetsequence in the target polynucleotide and a second Cascade complexcomprising a guide complementary to a second nucleic acid targetsequence in the target polynucleotide. The first and second nucleic acidtarget sequences are selected to flank the nucleic acid target sequencetargeted for deletion. Cas3 proteins comprising active endonucleaseactivity associate with each Cascade complex and then progressivelydelete both strands of the nucleic acid target sequence targeted fordeletion. When each Cas3 protein collides with one of the Cascadecomplexes, the Cas3 nuclease activity can be stopped at the first andsecond nucleic acid target sequences by the Cascade complexes. FIG. 23Ato FIG. 23D illustrate an example of a Cas3 deletion of both strands ofa nucleic acid target sequence. FIG. 23A shows a dsDNA comprisingnucleic acid target sequence 1 (FIG. 23A, NATS1) and nucleic acid targetsequence 2 (FIG. 23A, NATS2) that flank the nucleic acid target sequencetargeted for deletion. FIG. 23A shows the first Cascade complexcomprising a guide complementary to NATS1 (FIG. 23A, Cascade1), the Cas3proteins (FIG. 23A, Cas3), and the second Cascade complex comprising aguide complementary to NATS2 (FIG. 23A, Cascade2). FIG. 23B showsbinding of the Cascade complexes to NATS1 and NATS2, as well asassociation of the Cas3 proteins with the Cascade complexes. FIG. 23Cillustrates the progressive deletion by Cas3 of both strands of thenucleic acid target sequence targeted for deletion. FIG. 23D shows thedissociation of the Cas3 proteins from the dsDNA at the positions of theCascade complexes bound to NATS1 and NATS2.

The engineered Type I CRISPR-Cas effector complexes, as describedherein, can be incorporated into a kit. In some embodiments, a kitincludes a package with one or more containers holding the kit elements,as one or more separate compositions or, optionally if the compatibilityof the components allows, as admixture. In some embodiments, a kit alsocomprises one or more of the following excipients: a buffer, a bufferingagent, a salt, a sterile aqueous solution, a preservative, andcombinations thereof. Illustrative kits can comprise one or moreengineered Type I CRISPR-Cas effector complexes and one or moreexcipients, or one or more nucleic acid sequences encoding one or morecomponents of engineered Type I CRISPR-Cas effector complexes.

Furthermore, kits can further comprise instructions for using engineeredType I CRISPR-Cas effector complex compositions.

Another aspect of the invention relates to methods of making ormanufacturing one or more engineered Type I CRISPR-Cas effectorcomplexes, or components thereof. In one embodiment, a method of makingor manufacturing comprises production of engineered Type I CRISPR-Caseffector complexes in a cell and purification of the engineered Type ICRISPR-Cas effector complexes from cell lysates.

Engineered Type I CRISPR-Cas effector complex compositions can furthercomprise a detectable label, such as a moiety that can provide adetectable signal. Examples of detectable labels include, but are notlimited to, an enzyme, a radioisotope, a member of a specific bindingpair, a fluorophore (FAM), a fluorescent protein (green fluorescentprotein (GFP), red fluorescent protein, mCherry, tdTomato), a DNA or RNAaptamer together with a suitable fluorophore (enhanced GFP (eGFP),“Spinach”), a quantum dot, an antibody, and the like. A large number andvariety of suitable detectable labels are well-known to one of ordinaryskill in the art.

Cells comprising engineered Type I CRISPR-Cas effector complexes, cellsmodified through the use of engineered Type I CRISPR-Cas effectorcomplexes, or progeny of such cells can be used as pharmaceuticalcompositions formulated, for example, with a pharmaceutically acceptableexcipient. Illustrative excipients include carriers, stabilizers,diluents, dispersing agents, suspending agents, thickening agents, andthe like. The pharmaceutical compositions can facilitate administrationof engineered Type I CRISPR-Cas effector complexes to a subject.Pharmaceutical compositions can be administered in therapeuticallyeffective amounts by various forms and routes including, for example,intravenous, subcutaneous, intramuscular, oral, aerosol, parenteral,ophthalmic, and pulmonary administration.

Embodiments of the present invention include, but are not limited to,the following.

Embodiment 1. A composition comprising:

-   -   a first engineered Class 1 Type I CRISPR-Cas effector complex        comprising,        -   a first Cse2 subunit protein, a first Cas5 subunit protein,            a first Cas6 subunit protein, and a first Cas7 subunit            protein,        -   a first fusion protein comprising a first Cas8 subunit            protein and a first FokI, wherein the N-terminus of the            first Cas8 subunit protein or the C-terminus of the first            Cas8 subunit protein is covalently connected by a first            linker polypeptide to the C-terminus or N-terminus,            respectively, of the first FokI, and wherein the first            linker polypeptide has a length of between 10 amino acids to            40 amino acids, and        -   a first guide polynucleotide comprising a first spacer            capable of binding a first nucleic acid target sequence; and    -   a second engineered Class 1 Type I CRISPR-Cas effector complex        comprising,        -   a second Cse2 subunit protein, a second Cas5 subunit            protein, a second Cas6 subunit protein, and a second Cas7            subunit protein,        -   a second fusion protein comprising a second Cas8 subunit            protein and a second FokI, wherein the N-terminus of the            second Cas8 subunit protein or the C-terminus of the second            Cas8 subunit protein is covalently connected by a second            linker polypeptide to the C-terminus or N-terminus,            respectively, of the second FokI, and wherein the second            linker polypeptide has a length of between 10 amino acids to            40 amino acids, and    -   a second guide polynucleotide comprising a second spacer capable        of binding a second nucleic acid target sequence, wherein a        protospacer adjacent motif (PAM) of the second nucleic acid        target sequence and a PAM of the first nucleic acid target        sequence have an interspacer distance between 20 bp to 42 bp.

Embodiment 2. The composition of embodiment 1, wherein the first linkerpolypeptide has a length of between 15 amino acids and 30 amino acids.

Embodiment 3. The composition of embodiment 2, wherein the first linkerpolypeptide has a length of between 17 amino acids and 20 amino acids.

Embodiment 4. The composition of any one of embodiments 1-3, wherein thesecond linker polypeptide has a length of between 15 amino acids and 30amino acids.

Embodiment 5. The composition of embodiment 4, wherein the second linkerpolypeptide has a length of between 17 amino acids and 20 amino acids.

Embodiment 6. The composition of any preceding embodiment, wherein thelength of the first linker polypeptide and the second linker polypeptideare the same.

Embodiment 7. The composition of any preceding embodiment, wherein thesecond nucleic acid target sequence and the first nucleic acid targetsequence each has an interspacer distance between 22 bp to 40 bp.

Embodiment 8. The composition of embodiment 7, wherein the secondnucleic acid target sequence and the first nucleic acid target sequenceeach has an interspacer distance between 26 bp to 36 bp.

Embodiment 9. The composition of embodiment 8, wherein the secondnucleic acid target sequence and the first nucleic acid target sequenceeach has an interspacer distance between 29 bp to 35 bp.

Embodiment 10. The composition of embodiment 9, wherein the secondnucleic acid target sequence and the first nucleic acid target sequenceeach has an interspacer distance between 30 bp to 34 base bp.

Embodiment 11. The composition of any preceding embodiment, wherein thefirst FokI and the second FokI are monomeric subunits capable ofassociating to form a homodimer.

Embodiment 12. The composition of any one of embodiments 1-10, whereinthe first FokI and the second FokI are distinct monomeric subunitscapable of associating to form a heterodimer.

Embodiment 13. The composition of any preceding embodiment, wherein theN-terminus of the first Cas8 subunit protein is covalently connected bythe first linker polypeptide to the C-terminus of the first FokI.

Embodiment 14. The composition of any one of embodiments 1-12, whereinthe C-terminus of the first Cas8 subunit protein is covalently connectedby a first linker polypeptide to the N-terminus of the first FokI.

Embodiment 15. The composition of any preceding embodiment, wherein theN-terminus of the second Cas8 subunit protein is covalently connected bythe second linker polypeptide to the C-terminus of the second FokI.

Embodiment 16. The composition of any one of embodiments 1-14, whereinthe C-terminus of the second Cas8 subunit protein is covalentlyconnected by a second linker polypeptide to the N-terminus of the secondFokI.

Embodiment 17. The composition of any preceding embodiment, wherein thefirst Cas8 subunit protein and the second Cas8 subunit protein eachcomprises identical amino acid sequences.

Embodiment 18. The composition of any preceding embodiment, wherein thefirst Cse2 subunit protein and the second Cse2 subunit protein eachcomprises identical amino acid sequences, the first Cas5 subunit proteinand the second Cas5 subunit protein each comprises identical amino acidsequences, the first Cas6 subunit protein and the second Cas6 subunitprotein each comprises identical amino acid sequences, and the firstCas7 subunit protein and the second Cas7 subunit protein each comprisesidentical amino acid sequences.

Embodiment 19. The composition of any preceding embodiment, wherein thefirst guide polynucleotide comprises RNA.

Embodiment 20. The composition of any preceding embodiment, wherein thesecond guide polynucleotide comprises RNA.

Embodiment 21. The composition of any preceding embodiment, whereingenomic DNA comprises the PAM of the second nucleic acid target sequenceand the PAM of the first nucleic acid target sequence.

Embodiment 22. A cell comprising: the composition of any precedingembodiment.

Embodiment 23. The cell of embodiment 22, wherein genomic DNA of thecell comprises the PAM of the second nucleic acid target sequence andthe PAM of the first nucleic acid target sequence.

Embodiment 24. The cell of embodiment 22 or 23, wherein the cell is aprokaryotic cell.

Embodiment 25. The cell of embodiment 22 or 23, wherein the cell is aeukaryotic cell.

Embodiment 26. One or more nucleic acid sequences encoding the firstCse2 subunit protein, the first Cas5 subunit protein, the first Cas6subunit protein, the first Cas7 subunit protein, the first fusionprotein, and the first guide polynucleotide of any one of embodiments1-21.

Embodiment 27. One or more nucleic acid sequences encoding the secondCse2 subunit protein, the second Cas5 subunit protein, the second Cas6subunit protein, the second Cas7 subunit protein, the second fusionprotein, and the second guide polynucleotide of any one of embodiments1-21.

Embodiment 28. One or more expression cassettes comprising the one ormore nucleic acid sequences of embodiment 26, embodiment 27, orembodiment 26 and embodiment 27.

Embodiment 29. One or more vectors comprising the one or more expressioncassettes of embodiment 28.

Embodiment 30. A method of binding a polynucleotide comprising the firstnucleic acid target sequence and the second nucleic acid targetsequence, the method comprising:

providing the composition of any one of embodiments 1-21 forintroduction into a cell or a biochemical reaction; and

introducing the composition into the cell or the biochemical reaction,thereby facilitating contact of the first engineered Class 1 Type ICRISPR-Cas effector complex with the first nucleic acid target sequenceand contact of the second engineered Class 1 Type I CRISPR-Cas effectorcomplex with the second nucleic acid target sequence, resulting inbinding of the first engineered Class 1 Type I CRISPR-Cas effectorcomplex with the first nucleic acid target sequence and binding of thesecond engineered Class 1 Type I CRISPR-Cas effector complex with thesecond nucleic acid target sequence in the polynucleotide.

Embodiment 31. The method of embodiment 30, wherein genomic DNAcomprises the polynucleotide.

Embodiment 32. A method of cutting a polynucleotide comprising the firstnucleic acid target sequence and the second nucleic acid targetsequence, the method comprising:

providing the composition of any one of embodiments 1-21 forintroduction into a cell or a biochemical reaction; and

introducing the composition into the cell or the biochemical reaction,thereby facilitating contact of the first engineered Class 1 Type ICRISPR-Cas effector complex with the first nucleic acid target sequenceand contact of the engineered second Class 1 Type I CRISPR-Cas effectorcomplex with the second nucleic acid target sequence, resulting incutting of the first nucleic acid target sequence by the firstengineered Class 1 Type I CRISPR-Cas effector complex and cutting of thesecond nucleic acid target sequence by the second engineered Class 1Type I CRISPR-Cas effector complex.

Embodiment 33. The method of embodiment 32, wherein genomic DNAcomprises the polynucleotide.

Embodiment 34. A kit comprising: the composition of any one ofembodiments 1-21; and a buffer.

Embodiment 35. A kit comprising: the one or more nucleic acid sequencesof embodiment 26, embodiment 27, or embodiment 26 and embodiment 27; anda buffer.

Embodiment 36. A composition comprising:

-   -   an engineered Class 1 Type I CRISPR-Cas effector complex        comprising,        -   a Cse2 subunit protein, a Cas5 subunit protein, a Cas6            subunit protein, and a Cas7 subunit protein,        -   a first fusion protein comprising a Cas8 subunit protein and            a first FokI, wherein the N-terminus of the first Cas8            subunit protein or the C-terminus of the first Cas8 subunit            protein is covalently connected by a first linker            polypeptide to the C-terminus or N-terminus, respectively,            of the first FokI, and        -   a guide polynucleotide comprising a spacer capable of            binding a nucleic acid target sequence; and    -   a second fusion protein comprising an engineered Class 1 Type I        CRISPR-Cas3 fusion protein comprising a dCas3*protein and a        second FokI, wherein the N-terminus of the dCas3* protein or the        C-terminus of the dCas3* protein is covalently connected by a        second linker polypeptide to the C-terminus or N-terminus,        respectively, of the second FokI, and wherein the first linker        polypeptide has a length of between 10 amino acids to 40 amino        acids, effector complex comprising,

Embodiment 37. The composition of embodiment 36, wherein the firstlinker polypeptide has a length of between 5 amino acids to 40 aminoacids.

Embodiment 38. The composition of embodiment 36, wherein the firstlinker polypeptide has a length of between 5 amino acids to 40 aminoacids.

Embodiment 39. A cell comprising: the composition of any one ofembodiments 36 to 38.

Embodiment 40. The cell of embodiment 39, wherein the cell is aprokaryotic cell.

Embodiment 41. The cell of embodiment 39, wherein the cell is aeukaryotic cell.

Embodiment 42 One or more nucleic acid sequences encoding the Cse2subunit protein, the Cas5 subunit protein, the Cas6 subunit protein, theCas7 subunit protein, the first fusion protein, and the guidepolynucleotide of any one of embodiments 36 to 38.

Embodiment 43. One or more nucleic acid sequences encoding the secondfusion protein of any one of embodiments 36 to 38.

Embodiment 44. One or more expression cassettes comprising the one ormore nucleic acid sequences of embodiment 42, embodiment 43, orembodiment 42 and embodiment 43.

Embodiment 45. One or more vectors comprising the one or more expressioncassettes of embodiment 44.

Embodiment 46. A method of binding a polynucleotide comprising thenucleic acid target sequence, the method comprising:

providing the composition of any one of embodiments 36 to 38 forintroduction into a cell or a biochemical reaction; and

introducing the composition into the cell or the biochemical reaction,thereby facilitating contact of the engineered Class 1 Type I CRISPR-Caseffector complex with the nucleic acid target sequence and contact ofthe second fusion protein with the engineered Class 1 Type I CRISPR-Caseffector complex, resulting in binding of the engineered Class 1 Type ICRISPR-Cas effector complex and the second fusion protein to the nucleicacid target sequence in the polynucleotide.

Embodiment 47. The method of embodiment 46, wherein genomic DNAcomprises the polynucleotide.

Embodiment 48. A method of cutting a polynucleotide comprising thenucleic acid target sequence, the method comprising:

providing the composition of any one of embodiments 36 to 38 forintroduction into a cell or a biochemical reaction; and

introducing the composition into the cell or the biochemical reaction,thereby facilitating contact of the first engineered Class 1 Type ICRISPR-Cas effector complex with the first nucleic acid target sequenceand contact of the engineered second Class 1 Type I CRISPR-Cas effectorcomplex with the second nucleic acid target sequence, and

introducing the composition into the cell or the biochemical reaction,thereby facilitating contact of the second engineered Class 1 Type ICRISPR-Cas effector complex with the nucleic acid target sequence andcontact of the second fusion protein with the engineered Class 1 Type ICRISPR-Cas effector complex, resulting in cutting of the nucleic acidtarget sequence by the engineered Class 1 Type I CRISPR-Cas effectorcomplex and the second fusion protein.

Embodiment 49. The method of embodiment 48, wherein genomic DNAcomprises the polynucleotide.

Embodiment 50. A kit comprising: the composition of any one ofembodiments 36 to 38; and a buffer.

Embodiment 51. A kit comprising: the one or more nucleic acid sequencesof embodiment 42, embodiment 43, or embodiment 42 and embodiment 43; anda buffer.

Although preferred embodiments of the present invention have been shownand described herein, it will be obvious to those skilled in the artthat such embodiments are provided by way of example only. From thepresent Specification and the Examples, one skilled in the art canascertain essential characteristics of this invention, and withoutdeparting from the spirit and scope thereof, can make changes,substitutions, variations, and modifications of the invention to adaptit to various usages and conditions. Such changes, substitutions,variations, and modifications are also intended to fall within the scopeof the present disclosure.

EXPERIMENTAL

Aspects of the present invention are illustrated in the followingExamples. Efforts have been made to ensure accuracy with respect tonumbers used (e.g., amounts, concentrations, percent changes, and thelike) but some experimental errors and deviations should be accountedfor. Unless indicated otherwise, temperature is in degrees Centigradeand pressure is at or near atmospheric. It should be understood thatthese Examples are given by way of illustration only and are notintended to limit the scope of the present invention.

Example 1 In Silico Design of Polynucleotides Encoding CascadeComponents

This Example provides a description of the design of polynucleotidecomponents encoding Cascade using gene, protein, and CRISPR sequencesderived from a Type I-E CRISPR-Cas system.

Table 10 presents polynucleotide DNA sequences of genes encoding thefive proteins of Cascade from Type I-E, specifically from E. coli strainK-12 MG1655, as well as the amino acid sequences of the resultingprotein components. Genomic sequences were obtained from NCBI ReferenceSequence NZ_CP014225.1. In the Table, polynucleotide sequences wereeither amplified from E. coli genomic DNA or manufacturer-producedpolynucleotides encoding Cascade protein components that were codonoptimized specifically for expression in E. coli and also for expressionin human cells.

TABLE 10 Cas Protein DNA and Amino Acid Sequences DNA coding Amino acidProtein Type of sequence sequence sequence Cas8 genomic SEQ ID NO: 1 SEQID NO: 16 Cse2 genomic SEQ ID NO: 2 SEQ ID NO: 17 Cas7 genomic SEQ IDNO: 3 SEQ ID NO: 18 Cas5 genomic SEQ ID NO: 4 SEQ ID NO: 19 Cas6 genomicSEQ ID NO: 5 SEQ ID NO: 20 Cas8 E. coli codon-optimized SEQ ID NO: 6 SEQID NO: 16 Cse2 E. coli codon-optimized SEQ ID NO: 7 SEQ ID NO: 17 Cas7E. coli codon-optimized SEQ ID NO: 8 SEQ ID NO: 18 Cas5 E. colicodon-optimized SEQ ID NO: 9 SEQ ID NO: 19 Cas6 E. coli codon-optimizedSEQ ID NO: 10 SEQ ID NO: 20 Cas8 H. sapiens codon- SEQ ID NO: 11 SEQ IDNO: 16 optimized Cse2 H. sapiens codon- SEQ ID NO: 12 SEQ ID NO: 17optimized Cas7 H. sapiens codon- SEQ ID NO: 13 SEQ ID NO: 18 optimizedCas5 H. sapiens codon- SEQ ID NO: 14 SEQ ID NO: 19 optimized Cas6 H.sapiens codon- SEQ ID NO: 15 SEQ ID NO: 20 optimized

In addition, several fusion proteins comprising Cascade proteins weredesigned. Table 11 presents polynucleotide DNA sequences of genesencoding Cascade protein fusion proteins, as well as the amino acidsequences of the resulting protein components. In most instances, fusionproteins described in Table 11 include short tri-amino acid linkersconnecting the two polypeptide sequences within the fusion construct;this linker typically comprises glycine-glycine-serine (GGS) orglycine-serine-glycine (GSG). The exact tri-amino acid linker sequencesused in each particular fusion protein can be found in the full-lengthamino acid sequence in Table 11.

TABLE 11 Cascade Fusion Protein Sequences Heterologous polypeptide fusedExpression to the N- or C- system for Cascade Heterologous terminus ofthe DNA coding DNA coding Amino acid protein polypeptide Cascade proteinsequence sequence sequence Cse2 Strep-tag ® N SEQ ID E. coli SEQ IDII-HRV3C NO: 390 NO: 391 Cse2 His6-HRV3C N SEQ ID E. coli SEQ ID NO: 392NO: 393 Cse2 NLS N SEQ ID Mammalian SEQ ID NO: 394 NO: 395 Cas5 NLS NSEQ ID Mammalian SEQ ID NO: 396 NO: 397 Cas6 NLS N SEQ ID E. coli SEQ IDNO: 398 NO: 399 Cas6 NLS-HA N SEQ ID E. coli SEQ ID NO: 400 NO: 401 Cas6NLS N SEQ ID Mammalian SEQ ID NO: 402 NO: 403 Cas7 NLS C SEQ ID E. coliSEQ ID NO: 404 NO: 405 Cas7 HA-NLS C SEQ ID E. coli SEQ ID NO: 406 NO:407 Cas7 NLS N SEQ ID Mammalian SEQ ID NO: 408 NO: 409 Cas8 His6-MBP- NSEQ ID E. coli SEQ ID TEV NO: 410 NO: 411 Cas8 His6-MBP- N SEQ ID E.coli SEQ ID TEV-NLS- NO: 412 NO: 413 FokI-linker Cas8 NLS N SEQ IDMammalian SEQ ID NO: 414 NO: 415 Cas8 NLS-HA- N SEQ ID Mammalian SEQ IDFokI-linker NO: 416 NO: 417

The His6 (hexahistidine; SEQ ID NO:418) and Strep-tag™ II (GE HealthcareBio-Sciences, Pittsburgh, Pa.) (SEQ ID NO:419) peptide tags on the Cse2protein, when co-expressed with other Cascade proteins, enablepurification of the complex via either Nickel-nitriloacetic acid(Ni-NTA) resin or Strep-Tactin™ (GE Healthcare Bio-Sciences, Pittsburgh,Pa.) resin, respectively. The HRV3C (human rhinovirus 3C) proteaserecognition sequence (SEQ ID NO:420) is cleaved by an HRV3C protease andcan be used to remove N-terminal fusions from a protein of interest. TheNLS (nuclear localization signal; SEQ ID NO:421 peptide tag on the Cas6,Cas7, and/or Cas8 proteins enables nuclear trafficking in eukaryoticsystems. The HA (hemagglutinin; SEQ ID NO:422) peptide tag on the Cas6or Cas7 proteins enables detection of heterologous protein expression byWestern blotting with an anti-HA antibody. The MBP (maltose bindingprotein; SEQ ID NO:423) peptide fusion is a solubilization tag thatfacilitates purification of the Cas8 protein. The TEV (tobacco etchvirus) protease recognition sequence (SEQ ID NO:424) is cleaved by TEVprotease and can be used to remove N-terminal fusions from a protein ofinterest. The FokI nuclease domain comprises the Sharkey variantdescribed by Guo, et al. (Guo, J., et al., J. Mol. Biol. 400:96-107(2010)), two monomeric FokI subunits associate to form a homodimer, andcatalyze double-stranded DNA cleavage upon homo-dimerization. A linkersequence (SEQ ID NO:425) is used to fuse the FokI nuclease domain to theCas8 protein.

Additional linker sequences of varying length and amino acid compositionhave been designed that connect the FokI nuclease domain to the Cas8protein. These amino acid sequences can be found in Table 12.

TABLE 12 Amino Acid Linker Sequences Linker length SEQ ID NO:(amino acids) Amino acid sequence SEQ ID NO: 426  5 GGGGS SEQ ID NO: 427 8 TGPGAAAR SEQ ID NO: 428 10 GGSGSSGGSG SEQ ID NO: 429 12 TGPGAAARAASGSEQ ID NO: 430 15 GGSGSSGGSGSSGGS SEQ ID NO: 431 16 SGSETPGTSESATPESSEQ ID NO: 432 20 SGSETPGTSESATPESGGS G SEQ ID NO: 433 30SGSETPGTSESATPESGGS GSSGGSGSSGG

Table 13 contains the polynucleotide DNA sequence of four minimal CRISPRarrays that, when transcribed into precursor crRNA and processed by theRNA endonuclease protein of Cascade, generate mature crRNAs thatfunction as the guide RNA to target complementary DNA sequences inbiochemical assays and in cell culture gene editing experiments.

The minimal CRISPR array comprises two repeat sequences (underlined,lower case) flanking a spacer sequence, which represents the guideportion of the crRNA. RNA processing by the Cascade endonuclease proteingenerates a crRNA with repeat sequences on both the 5′ and 3′ ends,flanking the guide sequence. The CRISPR array may also be expanded toinclude three repeat sequences (underlined) flanking two spacersequences, which represent the guide portions of two distinct crRNAs byRNA processing by the endonuclease Cascade protein. The arrays can befurther expanded to include additional spacer sequences, if desired.

TABLE 13 CRISPR Array Sequences Cell SEQ ID NO: type TargetMinimal CRISPR array sequence SEQ ID NO: 434 E. coli BacteriophagegagttccccgcgccagcggggataaaccgCCAGTGATA λ J3 targetAGTGGAATGCCATGTGGGCTGTCgagttccc cgcgccagcggggataaaccg SEQ ID NO: 435E. coli Bacteriophage gagttccccgcgccagcggggataaaccgAGTGGCAGA λ L3 targetTATAGCCTGGTGGTTCAGGCGGCgagttccc cgcgccagcggggataaaccg SEQ ID NO: 436E. coli Bacteriophage gagttccccgcgccagcggggataaaccgCCAGTGATA λL3/J3 targets AGTGGAATGCCATGTGGGCTGTCgagttccccgcgccagcggggataaaccgAGTGGCAGATATAG CCTGGTGGTTCAGGCGGCgagttccccgcgccagcggggataaaccg SEQ ID NO: 437 H. TRAC genegagttccccgcgccagcggggataaaccgGTTGATTTG sapiensCCTGCATTGGTGTTACACAGTCTgagttcccc gcgccagcggggataaaccgTAAGTTGTGTTCTTCTTTGCCTAGGCCTTCAGgagttccccgcgccagcg gggataaaccg

Example 2 Design of Bacterial Expression Vectors for Production ofCascade Effector Complexes

This Example describes the design of bacterial expression vectors thatencode the Cascade-associated proteins, as well as a minimal CRISPRarray comprising the guide sequence as described in Example 1. Theconstruction of Cascade subunit protein expression systems for use withplasmids encoding minimal CRISPR arrays is described.

A single-plasmid Cascade protein expression system was constructed toexpress the proteins of either a complex of Cascade in E. coli, known asthe CasBCDE complex (which contains the Cse2, Cas7, Cas5, and Cashproteins, but not the Cas8 protein), or the entire functional Cascadecomplex in E. coli. The single plasmid system comprises either thecse2-cas7-cas5-cas6 operon, or the entire cas8-cse2-cas7-cas5-cas6operon on a single expression plasmid. The Cas8 protein can be expressedfrom its own expression plasmid, for use in biochemical experimentswhere it is mixed together with the CasBCDE complex to reconstituteCascade.

A starting plasmid for expression vector construction was used (seeBrouns, S. J. J. et al., Science 321:960-964 (2008)). The single plasmidCascade protein expression system comprising a Cas operon was assembledas follows. The coding sequences for the cas genes were arranged in theorder cse2-cas7-cas5-cas6 (CasBCDE complex or cas8-cse2-cas7-cas5-cas6(full Cascade complex), and were separated by sequences corresponding tothe wild-type bacterial gene arrangement (see NCBI Reference SequenceNZ_CP014225.1).

In order to append a polynucleotide sequence encoding an affinity tag(His6 or Strep-tag™ II), the corresponding coding sequence was insertedat the junction of the 3′ end of the cas8 gene and the 5′ end of thecse2 gene; these two open reading frames overlap in the wild-typegenomic DNA sequence.

In order to append polynucleotide sequences encoding N-terminal NLSand/or NLS-HA tags onto the 5′ end of the cas6 gene, additional spacingwas introduced between the cas6 and upstream cas5 genes, because theseopen reading frames overlap in the wild-type genomic DNA sequence, suchthat the Shine-Dalgarno sequence for the cas6 gene is within the 3′portion of the cas5 gene. A new Shine-Dalgarno sequence was insertedupstream of the new NLS-Cas6 or NLS-HA-Cas6 open reading frames, toimprove translational efficiency.

In order to append polynucleotide sequences encoding C-terminal NLSand/or HA-NLS tags onto the 3′ end of the cas7 gene, additional spacingwas introduced between the cas7 and downstream cas5 genes, because theseopen reading frames are in close proximity in the wild-type genomic DNAsequence, such that the Shine-Dalgarno sequence for the cas5 gene iswithin the 3′ portion of the cas7 gene. A new Shine-Dalgarno sequencewas inserted downstream of the new Cas7-NLS or Cas7-HA-NLS open readingframes, to improve translational efficiency for the cas5 gene.

In order to append polynucleotide sequences encoding N-terminalNLS-FokI-linker fusions to the Cas8 protein, the corresponding codingsequences were inserted at the 5′ end of the cas8 gene.

The cse2-cas7-cas5-cas6 and cas8-cse2-cas7-cas5-cas6 operons were clonedinto the pCDF (MilliporeSigma, Hayward, Calif.) vector backbone, whichconfers spectinomycin resistance due to the presence of the aadA gene.Transcription of the operon is driven by a T7 promoter and is undercontrol of the Lac operator; the vector also encodes the LacI repressor.A T7 terminator was cloned downstream of the cse2-cas7-cas5-cas6 orcas8-cse2-cas7-cas5-cas6 operon. The vector contains a CDF origin ofreplication.

For expression of Cas8 or FokI-Cas8 fusion proteins, the cas8 gene wascloned into a pET (MilliporeSigma, Hayward, Calif.) family vectorbackbone, which confers kanamycin resistance due to the presence of thekanR gene. Transcription of the operon is driven by a T7 promoter(P_(T7)), and is under control of the Lac operator (lacO); the vectoralso encodes the LacI repressor (lacI gene). A T7 terminator was cloneddownstream of the cas8 gene. The vector contains a ColE1 origin ofreplication.

FIG. 24A, FIG. 24B, FIG. 24C, FIG. 24D, and FIG. 24E present schematicdiagrams of overexpression vectors for the cas8, fokI-cas8, thecse2-cas7-cas5-cas6 operon, the cas8-cse2-cas7-cas5-cas6 operon, and thefokI-cas8-cse2-cas7-cas5-cash operon. The designations in FIG. 24A, FIG.24B, FIG. 24C, FIG. 24D, and FIG. 24E are described in this Example andin Example 1 and are as follows: P_(T7) (T7 promoter), lacO (Lacoperator), His6 (hexahistidine), MBP (maltose binding protein),Strep-tag™ II, HRV3C (human rhinovirus 3C) protease recognitionsequence, TEV (tobacco etch virus) protease recognition sequence, NLS(nuclear localization signal), kanR (kanamycin resistance gene), lacI(LacI repressor gene), colE1 ori (origin of replication), CDF ori(CloDF13 origin of replication), FokI nuclease domain (Sharkey variant),and aadA (gene encoding aminoglycoside resistance protein).

Table 14 provides sequences of bacterial expression plasmids encodingthe Cas8 protein, the 4 proteins of the CasBCDE complex(cse2-cas7-cas5-cas6 operon), and all 5 proteins of the Cascade complex(cas8-cse2-cas7-cas5-cas6 operon). Polynucleotide sequences are providedwith and without the N-terminal FokI fusion on the Cas8 protein.

TABLE 14 Bacterial Plasmid Sequences Arrangement of protein SEQ ID NO:Vector designation coding sequences (N to C) Notable characteristics SEQID NO: 438 Cas8 His6-MBP-TEV-Cas8 Can be added to CasBCDE expressionvector complex to reconstitute Cascade SEQ ID NO: 439 FokI-Cas8His6-MBP-TEV- FokI confers the ability to expression vectorNLS-FokI-linker- cleave double-stranded Cas8 DNA SEQ ID NO: 440 CasBCDEcomplex Strep-tag ™ II- When co-expressed with a expression vectorHRV3C- CRISPR array, generates Cse2_Cas7_Cas5_Cas6 CasBCDE complex SEQID NO: 441 Cascade complex Cas8_His6-HRV3C- When co-expressed with aexpression vector Cse2_Cas7_Cas5_Cas6 CRISPR array, generates Cascadecomplex SEQ ID NO: 442 FokI-Cascade NLS-FokI-linker- FokI confers theability to expression vector Cas8_His6-HRV3C- cleave double-strandedCse2_Cas7_Cas5_Cas6 DNA targeted by crRNA SEQ ID NO: 443 FokI-CascadeNLS-FokI-linker- FokI confers the ability to expression vector,Cas8_His6-HRV3C- cleave double-stranded extra NLS tag Cse2_Cas7- DNAtargeted by crRNA; NLS_Cas5_Cas6 extra NLS tag on Cas7 protein improvesnuclear trafficking

In order to purify the CasBCDE complex and Cascade complex containing acrRNA, the protein expression vectors encoding the cse2-cas7-cas5-cas6operon or the cas8-cse2-cas7-cas5-cas6 operon are combined with a vectorcontaining a minimal CRISPR array.

CRISPR arrays were cloned into the pACYC-Duet1 vector backbone, whichconfers chloramphenicol resistance due to the camR gene. Transcriptionof the array is driven by a T7 promoter and is under control of the Lacoperator (lacO); the vector also encodes the LacI repressor. A T7terminator was cloned downstream of the CRISPR array. The vectorcontains a p15A origin of replication.

FIG. 25 contains a schematic diagram of an expression vector containinga CRISPR array with 2 repeats (FIG. 25, “repeats”) and 1 spacer (FIG.25, “spacer”). The array can be expanded, as described herein. Thedesignations in FIG. 25 are described in this Example and in Example 1and are as follows: P_(T7) (T7 promoter), lacO (Lac operator), lacI(LacI repressor gene), p15A ori (origin of replication), and camR(chloramphenicol resistance gene).

Table 15 provides the sequences of bacterial expression plasmidsencoding examples of minimal CRISPR arrays.

TABLE 15 Bacterial Plasmid Sequences Vector DNA targeted by Notable SEQID NO: designation spacer characteristics SEQ ID NO: 444 CRISPR(J3)Bacteriophage λ Two repeats, expression vector J3 target one spacer SEQID NO: 445 CRISPR(L3) Bacteriophage λ Two repeats, expression vector L3target one spacer SEQ ID NO: 446 CRISPR(J3/L3) Bacteriophage λ Threerepeats, expression vector L3/J3 targets two spacers SEQ ID NO: 447CRISPR(TRAC) TRAC gene Three repeats, expression vector two spacers

Example 3 Design of Eukaryotic Expression Vectors for Production ofCascade Effector Complexes in Mammalian Cells

This Example describes the design of eukaryotic expression plasmidvectors that encode Cascade-associated proteins, as well as minimalCRISPR arrays comprising the component sequences as described in Example1.

A. Separate Plasmids Expressing Each Cascade Protein and Minimal CRISPRArray

Cascade proteins can be expressed in mammalian cells by encoding each ofthe protein components on a separate expression vector driven by thehuman cytomegalovirus (CMV) immediate-early promoter/enhancer andencoding the crRNA on a separate expression vector driven by the humanU6 promoter.

The starting plasmid for each expression plasmid was a derivative ofpcDNA3.1 (Thermo Scientific, Wilmington, Del.). Coding sequences for theCascade proteins, codon optimized for expression in human cells (seeExample 1), were inserted into the vector downstream of the CMV promoterand upstream of a bovine growth hormone (bGH) polyadenylation signal.The cse2 gene was fused to polynucleotide sequences at the 5′ end codingfor an N-terminal NLS and 3×-FLAG epitope tag. The cas5 gene was fusedto polynucleotide sequences at the 5′ end coding for an N-terminal NLS.The cash gene was fused to polynucleotide sequences at the 5′ end codingfor an N-terminal NLS and HA epitope tag. The cas7 gene was fused topolynucleotide sequences at the 5′ end coding for an N-terminal NLS andMyc epitope tag. The cas8 gene was fused to polynucleotide sequences atthe 5′ end coding for an N-terminal NLS; in another embodiment, the cas8gene was fused to polynucleotide sequences at the 5′ end coding for anN-terminal NLS, HA epitope tag, and FokI nuclease domain.

Each gene or gene fusion was cloned into a pcDNA3.1 derivative vectorbackbone, which confers ampicillin resistance due to the presence of theampR gene. The vector also encodes neomycin resistance due to thepresence of the neoR gene, which is downstream of an SV40 early promoter(P_(sv40)) and origin (SV40 ori), and upstream of an SV40 earlypolyadenylation signal (SV40 pA). In addition to the human CMVimmediate-early promoter/enhancer (P_(CMV)) and bGH (bovine growthhormone) polyadenylation signal, the vector contains a T7 promoterupstream of the gene of interest, allowing for in vitro transcription ofmRNA. The vector contains an f1 origin of replication as well as a ColE1origin of replication.

FIG. 26 contains a schematic diagram of a mammalian expression vectorencoding the FokI-Cas8 fusion protein. The designations in FIG. 26 aredescribed in this Example and in Example 1 and are as follows: the humanCMV immediate-early promoter/enhancer (P_(CMV)), NLS (nuclearlocalization signal), FokI (FokI nuclease domain (Sharkey variant)),Cas8 protein coding sequence, bGH pA (bovine growth hormonepolyadenylation signal), f1 ori (f1 phage origin of replication),P_(SV40) (SV40 early promoter), SV40 ori (SV40 origin), neoR (neomycinresistance gene), SV40 pA (SV40 early polyadenylation signal), colE1 ori(origin of replication), and ampR (ampicillin resistance gene). Vectorsencoding the other Cascade proteins were designed similarly.

Table 16 provides the sequences of individual mammalian expressionvectors encoding each of Cse2, Cas5, Cas6, Cas7, Cas8, and FokI-Cas8.

TABLE 16 Mammalian Expression Vectors Vector SEQ ID NO: designationNotable characteristics SEQ ID NO: 448 Mammalian Cse2 Cse2 containsN-terminal NLS- expression vector 3xFLAG tag SEQ ID NO: 449 MammalianCas5 Cas5 contains N-terminal NLS expression vector SEQ ID NO: 450Mammalian Cas6 Cas6 contains N-terminal NLS- expression vector Ha tagSEQ ID NO: 451 Mammalian Cas7 Cas7 contains N-terminal NLS- expressionvector Myc tag SEQ ID NO: 452 Mammalian Cas8 Cas8 contains N-terminalNLS expression vector SEQ ID NO: 453 Mammalian FokI-Cas8 Cas8 containsN-terminal NLS- expression vector HA-FokI; FokI confers the ability tocleave double-stranded DNA

The CRISPR RNA was encoded with a minimal CRISPR array containing threerepeats flanking two spacer sequences. The construct generating CRISPRRNA can be designed with additional sequences flanking the outermostrepeats in the minimal array. Processing of the precursor CRISPR RNA isenabled by the RNA processing protein of the Cascade complex (Cas6protein), which can be expressed on a separate plasmid.

The CRISPR array was cloned into the same pcDNA3.1 derivative vectorbackbone described above, except the human CMV promoter was replacedwith the human U6 promoter (P_(U6)), and the bGH polyadenylation signalwas replaced with a poly-T termination signal.

FIG. 27 contains a schematic diagram of a eukaryotic expression vectorencoding a representative CRISPR array targeting the TRAC gene. Thedesignations in FIG. 27 are described in this Example and in Example 1and are as follows: P_(U6) (human U6 promoter), repeats (CRISPR RNArepeats), TRAC spacer-1 (first spacer targeting the TRAC gene), TRACspacer-2 (second spacer targeting the TRAC gene), polyT (poly-Ttermination signal), f1 ori (f1 phage origin of replication), P_(SV40)(SV40 early promoter), SV40 ori (SV40 origin), neoR (neomycin resistancegene), SV40 pA (SV40 early polyadenylation signal), colE1 ori (origin ofreplication), and ampR (ampicillin resistance gene).

Table 17 provides the sequence of a representative mammalian expressionvector encoding a CRISPR array targeting the TRAC gene; a spacersequence that targets matching DNA sequences in the TRAC gene can befound in Table 13.

TABLE 17 Mammalian Expression Vector Spacer complementary SEQ ID NO:Vector designation to target Notable characteristics SEQ ID NO: 454Mammalian CRISPR TRAC gene Three repeats, two spacers RNA expressionvector

B. Cascade Protein Expression System Wherein Multiple Cascade ProteinCoding Sequences are Expressed from a Single Promoter

In order to express components of the Cascade complex off of fewerexpression vectors, polycistronic expression vectors were constructed.On each, a single CMV promoter drives expression of multiple codingsequences simultaneously that are separated by a 2A viral peptidesequence. The Thosea asigna virus 2A peptide sequence induces ribosomalskipping (Liu, Z., et al., Sci. Rep. 7:2193 (2017)), thus enablingmultiple protein-coding genes to be concatenated within a singlepolycistronic construct.

The starting plasmid for the polycistronic expression plasmid was thesame derivative of pcDNA3.1 described above, containing the CMV promoterand bGH polyadenylation signal. Coding sequences for the Cascadeproteins, codon optimized for expression in human cells (see Example 1),were joined in the order cas7-cse2-cas5-cas6-cas8, with a polynucleotidesequence coding for the Thosea asigna virus 2A (T2A) peptide inserted inbetween each pair of genes. In addition, polynucleotide sequencesencoding NLS tags were appended to the 5′ end of each Cascade proteingene, and a polynucleotide sequence encoding the FokI nuclease domainwas appended to the 5′ end of the cas8 gene, connecting by a 30-aminoacid linker sequence. The final construct has the following order ofelements:NLS-cas7-T2A-NLS-cse2-T2A-NLS-cas5-T2A-NLS-cash-T2A-NLS-fokI-linker-cas8.

FIG. 28 contains a schematic diagram of an exemplary polycistronicmammalian expression vector encoding all the Cascade proteins. Thedesignations in FIG. 28 are described in this Example and in Example 1and are as follows: the human CMV immediate-early promoter/enhancer(P_(CMV)), NLS (nuclear localization signal), T2A (polynucleotidesequence coding for the Thosea asigna virus 2A peptide), codingsequences for the Cas7, Cse2, Cas5, and Cash proteins, fokI (FokInuclease domain (Sharkey variant) a linker sequence, coding sequence forCas8 protein, bGH pA (bovine growth hormone polyadenylation signal), f1ori (f1 phage origin of replication), P_(SV40) (SV40 early promoter),SV40 ori (SV40 origin), neoR (neomycin resistance gene), SV40 pA (SV40early polyadenylation signal), colE1 ori (origin of replication), ampR(ampicillin resistance gene), and an MluI restriction site.

Table 18 provides the sequence of an exemplary polycistronic mammalianexpression vector encoding all the Cascade proteins. This vector can becombined with the mammalian expression vector encoding CRISPR RNAdescribed above to produce functional Cascade complexes in mammaliancells.

TABLE 18 Mammalian Expression Vectors Arrangement of protein SEQ ID NO:Vector designation coding sequences (N to C) Notable characteristics SEQID NO: 455 Polycistronic mammalian NLS-Cas7-T2A_NLS- Single proteinexpression vector expression vector encoding Cse2-T2A_NLS-Cas5- encodingall Cascade proteins, all 5 Cascade proteins T2A_NLS-Cas6- each withN-terminal NLS tag. T2A_NLS-FokI-Cas8 Cas8 contains N-terminalNLS-HA-FokI; FokI confers the ability to cleave double-stranded DNA

C. Single Plasmid Expression System

A single plasmid Cascade expression system was constructed to expressthe complete Cascade complex in human cells. The plasmid encodes theentire cas8-cse2-cas7-cas5-cas6 operon and a minimal CRISPR array on asingle plasmid. This plasmid was constructed from the polycistronicprotein expression vector (described above in Table 18 and FIG. 28) byinserting the minimal CRISPR array along with the upstream human U6promoter and downstream poly-T termination signal into the MluIrestriction site.

Table 19 provides the sequence of the single plasmid for expression ofall five Cascade proteins together with the crRNA to facilitateformation of Cascade complexes in human cells.

TABLE 19 Mammalian Expression Vector Arrangement of protein coding SEQID NO: Vector designation sequences (N to C) Notable characteristics SEQID NO: 456 Polycistronic mammalian hU6_CRISPR(TRAC), Single proteinexpression vector expression vector encoding CMV_NLS-Cas7-T2A_NLS-encoding crRNA and all Cascade all 5 Cascade proteins Cse2-T2A_NLS-Cas5-proteins, each with N-terminal NLS and crRNA T2A_NLS-Cas6_NLS- tag. Cas8contains N-terminal FokI-Cas8 NLS-HA-FokI; FokI confers the ability tocleave double-stranded DNA

Plasmids were also designed for the expression of the Cas3 protein (SEQID NO:21; monomer Cas3 nuclease/helicase E. coli K-12 substr. MG1655) inE. coli and in mammalian cells. Table 20 provides the constructs andsequences of these plasmids.

TABLE 20 Cas3 Protein Fusions SEQ ID NO: Protein Notable characteristicsSEQ ID NO: 457 Cas3 Genomic DNA gene sequence SEQ ID NO: 458 Cas3Protein amino acid sequence SEQ ID NO: 459 His6-MBP-TEV-Cas3 Derivedfrom genomic DNA gene sequence SEQ ID NO: 460 His6-MBP-TEV-Cas3 Proteinamino acid sequence SEQ ID NO: 461 His6-MBP-TEV-Cas3 Cas3 E. coliexpression vector SEQ ID NO: 462 Cas3, human codon- Homo sapienscodon-optimized optimized DNA gene sequence SEQ ID NO: 463 Cas3-NLS Homosapiens codon-optimized DNA gene sequence SEQ ID NO: 464 Cas3-NLSProtein amino acid sequence SEQ ID NO: 465 Cas3-NLS Cas3 mammalianexpression vector

Example 4 Introduction of Polynucleotides Encoding Cascade Componentsinto a Bacterial Production Strain

This Example describes for introduction and expression of Cas8 subunitprotein coding sequences, as well as coding sequences for components ofengineered Type I CRISPR-Cas effector complexes in bacterial cells usingE. coli expression systems.

A. Expression of Cas8 Protein

E. coli Type I-E Cas8 protein was expressed from a plasmid (Example 2,SEQ ID NO:438, Table 14, FIG. 24A) containing an operon for the IPTGinducible expression of His6-MBP-TEV-Cas8 from a T7 promoter. Theexpression plasmid conferred resistance to kanamycin.

In order to express Cas8 protein, E. coli cells were transformed withthe expression plasmid. Briefly, a 100 μL aliquot of chemicallycompetent E. coli cells (E. coli BL21 Star™ cells (Thermofisher,Waltham, Mass.)) in a microcentrifuge tube was thawed on ice for 10minutes. 35 ng of plasmid DNA was added to the thawed cells and thecells were incubated with the DNA on ice for 8 minutes. Heat shock wasperformed by a placing the microcentrifuge tube in a 42° C. water bathfor 30 seconds and then immediately placing the tube in ice for 2minutes. 900 μL of 2×YT media were added to the microcentrifuge tube,and the microcentrifuge tube was placed in a tube rotator at 37° C. for1 hour. Finally, 100 μL of the recovered cells were plated on LB solidkanamycin (50 μg/mL) and incubated overnight at 37° C.

A single colony was picked from the colonies that grew on the antibioticselection plates and was inoculated into 10 mL of 2×YT mediasupplemented with kanamycin (50 μg/mL). The culture was grown overnightat 37° C. while shaking in an orbital shaker at 200 RPMs. 6 mL of theovernight culture were transferred to a 2 L baffled flask having 1 L of2×YT media supplemented with chloramphenicol (34 μg/mL) andspectinomycin (100 μg/mL). The 1 L culture was grown at 37° C. whileshaking in an orbital shaker at 200 RPM until the optical density at 600nm was 0.56.

Expression from both plasmids was then induced by the addition of IPTGto a final concentration of 1 mM. The induced cultures were grownovernight at 16° C. while shaking in an orbital shaker at 200 RPM. Cellswere harvested by centrifugation at 4,000 RCF for 15 minutes at 4° C.The cell pellet was re-suspended in 15 mL of a lysis buffer composed of50 mM Tris pH 7.5, 100 mM NaCl, 5% glycerol, and 1 mM TCEP supplementedwith 1 Complete™ protease inhibitor tablet (Roche, Basel, Switzerland)per 50 mL of lysis buffer. The re-suspended cells were transferred to a50 mL conical tube for immediate downstream processing. The Cas8 proteinwas purified and the purified protein characterized essentially asdescribed below for the FokI-Cas8 fusion protein (Example 5C).

B. Expression of the Components of Cascade RNP Complexes

A complete set of the five E. coli Cascade proteins and RNA guides wereco-expressed in E. coli cells using a two-plasmid system to produceCascade RNP complexes. One plasmid (Example 2, SEQ ID NO:441, Table 14,FIG. 24D) contained an operon for IPTG inducible expression of the Cse2,Cas5, Cash, Cas7, and Cas8 proteins from a T7 promoter. A His6 affinitytag was included as a translational fusion to the N-terminus of Cse2(Example 1, SEQ ID NO:392, Table 11). The second plasmid coded for theIPTG inducible expression of the J3 guide (Example 2, SEQ ID NO:444,Table 15, FIG. 25). The Cascade protein expression plasmid conferredspectinomycin resistance, and the Cascade RNA guide expression plasmidconferred chloramphenicol resistance.

In order to co-express the Cascade proteins and RNA components in thesame cell, E. coli cells were simultaneously transformed with the twoplasmids. A 100 μL aliquot of chemically competent E. coli cells (E.coli, BL21 Star™ (DE3) (Thermofisher, Waltham, Mass.)) in amicrocentrifuge tube was thawed on ice for 10 minutes. 35 ng of eachplasmid was added to the thawed cells and the cells were incubated withthe DNA on ice for 8 minutes. Heat shock was performed by a placing themicrocentrifuge tube in a 42° C. water bath for 30 seconds and thenimmediately placing the microcentrifuge tube in ice for 2 minutes. 900μL of 2×YT media were added to the microcentrifuge tube and themicrocentrifuge tube placed in a tube rotator at 37° C. for 1 hour.Finally, 100 μL of the recovered cells were plated on LB solid mediawith chloramphenicol (34 μg/mL) and spectinomycin (50 μg/mL) andincubated overnight at 37° C.

A single colony was picked from the colonies that grew on the antibioticselection plates and was inoculated into 10 mL of 2×YT mediasupplemented with chloramphenicol (34 μg/mL) and spectinomycin (100μg/mL). The culture was grown overnight at 37° C. while shaking in anorbital shaker at 200 RPMs. 6 mL of the overnight culture weretransferred to a 2 L baffled flask having 1 L of 2×YT media supplementedwith chloramphenicol (34 μg/mL) and spectinomycin (100 μg/mL). The 1 Lculture was grown at 37° C. while shaking in an orbital shaker at 200RPM until the optical density at 600 nm was 0.56.

Expression from both plasmids was induced by the addition of IPTG to afinal concentration of 1 mM. The induced cultures were grown overnightat 16° C. while shaking in an orbital shaker at 200 RPM. Cells wereharvested by centrifugation for at 4,000 RCF for 15 minutes at 4° C. Thecell pellet was re-suspended in 15 mL of lysis buffer composed of 50 mMTris pH 7.5, 100 mM NaCl, 5% glycerol, and 1 mM TCEP supplemented with 1Complete™ protease inhibitor tablet (Roche, Basel, Switzerland) per 50mL of lysis buffer. The re-suspended cells were transferred to a 50 mLconical tube for immediate downstream processing. Cascade RNP complexeswere purified and characterized as described below.

Example 5 Purification of Cascade Components and Cascade RNP Complexes

This Example describes a method to purify E. coli Type I-E Cascaderibonucleoprotein (RNP) complexes produced by overexpression in bacteriaas described in Example 4. The method uses immobilized metal affinitychromatography followed by size exclusion chromatography. This Examplealso describes the methods used to assess the quality of the purifiedCascade RNP product. In addition, this Example describes purificationand characterization of Cascade components.

A. Purification of Cas8, Cas7, Cash, Cas5, and Cse2 Cascade RNPComplexes

E. coli Type I-E Cascade RNP complexes were produced as described inExample 4. The Cascade complexes were captured using immobilized metalaffinity chromatography. Briefly, the re-suspended cell pellets,produced as described in Example 4, were thawed on ice and the volumewas brought to 35 mL by of an additional 15 mL of lysis buffer composedof 50 mM Tris pH 7.5, 100 mM NaCl, 5% glycerol, and 1 mM TCEPsupplemented with 1 Complete™ protease inhibitor tablet (Roche, Basel,Switzerland) per 50 mL of lysis buffer.

The 50 mL conical tube was placed in an ice water bath and the cellswere lysed by two rounds of sonication using a Q500 sonicator with a ½inch tip (Qsonica, Newtown, Conn.). Each round of sonication consistedof a treatment cycle of 2.5 minutes with repeating cycles of 10 secondsof sonication at 50% amplitude followed by 20 seconds of rest. The tubewas allowed to cool in the ice water bath for one minute between roundsof sonication. The lysates were clarified by centrifugation at 48,384RCF for 30 minutes at 4° C. The clarified supernatant was then added toa Hispur™ Ni-NTA resin (Thermofisher, Waltham, Mass.), that had beenpre-equilibrated with Ni-wash buffer composed of 50 mM Tris pH 7.5, 100mM NaCl, 10 mM imidazole, 5% glycerol, and 1 mM TCEP. A 1.5 mL bedvolume of nickel affinity resin was used for each 1 L of E. coliexpression culture. After one hour of incubation at 4° C. with gentlemixing, the resin was pelleted by centrifugation at 500 RCF for 2minutes at 4° C. The supernatant was aspirated and the resin was washed5 times with 5 bed volumes of Ni-wash buffer. After each wash the resinwas pelleted at 500 RCF for 2 minutes at 4° C. and the supernatant wasremoved by aspiration. Finally, bound proteins (including the CascadeRNP complexes) were eluted by the addition of five bed volumes ofNi-elution buffer composed of 50 mM Tris pH 7.5, 100 mM NaCl, 300 mMimidazole, 5% glycerol, and 1 mM tris(2-carboxyethyl)phosphine (TCEP).After centrifugation at 500 RCF for 2 minutes at 4° C., the nickelaffinity eluate was aspirated into a clean 50 mL conical tube.

The nickel affinity eluate was further purified by size exclusionchromatography (SEC). The nickel affinity eluate was concentrated to afinal volume of 0.5 mL by ultrafiltration at 12° C. using an Amicon®ultrafiltration spin concentrator (Millipore Sigma, Billerica, Mass.)with an Ultracel®-50 membrane (Millipore Sigma, Billerica, Mass.). Theconcentrated sample was filtered using a 0.22 μM Ultrafree-MC GVCentrifugal Filter (Millipore Sigma, Billerica, Mass.) before beingfurther purified by separation at 4° C. with a flow rate of 0.5mL/minute on a HiPrep™ 16/60 Sephacryl® S-300 column (GE Healthcare,Uppsala, Sweden) equilibrated with SEC buffer composed of 50 mM Tris pH7.5, 500 mM NaCl, 5% glycerol, 0.1 mM EDTA, and 1 mM TCEP. Proteins wereeluted with SEC buffer and 1 ml fractions were collected. The earliesteluting peak, as judged by UV 280, was assumed to be high molecularweight aggregated material and the corresponding fractions werediscarded. Subsequent elution fractions were analyzed by Coomassiestained SDS-PAGE. Each properly formed complex contained one molecule ofCas8, six molecules of Cas7, one molecule each of Cas6 and Cas5, and twomolecules of Cse2. Elution fractions that had the approximate expectedstoichiometry of Cascade proteins, when visualized on the SDS-PAGE gel,were pooled. Pooled fractions were analyzed spectrophotometrically toconfirm they contained a significant nucleic acid component, asevidenced by an absorbance at 260 nm that is greater than the absorbanceat 280 nm.

The pooled samples were exchanged into storage buffer composed of 50 mMTris pH 7.5, 100 mM NaCl, 5% glycerol, 0.1 mM EDTA, and 1 mM TCEP byconcentrating the pooled samples to 100 uL with an Amicon® spinconcentrator with an Ultracel®-50 membrane (Millipore Sigma, Billerica,Mass.) and then diluting 50-fold with the storage buffer. Finally, thesample was concentrated to 10 mg/mL using the same ultrafiltrationdevice and stored at −80° C.

The final purified product was analyzed spectrophotometrically todetermine the final concentration of the Cascade RNP complexes and toconfirm the presence of a nucleic acid component as evidenced by anabsorbance at 260 nm that is greater than the absorbance at 280 nM. Theconcentration of the Cascade RNP complexes was determined by dividingthe absorbance at 280 nm by the calculated absorbance of a 0.1% solutionof the intact complex with a 1 cm path length. The predicted absorbanceof a 0.1% solution of the purified complex is 2.03 cm⁻¹ and wascalculated by dividing the sum of the calculated extinction coefficientsat 280 nm for each of the molecules in the complex (916940 M⁻¹ cm⁻¹) bythe sum of the molecular weights of each of the molecules in the complex(450832 g/mole).

Additionally, the final product was analyzed by SDS-PAGE with Coomassieblue staining to confirm that each protein component was present inapproximately the correct stoichiometry, and to assess the presence ofcontaminating proteins. SDS-PAGE gels were stained with a CoomassieInstantBlue™ (Expedeon, San Diego, Calif.) stain. Gels were imaged usinga Gel Doc™ EZ imager (Bio-Rad, Hercules, Calif.) and annotated usingImageLab software (Bio-Rad, Hercules, Calif.).

In view of the teachings of the Specification and the Examples, thismethod for purification of E. coli Type I-E Cascade complexes can beapplied to the production of other purified Type I Cascade complexes.

B. Purification of Cascade Complexes Comprising Cas7, Cas6, Cas5, andCse2 Proteins

A Cascade complex composed of the and the protein components Cas7, Cas6,Cas5, and Cse2 was purified. The L3 guide RNA (Example 2, SEQ ID NO:445,Table 15) was expressed from a first plasmid (Example 2, FIG. 25)essentially as described in Example 4.B. The Cascade proteins wereexpressed from a second plasmid (Example 2, SEQ ID NO:440, Table 14,FIG. 24C) essentially as described in Example 4B.

The complex was captured using affinity chromatography. Re-suspendedcell pellets were thawed on ice. In a 50 mL conical tube, the volume wasbrought up to 35 mL with an additional 15 mL of lysis buffer composed of50 mM Tris pH 7.5, 100 mM NaCl, 5% glycerol, 1 mM TCEP, and supplementedwith 1 Complete™ protease inhibitor tablet (Roche, Basel, Switzerland)per 50 mL of lysis buffer. The 50 mL conical tube was placed in an icewater bath, and the cells were lysed by six rounds of sonication using aQ500 sonicator with a ½ inch tip (Qsonica, Newtown, Conn.). Each roundof sonication consisted of a 1 minute treatment cycle with repeatingcycles of 3 seconds of sonication at 90% amplitude followed by 9 secondsof rest. The tube was allowed to cool in the ice water bath for oneminute between rounds of sonication. The lysate was clarified bycentrifugation at 48,384 RCF for 30 minutes at 4° C. The clarifiedsupernatant was affinity purified by addition of Strep-Tactin®Sepharose® resin (IBA Life Sciences, Gottingen, Germany) that had beenpre-equilibrated with Strep-wash buffer composed of 50 mM Tris pH 7.5,100 mM NaCl, 1 mM EDTA, 5% glycerol, and 1 mM TCEP. A 0.55 mL bed volumeof affinity resin was used for each 1 L of E. coli expression culture.After one hour of incubation at 4° C. with gentle mixing, the sample waspoured onto a 30 mL disposable gravity flow column (Bio-Rad, Hercules,Calif.) allowing the unbound material to flow through the column. Theresin was washed five times with five bed volumes of Strep-wash buffer.Finally, the bound proteins were eluted with two sequential additions offive bed volumes of Strep-elution buffer composed of 50 mM Tris pH 7.5,100 mM NaCl, 2.5 mM Desthiobiotin, 5% glycerol, 1 mM EDTA, and 1 mMTCEP.

The affinity eluate was further purified by SEC. The affinity eluate wasconcentrated to a final volume of 550 uL by ultrafiltration at 12° C.using an Amicon® spin concentrator with an Ultracel®-50 membrane(Millipore Sigma, Billerica, Mass.). The concentrated sample wasfiltered using a 0.22 μm 13 mm UltraCruz® PVDF syringe filter (SantaCruz Biotechnology, Dallas, Tex.) before being further purified byseparation at 4° C. with a flow rate of 0.4 mL/minute on a HiPrep™ 16/60Sephacryl® S-300 column (GE Healthcare, Uppsala, Sweden) equilibratedwith SEC buffer composed of 50 mM Tris pH 7.5, 500 mM NaCl, 5% glycerol,0.1 mM EDTA, and 1 mM TCEP. Protein was eluted with SEC buffer and 0.75ml fractions were collected. The earliest eluting peak, as judged by UV280, was assumed to be high molecular weight aggregated material and thecorresponding fractions were discarded. Fractions corresponding to thesecond peak (a shoulder on the back side of the first UV 280 peak) werepooled.

The pooled samples were exchanged into storage buffer composed of 50 mMTris pH 7.5, 100 mM NaCl, 5% glycerol, 0.1 mM EDTA, and 1 mM TCEP byconcentrating down to 200 uL with an Amicon® spin concentrator with anUltracel®-50 membrane (Millipore Sigma, Billerica, Mass.) and thendiluting 75-fold with storage buffer. The sample was concentrated asecond time to 700 uL and again diluted 20-fold with storage buffer.Finally, the sample was concentrated to 4.7 mg/mL in the sameultrafiltration device and stored at −80° C.

The final purified product was analyzed spectrophotometrically todetermine the final concentration of the Cascade RNP complexes and toconfirm the presence of a nucleic acid component as evidenced by anabsorbance at 260 nm that is greater than the absorbance at 280 nM. Theconcentration of the Cascade RNP complexes was determined by dividingthe absorbance at 280 nm by the calculated absorbance of a 0.1% solutionof the intact complex with a 1 cm path length. The predicted absorbanceof a 0.1% solution of the purified complex is 2.18 cm⁻¹ and wascalculated by dividing the sum of the calculated extinction coefficientsat 280 nm for each molecule in the complex (762240 M⁻¹ cm⁻¹) by the sumof the molecular weights of each molecule in the complex (348952.07g/mole).

Additionally, the final product was analyzed by SDS-PAGE with Coomassieblue staining to confirm that each Cascade protein was present inapproximately the correct stoichiometry, and to assess the presence ofcontaminating proteins. SDS-PAGE gels were stained with CoomassieInstantBlue™ (Expedeon, San Diego, Calif.) stain. Gels were imaged usinga Gel Doc™ EZ imager (Bio-Rad, Hercules, Calif.) and annotated usingImageLab software (Bio-Rad, Hercules, Calif.). Each properly formedcomplex contained six molecules of Cas7, one molecule each of Cas6 andCas5, and two molecules of Cse2.

C. Purification of FokI-Cas8 Fusion Protein

A method used to purify a fusion protein comprising a FokI nucleasefusion to the E. coli Type I-E Cas8 protein from bacterialover-expression pellets using immobilized metal affinity chromatography,cation exchange chromatography (CIEX), and finally size exclusionchromatography (SEC) is described herein.

The E. coli Type I-E FokI-Cas8 fusion protein, including a linkersequence, is described in Example 1 (SEQ ID NO:413, Table 11). Theexpression plasmid is described in Example 2 (SEQ ID NO:439, Table 14,FIG. 24B). Cells comprising the fusion protein were produced essentiallyas described in Example 4A. The Cas8 fusion protein contained aN-terminal His6 tag, a Maltose binding protein domain, a TEV cleavagesite, a FokI nuclease domain, and a 30 amino acid linker. The proteinwas captured using immobilized metal affinity chromatography. A 50 mLconical tube containing the re-suspended cell pellets was thawed on ice.The tube was then placed in an ice water bath, and the cells were lysedby sonication using a Q500 sonicator with a ¼ inch tip (Qsonica,Newtown, Conn.) for a treatment cycle of three minutes with repeatingcycles of 10 seconds of sonication at 40% amplitude followed by 20seconds of rest. The lysates were clarified by centrifugation at 30,970RCF for 30 minutes at 4° C. The clarified supernatant was then added toHispur™ Ni-NTA resin (Thermofisher, Waltham, Mass.), that had beenpre-equilibrated with Ni-wash buffer composed of 50 mM Tris pH 7.5, 100mM NaCl, 10 mM imidazole, 5% glycerol, and 1 mM TCEP. A 2 mL bed volumeof nickel affinity resin was used for 1 L of E. coli expression culture.After one hour of incubation at 4° C. with gentle mixing, the sample waspoured onto a 30 mL disposable gravity flow column (Bio-Rad, Hercules,Calif.), allowing the unbound material to flow through the column. Theresin was washed five times with five bed volumes of Ni-wash buffer.Finally, the bound proteins were eluted with five bed volumes ofNi-elution buffer composed of 50 mM Tris pH 7.5, 100 mM NaCl, 300 mMimidazole, 5% glycerol, and 1 mM TCEP.

The nickel affinity eluate was treated with TEV protease to remove theaffinity tag. TEV protease was added to the eluate at a ratio of 1:25(w/w). The sample, including TEV, was dialyzed overnight against Ni-washbuffer using a 12 mL Slid-A-Lyzer™, 10K MWCO dialysis cassette(Thermofisher, Waltham, Mass.).

The TEV protease and the cleaved His6-MBP fragment were removed from thedialyzed sample by Ni affinity chromatography. The dialyzed sample waspoured over a clean Hispur™ Ni-NTA resin (Thermofisher, Waltham, Mass.)column equilibrated with Ni-wash buffer. The resin was then washed with1 column volume of Ni-NTA wash buffer. The flow through and wash werecombined, concentrated, and exchanged into storage buffer (50 mM Tris pH7.5, 500 mM NaCl, 5% glycerol, and 1 mM TCEP) using an Amicon® spinconcentrator with an Ultracel®-10 membrane (Millipore Sigma, Billerica,Mass.). This sample was then frozen at −80C for storage.

The sample was thawed and further purified by cation exchangechromatography (CIEX). The sample was thawed on ice and diluted 10-foldfrom 0.475 mL to 4.75 mL with Cold CIEX_A buffer composed of 50 mM TrispH 7.5, 5% glycerol, and 1 mM TCEP, resulting in a final concentrationof 50 mM NaCl. A 10 mL capillary loop was used to load the sample onto a1 mL Hitrap™ SP HP column (GE Healthcare, Uppsala, Sweden), equilibratedwith a buffer comprising CIEX_A buffer and 5% CIEX_B buffer (50 mM TrispH 7.5, 1 M NaCl, 5% glycerol, and 1 mM TCEP). The flow rate throughoutthe separation was of 0.75 mL/min. The loop was emptied onto the columnwith 15 mL of with 5% CIEX_B buffer. The unbound sample was washed outwith an additional 2 mL of 5% CIEX_B buffer. 500 μL fractions werecollected as the bound proteins were eluted with an 8 mL linear gradientfrom 5% to 65% CIEX_B buffer. There were two major UV280 elution peaks.The four fractions corresponding to the first of those two peaks werepooled. The total pooled volume was 2 mL.

The pooled CIEX fractions were further purified by SEC. The pooled CIEXfractions were concentrated to a final volume of 0.3 mL byultrafiltration at 12° C. using an Amicon® spin concentrator with anUltracel®-10 membrane (Millipore Sigma, Billerica, Mass.). Theconcentrated sample was filtered using a 0.22 μm Ultrafree-MC GVCentrifugal spin filter (Millipore Sigma, Billerica, Mass.), and furtherpurified by separation at 4° C. with a flow rate of 0.6 mL/minute on a10/300 Superdex™ 200 GL Increase column (GE Healthcare, Uppsala, Sweden)equilibrated with a Cas8 SEC buffer (50 mM Tris pH 7.5, 200 mM NaCl, 5%glycerol, and 1 mM TCEP). The protein was eluted with the Cas8 SECbuffer and 0.5 ml fractions were collected. The earliest eluting peak,as judged by UV 280, was assumed to be high molecular weight aggregatedmaterial and the corresponding fractions were discarded. A second majorUV 280 peak was eluted after about 14 mL. The fractions corresponding tothis second peak were pooled. The pooled samples were concentrated to 40μL with an Amicon® spin concentrator with an Ultracel®-3 membrane(Millipore Sigma, Billerica, Mass.) The concentrated sample was storedat −80° C.

The final purified product was analyzed spectrophotometrically todetermine the final concentration of the fusion protein and to confirmthe absence of a significant nucleic acid component as evidenced by anabsorbance at 280 nm that is greater than the absorbance at 260 nm. Theconcentration of the FokI-Cas8 fusion was determined by dividing theabsorbance at 280 nm by the calculated absorbance of a 0.1% solution ofthe intact complex. The predicted absorbance of a 0.1% solution of thepurified complex is 1.05 cm⁻¹ and was calculated by dividing extinctioncoefficient at 280 nm for the FokI-Cas8 fusion (86290 M⁻¹ cm⁻¹) by itsmolecular weight (82171.32 g/mole). Additionally, the final product wasanalyzed by SDS-PAGE gels stained with InstantBlue™ stain (Expedeon, SanDiego, Calif.). Gels were imaged using a Gel Doc™ EZ imager (Bio-Rad,Hercules, Calif.) and annotated using ImageLab software (Bio-Rad,Hercules, Calif.). This analysis demonstrates that the purified fusionprotein was the expected size and that only a low level of contaminatingproteins were present.

Example 6 Production of Double-stranded DNA (dsDNA) Target Sequences forUse in Biochemical Cleavage Assays

Double-stranded DNA (dsDNA) target sequences for use in in vitro DNAbinding or cleavage assays with Cascade or Cascade-fusion effectorcomplexes can be produced using several different methods. This Exampledescribes three methods to produce target sequences, including annealingof synthetic single-stranded DNA (ssDNA) oligonucleotides, PCRamplification of selected nucleic acid target sequences from genomicDNA, and/or cloning of nucleic acid target sequences into bacterialplasmids. The dsDNA target sequences were used in Cascade binding orcleavage assays.

A. Production of dsDNA Target Sequences by Annealing SyntheticSingle-stranded DNA Oligonucleotides

DNA oligonucleotides encoding the target region of interest comprisingthe target sequence, also known as the protospacer, that is recognizedby the guide portion of CRISPR RNA, the neighboring protospacer adjacentmotif (PAM), and additional 5′ and 3′ flanking sequences were purchasedfrom a commercial manufacturer (Integrated DNA Technologies, Coralville,Iowa). Two oligonucleotides were ordered per construct, one comprisingthe sense strand and one comprising the nonsense strand. Table 21 listsoligonucleotide sequences that were ordered to contain a target sequencedenoted J3, which is derived from bacteriophage lambda genomic DNA. Thetarget and PAM sequences are flanked by 20-bp of additional sequence onboth the 5′ and 3′ ends.

TABLE 21 Single-stranded DNA Oligonucleotides Seq ID NO: DescriptionSequence SEQ ID Foward oligo, ATCATCCTCCTGACAATTTTGACAGCCCACATGGCNO: 466 J3 target ATTCCACTTATCACTGGCATCTTTAAAAGCCAGGA sequence CGGTCSEQ ID Reverse oligo, GACCGTCCTGGCTTTTAAAGATGCCAGTGATAAGT NO: 467J3 target GGAATGCCATGTGGGCTGTCAAAATTGTCAGGAG sequence GATGAT

The oligonucleotides were annealed by mixing both oligonucleotides atequimolar concentration (10 μM) in 1× annealing buffer (6 mM HEPES, pH7.0, and 60 mM KCl), heating at 95° C. for 2 minutes, and then slowcooling. Annealed oligonucleotides were then used directly in DNAbinding and/or DNA cleavage assays with Cascade and/or Cascade-effectordomain fusion RNPs.

5′ Cy5 fluorescently-labeled DNA oligonucleotides encoding the targetregion of interest comprising both the target sequence, also known asthe protospacer, recognized by the guide portion of CRISPR RNA, as wellas the flanking neighboring protospacer adjacent motif (PAM), andadditional 5′ and 3′ flanking sequences, were purchased from acommercial manufacturer (Integrated DNA Technologies, Coralville, Iowa).Four oligonucleotides were ordered per construct, one comprising the 5′fluorescent-labeled sense strand, one comprising the 5′ unlabeled sensestrand, one comprising the 5′ fluorescent-labeled nonsense strand, andone comprising the 5′ unlabeled nonsense strand. The target and PAMsequences are flanked by 20-bp of additional sequence on both the 5′ and3′ ends.

Table 22 lists oligonucleotide sequences that were ordered to contain atarget sequence denoted J3, which was derived from bacteriophage lambdagenomic DNA and a control target sequence denoted CCR5, which wasderived from the human CCR5 locus.

TABLE 22Single-stranded DNA (ssDNA) Oligonucleotides for Fluorescently LabeleddsDNA Target Sequence Formation SEQ ID NO: Description SequenceSEQ ID NO: 468 target strand 5′CGCCGAGCTCGAATTCTTTTGACAGCCCACATG J3GCATTCCACTTATCACTGGCATGGATCCTGGCTG TGGTGATG SEQ ID NO: 469 non target5′CATCACCACAGCCAGGATCCATGCCAGTGATA strand J3AGTGGAATGCCATGTGGGCTGTCAAAAGAATTC GAGCTCGGCG SEQ ID NO: 470target strand 5′CGCCGAGCTCGAATTCTTTTTAGGTACCTGGCT CCR5 SiteGTCGTCCATGCTGTGTTTGCATGGATCCTGGCTG TGGTGATG SEQ ID NO: 471 non target5′CATCACCACAGCCAGGATCCATGCAAACACAG strand CCR5CATGGACGACAGCCAGGTACCTAAAAAGAATTC GAGCTCGGCG SEQ ID NO: 472target strand 5′Cy5- J3 CGCCGAGCTCGAATTCTTTTGACAGCCCACATGGCATTCCACTTATCACTGGCATGGATCCTGGCTGT GGTGATG SEQ ID NO: 473 non target5′Cy5- strand J3 CATCACCACAGCCAGGATCCATGCCAGTGATAAGTGGAATGCCATGTGGGCTGTCAAAAGAATTCG AGCTCGGCG SEQ ID NO: 474 target strand5′Cy5- CCR5 Site CGCCGAGCTCGAATTCTTTTTAGGTACCTGGCTGTCGTCCATGCTGTGTTTGCATGGATCCTGGCTGT GGTGATG

The oligonucleotides were annealed by mixing a labeled and unlabeled ortwo labeled or two unlabeled oligonucleotides at equimolar concentration(1 μM) in 1× annealing buffer (6 mM HEPES, pH 7.0, 60 mM KCl), heatingat 95° C. for 2 minutes, and then slow cooling. Annealedoligonucleotides were then used directly in DNA binding assays withCascade and/or Cascade-effector domain fusion RNPs. Cy5fluorescently-labeled DNA oligonucleotides were imaged with an AZUREc600 Bioimager (Azure BioSystems, Dublin, Calif.).

This method can be applied to produce additional labeled or unlabeledtarget or dual-target sequences, whereby a dual target is defined as atarget that contains two protospacer sequences targeted by individualCascade molecules, separated by an interspacer sequence.

B. Production of dsDNA Target Sequences by PCR Amplification fromGenomic DNA

Double-stranded DNA target sequences for dual targets derived from humangenomic DNA were produced using PCR amplification directly from genomicDNA template material. Specifically, PCR reactions contained humangenomic DNA purified from K562 cells and Q5 Hot Start High-Fidelity 2×Master Mix (New England Biolabs, Ipswich, Mass.), as well as the primerslisted in Table 23, where the underlined portions correspond to primerbinding sites within genomic DNA.

TABLE 23 Primers for PCR Amplification SEQ ID NO: Description SequenceSEQ ID Forward primer to amplify Hsa07 CACTCTTTCCCTACACGACGCTCTT NO: 475dual-target from human genomic CCGATCTTTCCTCCCTAACCTCCAC DNA CT SEQ IDReverse primer to amplify Hsa07 GGAGTTCAGACGTGTGCTCTTCCG NO: 476dual-target from human genomic ATCTTAAAGAGCCCAACCAGATGC DNA

PCR was performed according to the manufacturer's instructions (NewEngland Biolabs, Ipswich, Mass.), and the desired product DNA, 288-bp inlength, was purified using a Nucleospin Gel and PCR Cleanup kit(Macherey-Nagel, Bethlehem, Pa.) This dsDNA was then used directly inDNA binding and/or DNA cleavage assays with Cascade and/orCascade-effector domain fusion RNPs.

C. Production of dsDNA Target Sequences by Cloning Target Sequences intoBacterial Plasmids

DNA oligonucleotides encoding the target region of interest comprisingthe target sequence, also known as the protospacer, that is recognizedby the guide portion of CRISPR RNA, the neighboring protospacer adjacentmotif (PAM), and additional 5′ and 3′ flanking sequences were purchasedfrom a commercial manufacturer (Integrated DNA Technologies, Coralville,Iowa). The oligonucleotides were designed such that, when annealed, thetermini regenerate sticky ends upon cleavage of their respectiverecognition sites by the restriction enzymes EcoRI and BlpI, or by BamHIand EcoRI. Oligonucleotides were designed to contain a single targetsequence derived from the bacteriophage lambda genome, denoted J3. Inaddition, oligonucleotides were designed to contain two tandem targetsequences derived from the bacteriophage lambda genome, denoted J3 andL3, separated from each other by a 15-bp interspacer sequence. Sequencesof these oligonucleotides are listed in Table 24.

TABLE 24 Oligonucleotides Comprising Target Sequences Restriction enzymeSEQ ID recognition NO: Description sites Sequence SEQ ID ForwardBamHI and GATCCATGCCAGTGATAAGTG NO: 477 oligonucleotide, J3 EcoRIGAATGCCATGTGGGCTGTCAA target sequence for AAG cloning into PACYC-Duet1SEQ ID Reverse BamHI and AATTCTTTTGACAGCCCACATG NO: 478oligonucleotide, J3 EcoRI GCATTCCACTTATCACTGGCAT target sequence for Gcloning into PACYC-Duet1 SEQ ID Foward EcoRI and AATTCTTTTGACAGCCCACATGNO: 479 oligonucleotide, J3- BlpI GCATTCCACTTATCACTGGCAT 15bp-L3 targetCCTAGGCCTCTCGAGATGAGTG sequences for GCAGATATAGCCTGGTGGTTCA cloning intoGGCGGCGCATGC pACYC-Duet1 SEQ ID Reverse EcoRI and TCAGCATGCGCCGCCTGAACCANO: 480 oligonucleotide, J3- BlpI CCAGGCTATATCTGCCACTCAT 15bp-L3 targetCTCGAGAGGCCTAGGATGCCA sequences for GTGATAAGTGGAATGCCATGT cloning intoGGGCTGTCAAAAG pACYC-Duet1

The oligonucleotides contain 5′-phosphorylated ends, which wereintroduced by the commercial manufacturer or phosphorylated in-houseusing T4 polynucleotide kinase (New England Biolabs, Ipswich, Mass.).The oligonucleotides were then annealed at a final concentration of 1 μMby mixing together equimolar amounts in annealing buffer (6 mM HEPES, pH7.0, 60 mM KCl), heating to 95° C. for 2 minutes, and then slow-coolingon the benchtop.

Separately, a pACYC-Duet1 (MilliporeSigma, Hayward, Calif.) plasmid wasdouble-digested with the corresponding pair of restriction enzymes,either BamHI and EcoRI, or EcoRI and BlpI, whose sticky ends match thesticky ends formed by the termini of the hybridized oligonucleotides.The double-digested vector was separated from the removed insert usingagarose gel electrophoresis.

In order to clone the hybridized oligonucleotides into thedouble-digested vector, the hybridized oligonucleotides were diluted toa 50 nM stock concentration, and then a 10 μL ligation reaction wasformed using hybridized oligonucleotides, the double-digested vector,and Quick Ligase from New England Biolabs. The ligation reaction wasthen used to transform chemically competent E. coli strains, and afterovernight growth on agarose plates, individual clones were isolated andgrown in liquid culture to generate sufficient bacterial cultures fromwhich to isolate plasmids. Sanger sequencing was then used to validatethe desired plasmid sequence. Table 25 provides complete vectorsequences for plasmids containing the J3 target sequence (SEQ ID NO:481)and plasmids containing the J3 and L3 targets sequences separated by the15-bp interspacer sequence (SEQ ID NO:482).

TABLE 25 Complete Plasmid Sequences SEQ ID NO: Description of plasmidSEQ ID NO: 481 J3 target sequence in pACYC-Duet1 SEQ ID NO: 482J3-15bp-L3 target sequences in pACYC-Duet1 SEQ ID NO: 483 J3-30bp-L3target sequences in pACYC-Duet1 SEQ ID NO: 484 multi-target plasmid

Further cloning manipulations were used to generate additionaldouble-target plasmid constructs. The 15-bp interspacer sequence of SEQID NO:482 contains unique Avrll and XhoI restriction sites. Thus,introduction of additional hybridized oligonucleotides into theserestriction sites expands the interspacer to longer lengths, forbiochemical testing with purified Cascade and Cascade-nuclease fusionRNPs. Because the crRNA-guided FokI-Cascade fusion complex targets twoadjacent DNA site, dimerization of the FokI domains from adjacentDNA-bound complexes leads to DNA cleavage within the interspacerseparating the two target sites. Variable interspacer lengths weredesigned and tested to evaluate a given interspacer length with a giventethering geometry between the FokI nuclease domain and its fusedCascade subunit protein. The complete vector sequence for a target DNAsubstrate containing an expanded interspacer sequence of 30-bp in lengthis given in Table 25 as SEQ ID NO:483.

In addition, the following cloning strategy provided a plasmid substratethat contains several target sequences serially connected along onelarge insert. A gene block was ordered from a commercial manufacturer(Integrated DNA Technologies, Coralville, Iowa) that contained 17consecutive dual targets. The gene block contained 4 bp separating eachdual target from a neighboring dual target, and contained 16 dualtargets derived from Homo sapiens genomic DNA, as well as one controldual target containing J3/L3 targets derived from the bacteriophagelambda genome. The genomic coordinates of the 16 consecutive human dualtargets are shown in Table 26. The gene block was ordered with flankingSacI and SbfI restriction sites on the ends, such that it could becloned into SacI and SbfI sites in the pACYC-Duet1 vector. The fullvector sequence of the multi-target plasmid substrate generated bycloning the gene block into pACYC-Duet1 is presented as SEQ ID NO:484 inTable 25. This multi-target sequence plasmid allowed for biochemicaltesting of multiple different FokI-Cascade preparations harboring crRNAstargeting one of the serially connected target sites within the plasmid.

TABLE 26 Human Dual Targets Target 5′ spacer target 3′ spacer target SEQID NO: name Gene genomic coordinates genomic coordinates SEQ ID NO: 485Hsa01 PDCD1 chr2: 241850348-241850382 chr2: 241850408-241850442 SEQ IDNO: 486 Hsa02 CTLA4 chr2: 203870664-203870698 chr2: 203870724-203870758SEQ ID NO: 487 Hsa03 TRAC chr14: 22509340-22509374 chr14:22509405-22509439 SEQ ID NO: 488 Hsa04 TRAC chr14: 22509785-22509819chr14: 22509850-22509884 SEQ ID NO: 489 Hsa05 TRAC chr14:22513932-22513966 chr14: 22513997-22514031 SEQ ID NO: 490 Hsa06 TRACchr14: 22515993-22516027 chr14: 22516058-22516092 SEQ ID NO: 491 Hsa07TRAC chr14: 22516265-22516299 chr14: 22516330-22516364 SEQ ID NO: 492Hsa08 CD52 chr1: 26320402-26320436 chr1: 26320467-26320501 SEQ ID NO:493 Hsa09 CTLA4 chr2: 203873012-203873046 chr2: 203873077-203873111 SEQID NO: 494 Hsa10 CTLA4 chr2: 203873195-203873229 chr2:203873260-203873294 SEQ ID NO: 495 Hsa11 TRAC chr14: 22551630-22551664chr14: 22551700-22551734 SEQ ID NO: 496 Hsa12 CTLA4 chr2:203872758-203872792 chr2: 203872828-203872862 SEQ ID NO: 497 Hsa13 TRACchr14: 22551862-22551896 chr14: 22551937-22551971 SEQ ID NO: 498 Hsa14TRBC2 chr7: 142801112-142801146 chr7: 142801187-142801221 SEQ ID NO: 499Hsa15 TRAC chr14: 22551630-22551664 chr14: 22551710-22551744 SEQ ID NO:500 Hsa16 CTLA4 chr2: 203867814-203867848 chr2: 203867894-203867928

Example 7 Use of Purified Cascade Complexes in Biochemical CleavageAssays

This Example illustrates the use of FokI-Cascade fusion proteincomplexes in biochemical double-stranded DNA (dsDNA) cleavage assays.Protein reagents were compared in terms of their activity in dsDNAcleavage.

FokI-Cascade RNPs derived from the E. coli Type I-E Cascade system weredesigned, recombinantly expressed in E. coli, and purified for use, asoutlined in Examples 1, 2, and 5. These RNPs were designed to containeither CRISPR RNAs that target the J3 and L3 target sequences derivedfrom bacteriophage lambda genomic DNA, or that target an intron in theTRAC gene within human genomic DNA. Each RNP preparation is aheterogeneous mixture comprising two FokI-Cascade complexes that areotherwise identical except for the guide portion of the crRNA.

A FokI-Cascade complex was reconstituted by mixing together a CasBCDEcomplex (produced using SEQ ID NO:440 and SEQ ID NO:446, as described inExample 2) with purified FokI-Cas8 comprising a 16-aa linker (thegeneral FokI-Cas8 expression vector sequence is described in Example 2,SEQ ID NO:439 in Table 14; the particular 16-aa linker is in Example 1,SEQ ID NO:431 in Table 12). Reconstitution was performed in 1× CascadeCleavage Buffer (20 mM Tris-Cl, pH 7.5, 200 mM NaCl, 5 mM MgCl₂, 1 mMTCEP, 5% glycerol) with CasBCDE and FokI-Cas8 both at 1 μM finalconcentrations.

In order to perform DNA cleavage assays, reaction mixtures were asfollows. A plasmid substrate comprising the J3/L3 double-target sequencewith a 30-bp interspacer (SEQ ID NO:483 in Table 25) was incubated withvarying concentrations of FokI-Cascade complex (3-100 nM) in a 15 μLreaction in 1× Cascade Cleavage Buffer, with the plasmid DNA at a finalconcentration of 13.3 ng/μL. Reactions were incubated for 30 minutes at37° C., after which 3 μL of 6×SDS loading dye was added. The loading dyewas added to denature bound FokI-Cascade complexes. The reaction mixturecomponents were resolved by 0.8% agarose gel electrophoresis. Gels werestained after electrophoresis with SYBR™ Safe DNA Gel Stain (ThermoScientific, Wilmington, Del.).

As a positive control, Streptococcus pyogenes Cas9 protein wasprogrammed with a single-guide RNA (sgRNA) targeting a 20-bp portion ofthe Cascade J3 target sequence (sgRNA-J3; the spacer sequence ispresented as SEQ ID NO:501). Cas9/sgRNA-J3 complexes were reconstitutedby mixing Cas9 together with a 2-fold molar excess of sgRNA in 1×CCEbuffer (20 mM HEPES pH 7.4, 10 mM MgCl2, 150 mM KCl, 5% glycerol).Cleavage by this Cas9/sgRNA-J3 complex was evaluated across the sameconcentration range (3-100 nM) by incubating reactions for 30 minutes at37° C. Also included in the experiment were control lanes containinguncut plasmid DNA, as well as plasmid DNA linearized with the NheIrestriction enzyme (New England Biolabs, Ipswich, Mass.). Target DNAcleavage is evidenced by a mobility shift in the plasmid, because uncutplasmid DNA is supercoiled and has a faster mobility than cleaved,linearized plasmid DNA. Nicked, open-circular plasmid DNA has a slowermobility than both supercoiled and linearized plasmid DNA.

The data obtained from these experiments demonstrate that, over theconcentration range, the FokI-Cascade complex exhibited similar targetDNA cleavage activity as Cas9-sgRNA. At the highest concentration tested(100 nM), the plasmid target was quantitatively linearized by theFokI-Cascade complex and Cas9-sgRNA.

FokI-Cascade complex reagents were also tested for their kinetics oftarget DNA cleavage. A plasmid substrate containing the J3/L3double-target sequence with a 30-bp interspacer (SEQ ID NO:483) wasincubated with 200 nM FokI-Cascade complex or 200 nM Cas9-sgRNA in a 15μL reaction, with the plasmid DNA at a final concentration of 13.3ng/μL. Reactions were quenched at either 0, 7, 10, 15, 20, 25, or 30minutes, and reaction components were resolved by agarose gelelectrophoresis as described above. The FokI-Cascade complex exhibitedsimilar but slightly slower rates of target DNA cleavage activity asCas9/sgRNA-J3 complex, with the target plasmid quantitatively linearizedby the 25 minute time-point for the FokI-Cascade complex and by the 20minute time point for the Cas9/sgRNA-J3 complex.

FokI-Cascade complex reagents were also tested for their non-specificDNA cleavage and/or nicking activity on the pACYC-Duet1 non-targetplasmid substrate, versus specific DNA cleavage of a the J3/L3double-target plasmid substrate. Table 27 contains the sequence of thepACYC-Duet1 non-target plasmid substrate used for this control (SEQ IDNO:502). Specifically, the dependence of non-specific and specific DNAtarget cleavage was investigated as a function of the monovalent saltconcentration in the reaction buffer. Modified variants of the 1×Cascade Cleavage Buffer (20 mM Tris-Cl, pH 7.5, 200 mM NaCl, 5 mM MgCl₂,1 mM TCEP, and 5% glycerol) were prepared, in which the NaClconcentration was dropped from 200 mM to either 150 mM, 100 mM or 50 mM,and the same cleavage reactions as described above were performed byincubating 200 nM FokI-Cascade complex with either 13.3 ng/μL of theJ3/L3 target plasmid or 13.3 ng/μL of the pACYC-Duet1 non-targetplasmid. Additional control reactions were performed, in which the NaClconcentration was maintained at 100 mM, but the 5 mM MgCl2 was replacedwith 10 mM EDTA, which was expected to abrogate cleavage because of therequirement of FokI for divalent metal ions for DNA cleavage.Accordingly, non-target plasmid and J3/L3 target plasmid were subjectedto the following reaction conditions: −FokI-Cascade complex;+FokI-Cascade complex, 100 mM NaCl buffer+10 mM EDTA; +FokI-Cascadecomplex, 50 mM NaCl buffer; +FokI-Cascade complex, 100 mM NaCl buffer;+FokI-Cascade complex, 150 mM NaCl buffer; +FokI-Cascade complex, 200 mMNaCl buffer. The data demonstrate that FokI-Cascade complex showednon-specific nicking of both the non-target and J3/L3 target plasmid atlow salt concentrations <200 mM NaCl, but that at a monovalent saltconcentration of 200 mM NaCl, the non-target plasmid remained intact,but the J3/L3 target plasmid was quantitatively linearized. Furthermore,buffer containing EDTA led to a complete abrogation of target cleavage,as expected.

In order to confirm that the FokI-Cascade complex cleaves the targetplasmid at the expected position, that is, within the middle of theinterspacer sequence separating the J3 and L3 targets, an experiment wasperformed in which the target plasmid was first incubated withFokI-Cascade complex, followed by incubation with the AfeI restrictionenzyme (New England Biolabs, Ipswich, Mass.), which cleaves elsewhere inthe plasmid substrate. Thus, cleavage by both FokI-Cascade 1 complex andAfeI converts the supercoiled, circular plasmid into two linearfragments migrating as distinct species on an agarose gel. Specifically,cleavage was expected to generate fragments that are 2427 bp and 1357 bpin length.

13.3 ng/μL J3/L3 target plasmid was incubated with 200 nM FokI-Cascade 1complex for 30 minutes, after which 1 μL of AfeI (10 Units/μL; NewEngland Biolabs, Ipswich, Mass.) was added to the reaction, followed byan additional 30-minute incubation at 37° C. Reaction products wereresolved by agarose gel electrophoresis, as described above.Additionally, for control experiments, the target plasmid was incubatedwith only FokI-Cascade 1 complex or only AfeI, and the same reactionswere performed with a non-target plasmid that can be cleaved by AfeI butnot by FokI-Cascade 1 complex (because the plasmid lacks the J3/L3 dualtarget). Table 27 contains the sequence of the pACYC-Duet1 non-targetplasmid substrate used for this control (SEQ ID NO:502). Accordingly,non-target plasmid and J3/L3 target plasmid were subjected to thefollowing reaction conditions: −AfeI/−FokI-Cascade complex;−AfeI/+FokI-Cascade complex; +AfeI/+FokI-Cascade complex; and+AfeI/−FokI-Cascade complex. The data demonstrate that FokI-Cascadecomplex cleaved the target plasmid in the expected location, becauseco-incubation with FokI-Cascade 1 complex and AfeI lead to two linearproducts of the expected lengths.

In order to further confirm the sequence specificity of DNA cleavage bythe FokI-Cascade complex, additional control plasmid substrates weregenerated that contain as follows: mutations in the PAM flanking the J3target, mutations in the PAM flanking the L3 target, mutations in bothPAMs flanking J3/L3 targets; mutations in the spacer sequence within theJ3 target, mutations in the spacer sequence within the L3 target,mutations in both spacer sequences within J3/L3 targets; and the J3target but not the L3 target, the L3 target but not the J3 target, andneither J3 nor L3 target. Accordingly, the plasmid substrates were asfollows: J3 PAM mutant, L3 PAM mutant, J3/L3 PAM mutant, J3 spacermutant, L3 spacer mutant, J3/L3 spacer mutant, non-target plasmid,J3-only target, L3-only target, and J3/L3 target plasmid. Each targetwas subjected to the following reaction conditions: −NdeI/−FokI-Cascadecomplex; +NdeI/−FokI-Cascade complex; and −NdeI/+FokI-Cascade 1 complex.Table 27 contains the sequences of all the mutated plasmid substratesdescribed above (SEQ ID NO:502 through SEQ ID NO:510).

TABLE 27 Mutated Plasmid Substrate Sequences SEQ ID NO: Description ofplasmid SEQ ID NO: 502 pACYC-Duet1 non-target plasmid SEQ ID NO: 503J3-30bp-L3 target plasmid, J3 PAM mutant SEQ ID NO: 504 J3-30bp-L3target plasmid, L3 PAM mutant SEQ ID NO: 505 J3-30bp-L3 target plasmid,J3/L3 PAM mutants SEQ ID NO: 506 J3-30bp-L3 target plasmid, J3 spacermutant SEQ ID NO: 507 J3-30bp-L3 target plasmid, L3 spacer mutant SEQ IDNO: 508 J3-30bp-L3 target plasmid, J3/L3 spacer mutants SEQ ID NO: 509J3-only target plasmid SEQ ID NO: 510 L3-only target plasmid

DNA cleavage reactions were performed as described above, using 200 nMFokI-Cascade complex and 13.3 ng/μL plasmid substrates; controlreactions to linearize each plasmid substrate were performed with NdeI(New England Biolabs, Ipswich, Mass.). Agarose gel electrophoresis wasperformed as described above. The data demonstrate that efficientdouble-strand beak introduction and linearization of the target plasmidis only observed for the J3/L3 target plasmids, but not for controlplasmids harboring PAM or seed mutations, or only one of the two targetsites.

Components for various FokI-Cascade complexes were cloned andoverexpressed. RNPs produced by these components were purified andtested for biochemical DNA cleavage, in order to compare activity fordifferent FokI-Cascade complexes. Specifically, DNA cleavage activitieswere compared for reconstituted FokI-Cascade complexes comprising thefollowing: separately purified CasBCDE complex (produced using SEQ IDNO:440 and SEQ ID NO:446) and FokI-Cas8 (produced using SEQ ID NO:439);FokI-Cascade harboring the J3/L3 guide crRNAs (produced using SEQ IDNO:442 and SEQ ID NO:446); FokI-Cascade harboring an additional nuclearlocalization signal on either the Cas7 subunit (produced using SEQ IDNO:443 and SEQ ID NO:446) or the Cas6 subunit; FokI-Cascade harboring anadditional nuclear localization signal and HA tag on either the Cas7subunit or the Cas6 subunit; FokI-Cascade that underwent a morestringent purification involving both size exclusion chromatography(SEC) and ion exchange chromatography (IEX); and FokI-Cascade that waspurified only by immobilized metal affinity chromatography (IMAC),without further clean-up.

Accordingly, non-target plasmid and J3/L3 target plasmid were subjectedto the following reaction conditions: negative control; AfeI;CasBCDE+FokI-Cas8 complex; FokI-Cascade complex; FokI-Cascade (NLS-Cas6)complex; FokI-Cascade (Cas7-NLS) complex; FokI-Cascade (NLS-HA-Cas6)complex; FokI-Cascade (Cas7-HA-NLS) complex; FokI-Cascade complex (IEX,SEC clean-up); and FokI-Cascade complex (no clean-up). DNA cleavagereactions were performed with these RNP reagents as described above,using either the non-target plasmid or the consensus J3/L3 targetplasmids, and reaction products were resolved by agarose gelelectrophoresis. The data demonstrate that all of the RNP reagents, withone exception, exhibit nearly identical and quantitative plasmid DNAcleavage, with no background cleavage of the non-target plasmid. Thesole exception was the FokI-Cascade purified without further clean-up,which exhibited more non-specific nicking activity, as seen for the lanein which it was incubated with the non-target plasmid.

Finally, using the NLS-tagged Cas7 variant of the FokI-Cascade complexas a starting point, 16 different paired guide crRNA were tested forbiochemical DNA cleavage of a plasmid substrate for Homo sapiens genomicsites Hsa01 through Hsa16 serially connected along one large insert (SEQID NO:484). Each pair of crRNAs contains two unique spacer sequencesthat correspond to two adjacent target sites in human genomic DNA,separated by an interspacer; the target sequences are described in SEQID NO:485 through SEQ ID NO:500. Table 28 contains sequences of bothcrRNAs within each pair that targets Hsa01 through Hsa16 genomic DNAsequences; the spacer of the crRNA is underlined and in lower case, andthe sequences 5′ and 3′ of the guide region correspond to repeatsequences from the CRISPR array.

TABLE 28 crRNA Sequences SEQ ID NO: DNA target crRNA sequenceSEQ ID NO: 511 Hsa01-1 AUAAACCGcgggcaggcagagcuggaggccuuucaggcccGAGUUCCCCGCGCCAGCGGGG SEQ ID NO: 512 Hsa01-2AUAAACCGggccugaggugcugccugggcauguguaaagg GAGUUCCCCGCGCCAGCGGGGSEQ ID NO: 513 Hsa02-1 AUAAACCGcacugucacccggaccucaguggcuuugccugGAGUUCCCCGCGCCAGCGGGG SEQ ID NO: 514 Hsa02-2AUAAACCGucugugcggcaaccuacaugauggggaaugag GAGUUCCCCGCGCCAGCGGGGSEQ ID NO: 515 Hsa03-1 AUAAACCGaugagcuuguuuguagcaccaccauaauucacGAGUUCCCCGCGCCAGCGGGG SEQ ID NO: 516 Hsa03-2AUAAACCGuacguaaguaguggcaugugucagguggauuc GAGUUCCCCGCGCCAGCGGGGSEQ ID NO: 517 Hsa04-1 AUAAACCGaaggcauuuggaccggcagacacauaauuguaGAGUUCCCCGCGCCAGCGGGG SEQ ID NO: 518 Hsa04-2AUAAACCGagacuccagagccauccuugggaagagugcug GAGUUCCCCGCGCCAGCGGGGSEQ ID NO: 519 Hsa05-1 AUAAACCGacaagagguguguuuccugaauucccacagugGAGUUCCCCGCGCCAGCGGGG SEQ ID NO: 520 Hsa05-2AUAAACCGuaaguguuucuagccauccuugauuuugauca GAGUUCCCCGCGCCAGCGGGGSEQ ID NO: 521 Hsa06-1 AUAAACCGuggcuacugcucugucuccugggauccugccuGAGUUCCCCGCGCCAGCGGGG SEQ ID NO: 522 Hsa06-2AUAAACCGgcccauaccuucaaggaaaauuaaggcaaaua GAGUUCCCCGCGCCAGCGGGGSEQ ID NO: 523 Hsa07-1 AUAAACCGguugauuugccugcauugguguuacacagucuGAGUUCCCCGCGCCAGCGGGG SEQ ID NO: 524 Hsa07-2AUAAACCGuaaguuguguucuucuuugccuaggccuucag GAGUUCCCCGCGCCAGCGGGGSEQ ID NO: 525 Hsa08-1 AUAAACCGgcacugccugucaacuucuacaaccuggugauGAGUUCCCCGCGCCAGCGGGG SEQ ID NO: 526 Hsa08-2AUAAACCGuaggggccaagcagugcccagcugggggucaa GAGUUCCCCGCGCCAGCGGGGSEQ ID NO: 527 Hsa09-1 AUAAACCGcuuucacugaaaguggagcugaugugacagaaGAGUUCCCCGCGCCAGCGGGG SEQ ID NO: 528 Hsa09-2AUAAACCGaugugggucaaggaauuaaguuagggaauggc GAGUUCCCCGCGCCAGCGGGGSEQ ID NO: 529 Hsa10-1 AUAAACCGgcauaaaauuuaacuugaaaagaucauuucggGAGUUCCCCGCGCCAGCGGGG SEQ ID NO: 530 Hsa10-2AUAAACCGgcuucaaaaauacucacauggcuauguuuuag GAGUUCCCCGCGCCAGCGGGGSEQ ID NO: 531 Hsa11-1 AUAAACCGaggggcaaugcagaggaaggagcgagggagcaGAGUUCCCCGCGCCAGCGGGG SEQ ID NO: 532 Hsa11-2AUAAACCGgaggugaaagcugcuaccaccucugugccccc GAGUUCCCCGCGCCAGCGGGGSEQ ID NO: 533 Hsa12-1 AUAAACCGgcugaaauugcuuuucacauucuggcucuguuGAGUUCCCCGCGCCAGCGGGG SEQ ID NO: 534 Hsa12-2AUAAACCGagaguccauauuucaauuuccaagagcugagg GAGUUCCCCGCGCCAGCGGGGSEQ ID NO: 535 Hsa13-1 AUAAACCGugcacagccaggggaggcugcagcagccuugcGAGUUCCCCGCGCCAGCGGGG SEQ ID NO: 536 Hsa13-2AUAAACCGauggaucuucaguggguucucuugggcucuag GAGUUCCCCGCGCCAGCGGGGSEQ ID NO: 537 Hsa14-1 AUAAACCGccuguggccaggcacaccagugUGGCCUUUUGGAGUUCCCCGCGCCAGCGGGG SEQ ID NO: 538 Hsa14-2AUAAACCGgaggugcacaguggggucagcacagacccgca GAGUUCCCCGCGCCAGCGGGGSEQ ID NO: 539 Hsa15-1 AUAAACCGaggggcaaugcagaggaaggagcgagggagcaGAGUUCCCCGCGCCAGCGGGG SEQ ID NO: 540 Hsa15-2AUAAACCGcugcuaccaccucugugcccccccggcaaugcG AGUUCCCCGCGCCAGCGGGGSEQ ID NO: 541 Hsa16-1 AUAAACCGgacuuuauauagauagcuuugaucccagauauGAGUUCCCCGCGCCAGCGGGG SEQ ID NO: 542 Hsa16-2AUAAACCGguuuugcucuacuuccugaagaccugaacacc GAGUUCCCCGCGCCAGCGGGG

After the 16 FokI-Cascade complexes were purified, cleavage reactionswere performed as described above, wherein the FokI-Cascade complexeswere incubated with the plasmid substrate containing Homo sapiensgenomic sites Hsa01 through Hsa16, and the reaction products wereresolved by agarose gel electrophoresis. The data demonstrate that, ofthe 16 RNP reagents, 14/16 (Hsa03-Hsa16) exhibited nearly quantitativeDNA cleavage, as evidenced by conversion of the supercoiled, circularplasmid substrate into the cleaved, linear form. Only constructs Hsa01and Hsa02 showed partial nicking activity.

Example 8 Introduction of FokI-Cascade RNP Complexes into Target Cells

This Example illustrates the design and delivery of E. coli Type I-ECascade complexes comprising FokI fusion proteins to facilitate genomeediting in human cells and describes their delivery into target cells aspre-assembled Cascade RNP complexes.

A. Production of Cascade RNP Complexes Comprising FokI forTransformation into Cells

Minimal CRISPR arrays were designed to target eight distinct loci in thehuman genome. Each minimal CRISPR array contained two spacer sequences,both of which were flanked by CRISPR repeat sequences. The two spacersequences targeted loci in the genome separated by 30 bp (i.e., a 30-bpinterspacer region), and each spacer was designed to bind a targetsequence adjacent to an AAG or ATG protospacer adjacent motif (PAM)sequence in the target cell genome. Plasmid vectors containing eachminimal CRISPR array were produced by ligating annealed oligonucleotides(Integrated DNA Technologies, Coralville, Iowa) into a pACYC-Duet1(Millipore Sigma, Billerica, Mass.) vector backbone for bacterialexpression.

Overlapping primers to produce selected spacers in minimal CRISPR arraysare set forth in Table 29, and the sequences of the primers aredescribed in Table 30.

TABLE 29 Overlapping Primers for Generation of Minimal CRISPR arraysComponent Gene target Primers Hsa03 Minimal CRISPR array TRAC intron A,B Hsa04 Minimal CRISPR array TRAC intron C, D Hsa05 Minimal CRISPR arrayTRAC intron E, F Hsa06 Minimal CRISPR array TRAC intron G, H Hsa07Minimal CRISPR array TRAC intron I, J Hsa08 Minimal CRISPR array CD52exon K, L Hsa09 Minimal CRISPR array CTLA4 exon M, N Hsa10 MinimalCRISPR array CTLA4 exon O, P

TABLE 30 DNA Primer Sequences Oligo- SEQ ID NO: nucleotide SequenceSEQ ID A /5Phos/ACCGATGAGCTTGTTTGTAGCACCACCATAATTC NO: 543ACGAGTTCCCCGCGCCAGCGGGGATAAACCGTACGTA AGTAGTGGCATGTGTCAGGTGGATTC SEQ IDB /5Phos/ACTCGAATCCACCTGACACATGCCACTACTTACG NO: 544TACGGTTTATCCCCGCTGGCGCGGGGAACTCGTGAATT ATGGTGGTGCTACAAACAAGCTCAT SEQ IDC /5Phos/ACCGAAGGCATTTGGACCGGCAGACACATAATT NO: 545GTAGAGTTCCCCGCGCCAGCGGGGATAAACCGAGACT CCAGAGCCATCCTTGGGAAGAGTGCTG SEQ IDD /5Phos/ACTCCAGCACTCTTCCCAAGGATGGCTCTGGAGT NO: 546CTCGGTTTATCCCCGCTGGCGCGGGGAACTCTACAATT ATGTGTCTGCCGGTCCAAATGCCTT SEQ IDE /5Phos/ACCGACAAGAGGTGTGTTTCCTGAATTCCCACA NO: 547GTGGAGTTCCCCGCGCCAGCGGGGATAAACCGTAAGT GTTTCTAGCCATCCTTGATTTTGATCA SEQ IDF /5Phos/ACTCTGATCAAAATCAAGGATGGCTAGAAACAC NO: 548TTACGGTTTATCCCCGCTGGCGCGGGGAACTCCACTGT GGGAATTCAGGAAACACACCTCTTGT SEQ IDG /5Phos/ACCGTGGCTACTGCTCTGTCTCCTGGGATCCTGC NO: 549CTGAGTTCCCCGCGCCAGCGGGGATAAACCGGCCCAT ACCTTCAAGGAAAATTAAGGCAAATA SEQ IDH /5Phos/ACTCTATTTGCCTTAATTTTCCTTGAAGGTATGG NO: 550GCCGGTTTATCCCCGCTGGCGCGGGGAACTCAGGCAG GATCCCAGGAGACAGAGCAGTAGCCA SEQ IDI /5Phos/ACCGGTTGATTTGCCTGCATTGGTGTTACACAGT NO: 551CTGAGTTCCCCGCGCCAGCGGGGATAAACCGTAAGTTG TGTTCTTCTTTGCCTAGGCCTTCAG SEQ IDJ /5Phos/ACTCCTGAAGGCCTAGGCAAAGAAGAACACAAC NO: 552TTACGGTTTATCCCCGCTGGCGCGGGGAACTCAGACTG TGTAACACCAATGCAGGCAAATCAAC SEQ IDK /5Phos/ACCGGCACTGCCTGTCAACTTCTACAACCTGGTG NO: 553ATGAGTTCCCCGCGCCAGCGGGGATAAACCGTAGGGG CCAAGCAGTGCCCAGCTGGGGGTCAA SEQ IDL /5Phos/ACTCTTGACCCCCAGCTGGGCACTGCTTGGCCCC NO: 554TACGGTTTATCCCCGCTGGCGCGGGGAACTCATCACCA GGTTGTAGAAGTTGACAGGCAGTGC SEQ IDM /5Phos/ACCGCTTTCACTGAAAGTGGAGCTGATGTGACA NO: 555GAAGAGTTCCCCGCGCCAGCGGGGATAAACCGATGTG GGTCAAGGAATTAAGTTAGGGAATGGC SEQ IDN /5Phos/ACTCGCCATTCCCTAACTTAATTCCTTGACCCAC NO: 556ATCGGTTTATCCCCGCTGGCGCGGGGAACTCTTCTGTC ACATCAGCTCCACTTTCAGTGAAAG SEQ IDO /5Phos/ACCGGCATAAAATTTAACTTGAAAAGATCATTT NO: 557CGGGAGTTCCCCGCGCCAGCGGGGATAAACCGGCTTC AAAAATACTCACATGGCTATGTTTTAG SEQ IDP /5Phos/ACTCCTAAAACATAGCCATGTGAGTATTTTTGAA NO: 558GCCGGTTTATCCCCGCTGGCGCGGGGAACTCCCGAAAT GATCTTTTCAAGTTAAATTTTATGC SEQ IDQ CACTCTTTCCCTACACGACGCTCTTCCGATCTAGCCTGG NO: 559 AAAGACACAAAGC SEQ ID RGGAGTTCAGACGTGTGCTCTTCCGATCTCAGCCATCCT NO: 560 TTCCACCTAA SEQ ID SCACTCTTTCCCTACACGACGCTCTTCCGATCTATGCTGC NO: 561 AGGCTTTATGCTT SEQ ID TGGAGTTCAGACGTGTGCTCTTCCGATCTTTAGGCCTGC NO: 562 CTGACTTCTC SEQ ID UCACTCTTTCCCTACACGACGCTCTTCCGATCTGGGAAG NO: 563 AAGACCAACAAGAGG SEQ ID VGGAGTTCAGACGTGTGCTCTTCCGATCTTTCAAGGGAA NO: 564 GAAGCCATTG SEQ ID WCACTCTTTCCCTACACGACGCTCTTCCGATCTAAGGCA NO: 565 GGAATTGGATGAAA SEQ ID XGGAGTTCAGACGTGTGCTCTTCCGATCTAACCTGAGAT NO: 566 GACTGCCCAT SEQ ID YCACTCTTTCCCTACACGACGCTCTTCCGATCTTTCCTCC NO: 567 CTAACCTCCACCT SEQ ID ZGGAGTTCAGACGTGTGCTCTTCCGATCTTAAAGAGCCC NO: 568 AACCAGATGC SEQ ID A2CACTCTTTCCCTACACGACGCTCTTCCGATCTGTCTCAG NO: 569 CCTTAGCCCTGTG SEQ ID B2GGAGTTCAGACGTGTGCTCTTCCGATCTCCCACTGCAA NO: 570 GTACAAGGGT SEQ ID C2CACTCTTTCCCTACACGACGCTCTTCCGATCTGGATGC NO: 571 GGAACCCAAATTA SEQ ID D2GGAGTTCAGACGTGTGCTCTTCCGATCTTAGTCTTCTCC NO: 572 CTCGCTCCC SEQ ID E2CACTCTTTCCCTACACGACGCTCTTCCGATCTTGCAGCA NO: 573 TTATGATGTGGGT SEQ ID F2GGAGTTCAGACGTGTGCTCTTCCGATCTCAACCTTTAG NO: 574 CATCACTGGCT SEQ ID G2CAAGCAGAAGACGGCATACGAGATNNNNNNNNG NO: 575 TGACTGGAGTTCAGACGTGTGCTCSEQ ID H2 AATGATACGGCGACCACCGAGATCTACACNNNNN NO: 576NNNACACTCTTTCCCTACACGACG

The design of bacterial expression vectors for production of Cascade RNPcomplexes is detailed in Example 2. In brief, each cas gene wasexpressed from a single operon, and the coding sequences for the casgenes were arranged in the order of cas8-cse2-cas7-cas5-cas6. The FokImoiety was attached by a 30-aa linker to Cas8, and a nuclearlocalization signal (NLS) was attached to the N-terminus of FokI-Cas8(FokI-Cascade complex) and the N-terminus of Cas6 (hereafter referred toas FokI-Cascade-NLS-Cas6 complex, SEQ ID NO:577).

FokI-Cascade-NLS-Cas6 complexes were purified as assembled complexesfrom E. coli essentially as described in Example 5A.

B. Transfection of Cascade RNP Complexes Comprising FokI into EukaryoticCells

HEK293 cells (ATCC, Manassas, Va.) were cultured in suspension in DMEMmedium supplemented with 10% FBS and 1× Antibiotic-Antimycotic Solution(Mediatech, Inc., Manassas, Va.) at 37° C., 5%© CO₂ and 100% humidity.HEK293 cells were transfected using the Nucleofector® 96-well ShuttleSystem (Lonza, Allendale, N.J.). Prior to nucleofection, 5 μl ofFokI-Cascade RNPs were transferred to individual wells of a 96-wellplate. Each well contained ˜225-500 pmol of FokI-Cascade-NLS-Cas6complexes, depending on the RNP. HEK293 cells were transferred to a 50ml conical centrifuge tube and centrifuged at 200×G for 3 minutes. Themedia was aspirated and the cell pellet was washed in calcium andmagnesium-free PBS. The cells were centrifuged once more andre-suspended in Nucleofector SF buffer (Lonza, Allendale, N.J.) at aconcentration of 1×10⁷ cells/ml. 20 μl of this cell suspension was addedto the FokI-Cascade-NLS-Cas6 complexes in the 96-well plate, mixed, andthen the entire volume was transferred to a 96-well Nucleocuvette™Plate. The plate was then loaded into the Nucleofector™ 96-well Shuttle™and cells were nucleofected using the 96-CM-130 Nucleofector™ program(Lonza, Allendale, N.J.). Immediately following nucleofection, 80 μl ofcomplete DMEM medium was added to each well of the 96-wellNucleocuvette™ Plate. The entire contents of the well were thentransferred to a 96-well tissue culture plate containing 100 μl ofcomplete DMEM medium. The cells were cultured at 37° C., 5% CO₂ and 100%humidity for ˜72 hours.

After ˜72 hours, the HEK293 cells were centrifuged at 500×G for 5minutes and the medium was removed. The cells were washed in calcium andmagnesium-free PBS. The cell pellets were then re-suspended in 50 μl ofQuickExtract DNA Extraction solutions (Epicentre, Madison, Wis.). ThegDNA samples obtained were then incubated at 37° C. for 10 minutes, 65°C. for 6 minutes, and 95° C. for 3 minutes to stop the reaction. gDNAsamples were then diluted with 50 μl of water and stored at −20° C. forsubsequent deep sequencing analysis.

C. Deep Sequencing of gDNA from Transfected Cells

Using the isolated gDNA, a first PCR was performed using Q5 Hot StartHigh-Fidelity 2× Master Mix (New England Biolabs, Ipswich, Mass.) at 1×concentration, primers at 0.5 μM each, 3.75 μL of gDNA in a final volumeof 10 μL and amplified 98° C. for 1 minute, 35 cycles of 10 seconds at98° C., 20 seconds at 60° C., 30 seconds at 72° C., and a finalextension at 72° C. for 2 minutes. PCR reaction was diluted 1:100 inwater. Target-specific primers are shown in Table 31. Thetarget-specific primers contained Illumina-compatible sequences so thatthe amplification products could be analyzed using a MiSeq Sequencer(Illumina, San Diego).

TABLE 31 Target-specific Primers Used for Sequencing TargetOligonucleotide* Hsa03 on-target Q, R Hsa04 on-target S, T Hsa05on-target U, V Hsa06 on-target W, X Hsa07 on-target Y, Z Hsa08 on-targetA2, B2 Hsa09 on-target C2, D2 Hsa10 on-target E2, F2 *DNA primersequences are shown in Table 30

A second “barcoding” PCR was set up such that each target was amplifiedwith primers (G2 and H2 in Table 30) that each contained unique 8 bpindices (denoted by “NNNNNNNN” in the primer sequence (see SEQ ID NO:575and SEQ ID NO:576), thus allowing de-multiplexing of each ampliconduring sequence analysis.

The second PCR was performed using Q5 Hot Start High-Fidelity 2× MasterMix (New England Biolabs, Ipswich, Mass.) at 1× concentration, primersat 0.5 μM each, 1 μL of 1:100 diluted first PCR, in a final volume of 10μL and amplified 98° C. for 1 minute, 12 cycles of 10 seconds at 98° C.,20 seconds at 60° C., 30 seconds at 72° C., and a final extension at 72°C. for 2 minutes. PCR reactions were pooled into a single microfuge tubefor SPRIselect bead (Beckman Coulter, Pasadena, Calif.)-based cleanup ofamplicons for sequencing.

To pooled amplicons, 0.9× volumes of SPRIselect beads were added, mixedand incubated at room temperature for 10 minutes. The microfuge tube wasplaced on a magnetic tube stand (Beckman Coulter, Pasadena, Calif.)until solution had cleared. Supernatant was removed and discarded, andthe residual beads were washed with 1 volume of 85% ethanol, andincubated at room temperature (RT) for 30 seconds. After incubation,ethanol was aspirated and beads were air dried at room temperature for10 minutes. The microfuge tube was then removed from the magnetic standand 0.25× volumes of water (Qiagen, Hilden, Germany) was added to thebeads, mixed vigorously, and incubated for 2 min. at RT. The microfugetube was spun in a microcentrifuge to collect the contents of the tube,and was then returned to the magnet, incubated until solution hadcleared, and the supernatant containing the purified amplicons weredispensed into a clean microfuge tube. The purified amplicon library wasquantified using the Nanodrop™ 2000 system (Thermo Scientific,Wilmington, Del.).

The amplicon library was normalized to 4 nM concentration as calculatedfrom optical absorbance at 260 nm (Nanodrop™ 2000 system; ThermoScientific, Wilmington, Del.) and size of the amplicons. Library wasanalyzed on MiSeq Sequencer with MiSeq Reagent Kit v2, 300 cycles(Illumina, San Diego), with two 151-cycle paired-end run plus twoeight-cycle index reads.

D. Deep Sequencing Data Analysis

The identity of products in the sequencing data was analyzed based uponthe index barcode sequences adapted onto the amplicons in the secondround of PCR. A computational script executing the following tasks wasused to process the MiSeq data:

Reads were aligned to the human genome (build GRCh38/38) using Bowtie(bowtie-bio.sourceforge.net/index.shtml) software.

Aligned reads were compared to wild-type loci; reads not aligning to anypart of the loci were discarded.

Reads matching wild-type sequence were tallied. Reads with indels(surrounding 10 bp from the FokI-Cascade RNP putative cut site) werecategorized by indel type and tallied.

Total indel reads were divided by the sum of wild-type reads and indelreads to give percent-mutated reads.

FIG. 29 shows genome editing as a function of FokI-Cascade-NLS-Cas6complex nucleofection (n=1). FokI-Cascade-NLS-Cas6 complexes inducedediting at all eight loci. Editing ranged from ˜0.2-5% indels, andindels were centered around the predicted cut site, in the middle of theinterspacer region.

Example 9 Introduction of Plasmids Encoding Components of FokI-CascadeRNP Complexes into Target Cells

This Example illustrates the design and delivery of E. coli Type I-ECascade complexes comprising FokI fusion proteins to facilitate genomeediting in human cells. This Example also describes the delivery ofplasmid vectors expressing Cascade complex components into eukaryoticcells.

A. Production of a Vector Encoding FokI-Cascade RNP Components to beTransfected into Target Cells

A minimal CRISPR array was designed to target the TRAC locus in thehuman genome. The minimal CRISPR array contained two spacer sequences,both of which were flanked by CRISPR repeat sequences, as described inExamples 1 and 3. The two spacer sequences targeted loci in the genomeseparated by 30 bp and each spacer was complementary to a genomicsequence adjacent to an AAG PAM sequence. The plasmid vector containingthe minimal CRISPR array was produced by ligating annealedoligonucleotides (Integrated DNA Technologies, Coralville, Iowa)encoding a CRISPR repeat flanked by two spacer sequences into amammalian expression vector with two CRISPR repeat sequences. Theresulting plasmid contained a “repeat-spacer-repeat-spacer-repeat” dualguide expressed from the human U6 (hU6) promoter (SEQ ID No:454).

FokI-Cascade RNP protein component-encoding genes were cloned intoplasmid vectors containing CMV promoters to enable delivery andexpression in mammalian cells. Cas genes were cloned into separateplasmids (SEQ ID NO:448 through SEQ ID NO:451 and SEQ ID NO:453) or in asingle plasmid as a polycistronic construct with each gene linked via 2Aviral peptide “ribosome-skipping” sequences (in SEQ ID NO:455).FokI-Cascade RNP complexes were delivered into eukaryotic cells via twodifferent methods: cas genes and the minimal CRISPR array were suppliedon separate plasmids (“six plasmid”-delivery system, SEQ ID NO:448through SEQ ID NO:451, SEQ ID NO:453 and SEQ ID NO:454), or one plasmidencoding all cas genes as a polycistronic construct and a second plasmidencoding the minimal CRISPR array (“two plasmid”-delivery system, SEQ IDNO:454 and SEQ ID NO:455).

B. Transfection of Plasmid(s)-Encoding FokI-Cascade Complex RNPs

Transfection conditions for the six plasmid-delivery system and twoplasmid-delivery systems were performed as detailed in Example 8 withthe following modifications. Prior to nucleofection, 5 μl of plasmidvector solution was transferred to individual wells of a 96-well plate.The six plasmid-delivery system was initially tested by examining thenecessity of each component for genome editing. More specifically,plasmid “cocktails” were added to each well such that there was aconstant amount (420 ng) of five plasmids and a variable amount of thesixth plasmid (either 0 ng, 70 ng, 700 ng, or 1,400 ng). Next, the sixplasmid delivery system and the two plasmid-delivery system werecompared by nucleofecting in a fixed amount (3.5 μg) of total plasmidDNA while varying the ratio of minimal CRISPR array plasmid tocas-encoding plasmid(s). Finally, lysate was harvested ˜72 hours afternucleofection for subsequent deep sequencing analysis.

C. Deep Sequencing of gDNA from Transfected Cells and Data Analysis

Deep sequencing was performed as detailed in Example 8, but only usingtarget-specific primers Y and Z from Table 31.

D. Deep Sequencing Data Analysis

Deep sequencing data analysis was performed as detailed in Example 8.FIG. 30 shows genome editing at the TRAC locus as a function of eachFokI-Cascade component in the six plasmid-delivery strategy (n=1). As isshown, editing was abolished or dramatically reduced (in the case ofCse2) if a given component was lacking. This confirms that each Cascadecomponent is necessary for editing via plasmid delivery.

FIG. 31 shows data comparing genome editing with the sixplasmid-delivery system or the two plasmid-delivery system. Across bothmethods, the highest levels of editing were achieved with the highestratio of cas:minimal CRISPR array plasmids. Additionally, thepolycistronic plasmid enabled higher levels of editing, potentially dueto increased transcription perm of plasmid.

Example 10 Circular Permutations of Cascade Subunit Proteins

This Example illustrates in silico design, cloning, expression, andpurification of a circularly-permuted (cp) E. coli Type I-E Cas7 proteinusing a structure-guided modelling approach.

A. In Silico Design

An E. coli Type I-E Cas7 protein (SEQ ID NO:18) was circularly permutedusing a structure-guided approach based on the E. coli Cascade crystalstructure 5H9E.pdb (www.rcsb.org/pdb/; Hayes, R. P, et al., Nature530(7591):499-503 (2016)). The native Cas7 N-terminus and C-terminuswere connected with a two-amino acid peptide linker having the sequenceglycine-serine (G-S). The polypeptide sequence of this circularized Cas7was opened at the position corresponding to the peptide bond betweenresidues 301 and 302 in wild-type Cas7 polypeptide sequence to form anew N-terminus (residue 302) and a new C-terminus (residue 301),resulting in a circular permuted version of Cas7 protein (cp-Cas7 V1protein). The new N-terminus and new C-terminus were designed to bepositioned for connection with a fusion protein or linker region withoutdisturbing the Cas7 protein fold or the Cascade complex assembly. Amethionine residue was added to the new N-terminus (i.e., the amino acidresidue corresponding to residue 302 of the wild-type Cas7 protein) ofthe cp-Cas7 V1 protein (SEQ ID NO:578).

A second cp-Ca.s7 protein, cp-Cas7 V2 protein, was similarly engineeredusing the G-S linker. The N-terminus and C-terminus of the cp-Cas7 V2protein correspond to residues 338 and 339, respectively, in thewild-type Cas7 sequence. The new N-terminus and new C-terminus weredesigned to be positioned for connection with a fusion protein or linkerregion without disturbing the Cas7 protein fold or the Cascade complexassembly. A methionine residue was added to the N-terminus (i.e., theamino acid residue corresponding to residue 339 of the wild-type Cas7protein) of the cp-Cas7 V2 protein (SEQ ID NO:579).

B. Cloning, Expression, and Purification of Cascade Complexes ComprisingCp-Cas7

DNA coding sequences of the in silico designed polypeptide sequences ofcp-Cas7 V1 protein and cp-Cas7 V2 protein were codon optimized forexpression in E. coli.

These DNA coding sequences were provided to a commercial manufacturer(GenScript, Piscataway, N.J.) for synthesis. The DNA sequences wereindividually introduced into a Cascade-operon expression vector (Table14; SEQ ID NO:441) to replace the wild-type Cas7 protein in theexpression vector as described in Example 2.

Each expression vector was transfected into E. coli BL21 Star™ cells(Thermofisher, Waltham, Mass.) with a second vector encoding a guide RNAfor the J3 target (SEQ ID NO:444) Table 15, as described in Example 2.Cells were cultured as described in Example 4. E. coli Type I-E Cascadecomplexes containing Cas5, Cas6, cp-Cas7 V1, Cse2, and Cas8 proteins, aswell as guide RNA/target J3; and Cas5, Cas6, cp-Cas7 V2, Cse2, and Cas8proteins as well as guide RNA/target J3, were purified as described inExample 5.

Purification of the Cascade complexes comprising the circularly-permutedCas7 variants demonstrate that circularly-permuted Type I-E CRISPR-Cassubunit proteins can be successfully used to form Cascade complexeshaving essentially the same composition (based on molecular weight) asCascade complexes comprising wild-type proteins.

C. EMSA (Electrophoretic Mobility Shift Assays) of Cascade/cp-Cas7 andJ3 Target

Purified Cascade/cp-Cas7 complexes were purified as described in thisExample and subjected to an EMSA to demonstrate specific binding totheir respective target sequence. Briefly, Cascade/cp-Cas7 andCascade/WT-Cas7 were purified and concentrated to 10 mg/mL. Cy5double-stranded target DNA was produced as described in Example 6 anddiluted to 1 μM in TE buffer (J3 target SEQ ID NO:469 and SEQ ID NO:472and CCR5 target SEQ ID NO:474 and SEQ ID NO:470). Cascade complexes andlabeled double-stranded target DNA were incubated for 30 min at 37° C.at different protein/target ratios. Immediately following theincubation, 2 μl of 50% glycerol was added to the samples and they wereloaded on a 5% native PAA gel. Gels were run at 4° C. at 70V for 90 minin 0.5×TBE buffer and imaged on an AZURE c600 Bioimager (AzureBioSystems, Dublin, Calif.) and the bands were quantitated. The data arepresented in Table 32.

TABLE 32 Results of Cascade/cp-Cas7 V2 EMSA Cascade:dsDNA Cascade ID andguide Target DNA ratio Gel shift % Cascade/WT-Cas7 J3 J3 6.7 44Cascade/cp-Cas7 V2 J3 J3 6.7 90 Cascade/WT-Cas7 J3 CCR5 6.7 LOD*Cascade/cp-Cas7 V2 J3 CCR5 6.7 LOD  *LOD = below the limit of detection

Example 11 Cascade Subunit Fusion Proteins

A. Cascade Subunit Fusion with FokI

This Example illustrates in silico design, cloning, expression, andpurification of a E. coli Type I-E Cas8 protein fused to a FokI nucleasedomain to confer nuclease activity to the Cascade complex.

E. coli Type I-E Cas8 was fused N-terminally with a Flavobacteriumokeanokoites FokI nuclease domain (GenBank no. AAA24927.1). The FokInuclease domain comprises residues contained in the Sharkey variantdescribed by Guo, et al. (Guo, J., et al., J. Mol. Biol. 400:96-107(2010)), and catalyzes double-stranded DNA cleavage uponhomo-dimerization. The amino acid sequence for the FokI nuclease (SEQ IDNO:580) contained residues Q384 to F579 (GenBank no. AAA24927.1) and hadthe following point mutations: E486Q, L4991, and D469N. Briefly, theFokI Sharkey nuclease domain (SEQ ID NO:581) was fused N-terminal toCas8 using a linker sequence (SEQ ID NO:582). For purification purposes,a hexahistine tag (His6, SEQ ID NO:583), followed by a MBP tag (SEQ IDNO:584), followed by a TEV protease cleavage sequence (SEQ ID NO:585), anuclear localization signal (NLS, SEQ ID NO:586), and a GGS linker wereappended N-terminal to residue 384 of FokI. The final constructcomprised NH3-His6-MBP-TEV-NLS-GGS-FokISharkey-30aa-linker-Cas8-COOH inthe protein sequence (SEQ ID NO:413).

In silico designed DNA sequences were provided to a commercialmanufacturer (GenScript, Piscataway, N.J.) for synthesis. The DNAsequences were cloned into a pET expression (MilliporeSigma, Hayward,Calif.) family vector backbone, which confers kanamycin resistance dueto the presence of the kanR gene as described in Example 2 resulting ina vector carryingNH3-His6-MBP-TEV-NLS-GGS-FokISharkey-30aa-linker-Cas8-COOH (SEQ IDNO:439).

The E. coli Type I-E CascadeH3-His6-MBP-TEV-NLS-GGS-FokISharkey-30aa-linker-Cas8-COOH (SEQ IDNO:439) was expressed and purified as described in Example 4 and Example5C. The protein sequence after TEV cleavage comprisesNH3-NLS-GGS-FokISharkey-30aa-linker-Cas8-COOH (SEQ ID NO:587).

Similarly, a FokI-Cas8 fusion protein was constructed in a vector thatcarries NLS-FokI-linker-Cas8_His6-HRV3C-Cse2_Cas7_Cas5_Cas6_as describedin Examples 1 and 2 (SEQ ID NO:442). Each expression vector wastransfected into E. coli BL21 Star™ cells (Thermofisher, Waltham, Mass.)with a second vector encoding a guide RNA for the J3 target (SEQ IDNO:444), as described in Example 2. This construct was expressed andpurified as described in Example 4B and Example 5A. Purification of theCascade complexes comprising the fused FokI-Cas8 variants demonstratethat nuclease fused Type I-E CRISPR-Cas subunit proteins can besuccessfully used to form Cascade complexes having essentially the samecomposition (based on molecular weight) as Cascade complexes comprisingwild-type proteins. FokI-Cas8 fusions were successfully used forbiochemical cleavage of target nucleic acid (Example 7) and for in-cellcleavage of genomic sequences in eukaryotic cells (Examples 8 and 9).

Table 33 lists further examples of Cas subunit protein-enzyme fusions.In Table 33, APOBEC corresponds to a gene that is member of the cytidinedeaminase pathway (human APOBEC I Genbank no. AB009426, human APOBEC 3FGenbank no. CH471095, human APOBEC 3G Genbank no. CR456472, rat APOBECUCSC genome browser ID RGD:2133 rat); AID corresponds to anactivation-induced cytidine deaminase (Genbank no. AY536516); PmCDA1 isan AID ortholog (Nishida, et al., Science 16:353 (2016); Iwamatsu, etal., J Biochem 110:151-158 (1991)); PvuIIHIFIT46G is a PvuII highfidelity variant T46G (Fonfara, et al., Nucleic Acids Res, 40:847-860(2012)); PvullsinglechainT46G is described in pdbID 3KSK); I-Teel is asite-specific, sequence-tolerant homing endonuclease from bacteriophageT4 and comprises an N-terminal catalytic domain as well as a C-terminalDNA-binding domain (the domains are connected by a long, flexiblelinker) (Van Roey, et al., EMBO J, 20:3631-3637 (2001)); BcnI(Sokolowska, et al., J Mol Biol 369:722-734 (2007)); and MvaI(Kaus-Drobek, et al., Nucleic Acids Res 35:2035-2046 (2007)) arerestriction enzymes.

TABLE 33 Other Enzyme Fusions such as Nucleases and Cytidine Deaminaseswith Cas8 SEQ ID NO: Enzyme Fusion to Cas8 SEQ ID NO: 593 Cas8_rAPOBEC1C terminal SEQ ID NO: 594 Cas8_AID C terminal SEQ ID NO: 595 Cas8_PmCDA1C terminal SEQ ID NO: 596 Cas8_Human APOBEC1 C terminal SEQ ID NO: 597Cas8_APOBEC3F C terminal SEQ ID NO: 598 Cas8_APOBEC3G C terminal SEQ IDNO: 599 PvuIIHIFIT46G N terminal SEQ ID NO: 600 PvuIIsinglechainT46G Nterminal SEQ ID NO: 601 I-TevI1-169Q158R N terminal SEQ ID NO: 602I-TevI1-169 N terminal SEQ ID NO: 603 BcnI singlechain N terminal SEQ IDNO: 604 MvaI singlechain N terminal SEQ ID NO: 605 DNaseI N terminal, Cterminal SEQ ID NO: 606 Cas3 N terminal SEQ ID NO: 607 S1Aspergillus Nterminal, C terminal

B. Cascade Subunit Protein Fusion with Another Cascade Subunit Protein

The two Cse2 proteins of the Cascade complex were fused together using astructure-guided approach based on the E. coli Cascade crystal structure5H9E.pdb (www.rcsb.org/pdb/; Hayes, R. P, et al., Nature530(7591):499-503 (2016)). Briefly, the C-terminus of one Cse2 and theN-terminus of a second Cse2 were fused together using a 10-aa flexiblelinker (SEQ ID NO:589). The full sequence of the Cse2-Cse2 (CasB_CasB)fusion protein is shown in SEQ ID NO:588.

In silico designed DNA sequences were provided to a commercialmanufacturer (GenScript, Piscataway, N.J.) for synthesis. The DNAsequences were cloned into the expression vector designed in Example 2(SEQ ID NO:441). The Cse2 sequence was exchanged with SEQ ID NO:588.

Each expression vector was transfected into E. coli BL21 Star™ cells(Thermofisher, Waltham, Mass.) with a second vector encoding a guide RNAfor the J3 target (SEQ ID NO:444), as described in Example 2. The E.coli Type I-E Cascade complex containing Cas5, Cash, Cas7, Cse2-Cse2,and Cas8 was expressed and purified as described in Example 4B and 5B.Purification of the Cascade complexes comprising the fused Cse2-Cse2variant demonstrate that fused Type I-E CRISPR-Cas subunit proteinssuccessfully formed Cascade complexes having essentially the samecomposition (based on molecular weight) as Cascade complexes comprisingwild-type proteins.

C. Electrophoretic Mobility Shift Assays (EMSA) of Cascade/Cse2-Cse2 andJ3 Target

Purified Cascade/Cse2-Cse2 complexes were purified as described in thisExample and subjected to an EMSA to demonstrate specific binding totheir respective target sequence. Briefly, Cascade/Cse2-Cse2 andCascade/WT-Cse2 were purified and concentrated to 10 mg/mL. Cy5double-stranded target DNA was produced as described in Example 6 anddiluted to 1M in TE buffer (J3 target SEQ ID NO:469 and SEQ ID NO:472and CCR5 target SEQ ID NO:474 and SEQ ID NO:470). Cascade complexes andlabeled double-stranded target DNA were incubated for 30 min at 37° C.at different protein/target ratios. Immediately following theincubation, 2 μl of 50% glycerol was added to the samples and they wereloaded on a 5% native PAA gel. Gels were run at 4° C. at 70V for 90 minin 0.5×TBE buffer and imaged on an AZURE c600 Bioimager (AzureBioSystems, Dublin, Calif.) and the bands were quantitated. The data arepresented in Table 34.

TABLE 34 Results of Cascade/Cse2-Cse2 EMSA Cascade:dsDNA Cascade ID andguide Target DNA ratio Gel shift % Cascade/WT-Cse2 J3 J3 6.7 44Cascade/Cse2-Cse2 J3 J3 6.7 46 Cascade/WT-Cse2 J3 CCR5 6.7 LOD*Cascade/Cse2-Cse2 J3 CCR5 6.7 LOD  *LOD = below the limit of detection

D. Cascade Subunit Protein Fusion with Another Cascade Subunit Proteinand an Enzymatic Protein Domain

The cytidine deaminase rAPOBEC1 (apolipoprotein B mRNA editing enzymecatalytic subunit 1, Rattus norvegicus; NCBI Gene ID: 25383,uEnsembl:ENSRNOG00000015411) was selected for fusion. The Cse2-Cse2protein was fused with rAPOBEC1 using a structure-guided approach basedon the E. coli Cascade crystal structure 5H9E.pdb (www.rcsb.org/pdb/;Hayes, R. P, et al., Nature 530(7591):499-503 (2016)). Briefly, theC-terminus of rAPOBEC1 (SEQ ID NO:590) was fused to the N-terminus ofthe Cse2-Cse2 dimer (described above) using a 9-aa flexible linker (SEQID NO:591). The full sequence of the rAPOBEC1_Cse2-Cse2 fusion proteinis shown in SEQ ID NO:592.

In silico designed DNA sequences were provided to a commercialmanufacturer (GenScript, Piscataway, N.J.) for synthesis. The DNAsequences were cloned into the expression vector (SEQ ID NO:441),replacing the Cse2 sequence. Each expression vector was transfected intoE. coli BL21 Star™ cells (Thermofisher, Waltham, Mass.) with a secondvector encoding a guide RNA for the J3 target (SEQ ID NO:444), asdescribed in Example 2. The E. coli Type I-E Cascade complex containingCas5, Cash, Cas7, rAPOBEC1_Cse2-Cse2, and Cas8 was expressed andpurified as described in Example 4B and 5B. Purification of the Cascadecomplexes comprising the fused rAPOBEC1_Cse2-Cse2 variant demonstratethat cytidine deaminase fusions to Type I-E CRISPR-Cas subunit proteinswere successfully used to form Cascade complexes having essentially thesame composition (based on molecular weight) as Cascade complexescomprising wild-type proteins. Table 35 presents examples of enzymefusions with Cse2-Cse2.

TABLE 35 Other Enzyme Fusions Such as Cytidine Deaminases with Cse2-Cse2SEQ ID NO: Enzyme Fusion to Cse2-Cse2 SEQ ID NO: 608 rAPOBEC1 N terminalSEQ ID NO: 609 AID C terminal SEQ ID NO: 610 CPmCDA1 C terminal SEQ IDNO: 611 Human APOBEC1 N terminal SEQ ID NO: 612 Human APOBEC3F Nterminal SEQ ID NO: 613 APOBEC3G N terminal

Example 12 Cascade Subunit Protein Fusions to TranscriptionActivation/Repression Domains

This Example illustrates the design of a E. coli Type I-E cp-Cas7protein fused to a VP64 activation domain to confer transcriptionalactivation activity to the Cascade complex.

VP64 is a transcriptional activator comprising four tandem copies ofVP16 (herpes simplex viral protein 16, DALDDFDLDML (SEQ ID NO:614);amino acids 437-447, UNIPROT:UL48) connected with glycine-serine (GS)linkers. When fused to a protein domain that can bind near the promoterof a gene, VP64 (SEQ ID No:615) acts as a strong transcriptionalactivator. The E. coli Type I-E cp-Cas7 V2 (SEQ ID NO:616) can beselected for engineering.

The activation domain VP64 can be fused to the N-terminus of cpCas7 V2(described in Example 10). A linker (e.g., 5 to 50 amino acids inlength) can be selected to operably link cpCas7 V2 and the VP64 domain.

In silico designed DNA sequences can be provided to a commercialmanufacturer for synthesis. The DNA sequences encoding a VP64-cpCas7 V2fusion protein can be cloned into an expression vector (e.g., SEQ IDNO:455, wherein VP64-cpCas7 V2 can be substituted for Cas7). Eachexpression vector can be transfected into E. coli BL21 Star™ cells(Thermofisher, Waltham, Mass.) with a second vector encoding a guide RNAfor the J3 target (SEQ ID NO:444), as described in Example 2. The E.coli Type I-E Cascade complex containing Cas5, Cas6, VP64 cpCas7 V2,Cse2, and Cas8 can be expressed and purified as described in Examples 4and 5. Purification of the Cascade complexes comprising the fused VP64cpCas7 V2 variant can be used to form Cascade complexes havingessentially the same composition (based on molecular weight) as Cascadecomplexes comprising wild-type proteins.

Selection of a guide targeted to the promoter region of a particulargene can be used to verify the ability of the Cascade complex comprisingthe fused VP64 cpCas7 V2 to facilitate transcriptional activation of thegene.

Example 13 Site-Directed Recruitment of Functional Domains Fused toCascade Subunit by dCas9/Guide Complex

This Example describes a method of modifying a Class 2 Type II CRISPRsgRNA, crRNA, tracrRNA, or crRNA and tracrRNA sequence with a Class 1Type I CRISPR repeat stem sequence (e.g., a Type I-F CRISPR repeat stemsequence) for the recruitment of one or more Cascade subunit proteins(i.e., Cas6, Cas5, etc.) fused to a functional domain, to a Type IICRISPR Cas protein/guide RNA complex binding site. This method here isadapted from Gilbert, Let. al., Cell 154(2):442-451 (2013) and Ferry, Qet. al., Nature Communication 8, 14633 doi: 10.1038/ncomms14633 (2017).

A. Modifying a Type II Guide RNA

A Type II CRISPR sgRNA, crRNA, tracrRNA, or crRNA and tracrRNA(collectively referred to a “Type II guide RNA”) can be selected forengineering.

A Type II guide RNA sequence can be evaluated in silico for regions ofincorporation of a Type I CRISPR repeat stem sequence. The Type I CRISPRrepeat stem sequence can be attached at the 5′ or 3′ end of the Type IIguide RNA, internal to the Type II guide RNA, or can replace secondarystructure in the Type II guide RNA (e.g., 3′ hairpin elements).Incorporation of the Type I CRISPR repeat stem sequence can beaccompanied by a linker element nucleotide sequence. An example of aType II tracrRNA 3′ modified with a Type I CRISPR repeat stem sequenceis presented in Table 36.

TABLE 36 Exemplary Type II tracrRNA with 3′ Type I CRISPRRepeat Stem Sequence SEQ ID NO: Sequence* SEQ ID 5′- NO: 617AGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUAAGUUCAcug ccguauaggcagCUUU-3′ *Type ICRISPR repeat stem sequence is underlined and in lower case letters. Acorresponding DNA coding sequence is presented as SEQ ID NO: 618.

A mammalian gene, such as C-X-C chemokine receptor type 4 (CXCR4), canbe selected for targeting. The junction between the 5′ UTR and exon 1can be scanned in silico for a Type II CRISPR Cas protein targetsequence occurring adjacent a Type II CRISPR Cas protein PAM sequence(e.g., 5′-NGG). The 20-nucleotide target sequence occurring upstream, ina 5′ direction, can be incorporated into the Type II crRNA. An exampleof a Type II crRNA targeting CXCR4 is shown in Table 37.

TABLE 37 Exemplary Type II crRNA Targeting CXCR4 SEQ ID NO: Sequence*SEQ ID 5′-GAACCAGCGGUUACCAUGGAGUUUUAGAGCUAUG NO: 619 CU-3′ *Acorresponding DNA coding sequence is presented as SEQ ID NO: 620.

Alternatively, the 3′ end of the CXCR4 targeting spacer (RNA) (SEQ IDNO:619) can be covalently linked to the 5′ end of the Type II tracrRNAwith 3′ Type I CRISPR repeat stem sequence (RNA) (SEQ ID NO:617) with alinker. A suitable linker element is 5′-GAAA-3′.

In silico designed Type II guide RNAs with the incorporated Type ICRISPR repeat stem sequence can be provided to a commercial manufacturerfor synthesis.

A Type I Cascade subunit protein (e.g., Cas6) can be operably linked toa transcriptional activation or repression domain (e.g., KRAB) andc-terminally tagged with a nuclear localization signal (NLS) asdescribed in Example 12.

A Type II Cas protein (e.g., Cas9) can be mutated such that it iscatalytically inactive (e.g. dCas9) and tagged with a NLS sequence.

The Cas6-KRAB-NLS protein and the dCas9-NLS protein can be recombinantlyexpressed and purified from E. coli.

Ribonucleoprotein complexes can be formed at a concentration of 60 pmoldCas9 protein:60 pmol Cas6-KRAB-NLS:120 pmol:CXCR4 targeting crRNA:120pmol tracrRNA 3′ modified with a Type I CRISPR repeat stem sequence.Prior to assembly with the dCas9 and the Cas6-KRAB-NLS, each of the 120pmol CXCR4 targeting crRNA and 120 pmol tracrRNA 3′ modified with a TypeI CRISPR repeat stem sequence (herein referred to as “modified Type IIguide RNA”) can be diluted to the desired total concentration (120 pmol)in a final volume of 2 μL, incubated for 2 minutes at 95° C., removedfrom a thermocycler, and allowed to equilibrate to room temperature.dCas9 and the Cas6-KRAB-NLS protein can be diluted to an appropriateconcentration in binding buffer (20 mM HEPES, 100 mM KCl, 5 mM MgCl₂,and 5% glycerol at pH 7.4) to a final volume of 3 μL and mixed with the2 μL of Type II guide RNA, followed by incubation at 37° C. for 30minutes. A nontransfected control (e.g., buffer only), unmodified TypeII guide RNA, or a Cas6 not linked to a repression domain, can be usedto assemble negative control RNPs.

B. Cell Transfections Using dCas9:Cas6-KRAB-NLS: Modified Type II GuideRNA

dCas9:Cas6-KRAB-NLS: modified Type II guide RNA nucleoprotein complexescan be transfected into HEK293 cells (ATCC, Manassas Va.), using theNucleofector® 96-well Shuttle System (Lonza, Allendale, N.J.) and thefollowing protocol: The complexes can be dispensed in a 5 μL finalvolume into individual wells of a 96-well plate. The cell culture mediumcan be removed from the HEK293 cell culture plate and the cells detachedwith TrypLE™ (Thermo Scientific, Wilmington, Del.). Suspended HEK293cells can be pelleted by centrifugation for 3 minutes at 200×g, TrypLEreagents aspirated, and cells washed with calcium and magnesium-freephosphate buffered saline (PBS). Cells can be pelleted by centrifugationfor 3 minutes at 200×g, the PBS aspirated, and the cell pelletre-suspended in 10 mL of calcium and magnesium-free PBS.

The cells can be counted using the Countess® II Automated Cell Counter(Life Technologies; Grand Island, N.Y.). 2.2×10⁷ cells can betransferred to a 1.5 ml microfuge tube and pelleted. The PBS can beaspirated and the cells re-suspended in Nucleofector™ SF (Lonza,Allendale, N.J.) solution to a density of 1×10⁷ cells/m. 20 μL of thecell suspension can be then added to each individual well containing 5μL of ribonucleoprotein complexes, and the entire volume from each wellcan be transferred to a well of a 96-well Nucleocuvette™ Plate (Lonza,Allendale, N.J.). The plate can be loaded onto the Nucleofector™ 96-wellShuttle™ (Lonza, Allendale, N.J.) and cells nucleofected using the96-CM-130 Nucleofector™ program (Lonza, Allendale, N.J.).Post-nucleofection, 70 μL Dulbecco's Modified Eagle Medium (DMEM; ThermoScientific, Wilmington, Del.), supplemented with 10% Fetal Bovine Serum(FBS; Thermo Scientific, Wilmington, Del.), penicillin and streptomycin(Life Technologies, Grand Island, N.Y.) can be added to each well, and50 μL of the cell suspension can be transferred to a 96-well cellculture plate containing 150 μL pre-warmed DMEM complete culture medium.The plate can be transferred to a tissue culture incubator andmaintained at 37° C. in 5% CO₂ for 48 hours.

72 hours after nucleofection of the dCas9:Cas6-KRAB-NLS: modified TypeII guide RNA nucleoprotein complexes, cells can be evaluated forrepression of CXCR4 expression. Culture medium can be aspirated from theHEK293, and the cells can be washed once with calcium and magnesium-freePBS then are trypsinized by the addition of TrypLE (Life Technologies,Grand Island, N.Y.) followed by incubation at 37° C. for 3-5 minutes.Trypsinized cells can be gently pipetted up and down to form a singlecell suspension, and the cells can then be pelleted by centrifugationfor 3 minutes at 200×g. After centrifugation the culture medium can beaspirated and cells are re-suspended in a 10 mM EDTA/PBS buffer andgently mixed into a singles cell suspension. The single-cell suspensioncan be stained using 0.05% FITC conjugated to an anti-human CXCR4antibodies (Medical & Biological Laboratories Co., Japan) in PBScontaining 10% FBS for 1 hour at room temperature. Isotype controls andnative RNP controls can be similarly stained for reference. Stainedcells can then be sorted LSR II flow cytometer (BD laboratories, SanJose Calif.) and population of FITC positive fluorescent cells tallied.

Reduction in CXCR4 expression is measure by a decrease in detectedfluorescence of a dCas9:Cas6-KRAB-NLS: modified Type II guide RNAnucleofected sample compared to the measured fluorescence of anon-transfected control. Decrease in fluorescence from the flowcytometer can be used to demonstrate that a modified Type II guide RNAwith a Type I CRISPR repeat stem sequence can be used in combinationwith a nuclease-deficient Type II Cas9 protein to recruit and localize aType I CRISPR Cascade subunit protein fused to repression domain to agene target and repress transcription of said gene target.

Example 14 Identification and Screening of Type I Cas Genes

This Example describes a method to identify and screen Type I cas genesfrom different species. The method presented here is adapted fromShmakov, S., et al., Molecular Cell 60(3):385-397 (2015).

A. Identification of Type I CRISPR-Cas Genes

Using the Basic Local Alignment Search Tool (BLAST,blast.ncbi.nlm.nih.gov/Blast.cgi), a search of the genomes of variousspecies can be conducted to identify one or more genes coding for thevarious gene component of the Type I CRISPR-Cas complex. The cas1integrase gene is a component of both Class 1 and Class 2 CRISPR-Casfamilies, and upon identification of species containing the cas1 gene,subsequence searcher in these genomes can be conducted to isolategenomes comprising Type I-specific genes. Genome searches can beanchored upon the CRISPR-Cas integrase genes cas1, an exemplary cas1sequence from the Type I-E system from E. coli K-12 MG1655 that can beused is SEQ ID. NO:621. Particular genes (e.g., cas7 and cas5) are corecomponents of the interference complexes of the Type I systems and canbe used to further differentiate species containing Type I systems.Exemplary sequences of E. coli K-12 MG1655 cas7 and cas5 genes that canbe used are SEQ ID. NO:622 and SEQ ID. NO:623, respectively. Genomesidentified possessing cas7 and cas5 genes can be further parsed throughthe identification of the Type I-specific nuclease-helicase cas3 gene orhomologs thereof. An exemplary sequences of a E. coli K-12 MG1655 cas3sequence that can be used is SEQ ID. NO:624.

Genomes containing CRISPR-Cas integrase genes cas1, Type I interferencecomplex genes cas7 and cas5, and the nuclease-helicase cas3 gene, orsome combination thereof, are likely candidates of Type I CRISPR-Cassystem(s). Type I CRISPR-Cas genes are generally found in proximity toone in a single genomic locus, typically within 20 kilobases (kb). Thearea around the cas1, cas7, cas5, or cas3 genes can be searched forother open reading frames (ORFs) of the remaining cas genes thatconstitute a Type I interference complex. The amino acid sequence ofputative ORFs can be compared to known Type I genes for homology or thepresence of characteristic protein domains of the Type I proteincomponents can be analyzed using the homology detection and structureprediction search tools available through the Max Planck InstituteBioinformatics Toolkit (https://toolkit.tuebingen.mpg.de/#/), orequivalent.

B. Screening of Identified Type I Components

Once a putative collection of Type I components (e.g., cas genes and thecorresponding crRNA) have been identified, the Type I components can betested for their ability to carry out programmable DNA targeting.

Putative cas genes and the crRNA can be encoded into expression vectorsfollowing the guidance of Examples 1, 2, and 3. Vectors encoding thevarious cas genes and crRNA can be introduced into a bacteria strain andthe Type I interference complex expressed and purified as described inExamples 4 and 5. The elution fraction from the size-exclusionchromatography (SEC) column, can be analyzed via SDS-PAGE gel todetermine the identity, based on weight, of the protein componentscomprising a complete Type I interference complex. An ethidium bromidegel can also be run to detect the presence of crRNA as part of theinterference complex.

Purified Cascade complexes can be tested for their ability to support invitro biochemical cleavage of a DNA target as described in Examples 6and 7.

Control expressions and purification samples, where single putative casgene are not expressed, can be used to determine the required cas genesthat constitute a complete Type I interference complex capable ofprogrammable DNA target.

For certain applications, identification of individual cas gene homologs(e.g., cas7) from a genomic sequence is sufficient and additional casgenes need not be identified nor screening performed.

Example 15 Identification of Type I crRNAs

This Example describes a method to identify Type I crRNAs in differentspecies. The method presented here is adapted from Chylinski, K., etal., RNA Biology 10(5):726-737 (2013).

A search of genomes of various species can be conducted to identify TypeI CRISPR-Cas genes as described in Example 17A. Genomes that compriseone of more Type I specific cas genes are candidate genomes that likelyto contain CRISPR RNAs (crRNAs) encoded within the CRISPR repeat-spacerarray. The sequences adjacent to the identified Type I cas genes (e.g.,a cas7, cas5, or cas3 gene) can be probed for an associated CRISPRrepeat-spacer array. Methods for in silico predictive screening can beused to extract the crRNA sequence from the repeat array followingGrissa, I. V., et. al. Nucleic Acids Research 35 (Web Serverissue):W52-W57 (2007). The crRNA sequence is contained within CRISPRrepeat array and can be identified by its hallmark repeating sequencesinterspaced by foreign spacer sequences.

A. Preparation of RNA-Seq Library

The putative CRISPR array containing the individual crRNA identified insilico can be further validated using RNA sequencing (RNA-seq).

Cells from species identified as comprising putative Type I cas genesand crRNA components can be procured from a commercial repository (e.g.,ATCC, Manassas, Va.; German Collection of Microorganisms and CellCultures GmbH (DSMZ), Braunschweig, Germany).

Cells can be grown to mid-log phase and total RNA prepped using Trizolreagent (SigmaAldrich, St. Louis, Mo.) and treated with DNasel(Fermentas, Vilnius, Lithuania).

10 μg of the total RNA can be treated with Ribo-Zero rRNA Removal Kit(Illumina, San Diego, Calif.) and the remaining RNA purified using RNAClean and Concentrators (Zymo Research, Irvine, Calif.).

A library can be prepared using a TRUSEQ™ Small RNA Library PreparationKit (Illumina, San Diego, Calif.), following the manufacturer'sinstructions. This will result in cDNAs having adapter sequences.

The resulting cDNA library can be sequenced using MiSeq Sequencer(Illumina, San Diego, Calif.).

B. Processing of Sequencing Data

Sequencing reads of the cDNA library can be processed, for example,using the following method.

Adapter sequences can be removed using cutadapt 1.1(pypi.python.org/pypi/cutadapt/1.1) and about 15 nucleotides trimmedfrom the 3′ end of the read to improve read quality.

Reads can be aligned to the genome of the respective species (i.e., fromwhich the putative crRNA is to be identified) using Bowtie 2(http://bowtie-bio.sourceforge.net/bowtie2/index.shtml). The SequenceAlignment/Map (SAM) file, which is generated by Bowtie 2, can beconverted into a Binary Alignment/Map (BAM) file using SAMTools(http://samtools.sourceforge.net/) for subsequent sequencing analysissteps.

Read coverage mapping to the CRISPR locus or loci can be calculated fromthe BAM file using BedTools (bedtools.readthedocs.org/en/latest/).

The BED file, as generated in the previous step, can be loaded intoIntegrative Genomics Viewer (IGV; www.broadinstitute.org/igv/) tovisualize the sequencing read pileup. Read pile can be used to identifythe 5′ and 3′ termini of the transcribed putative crRNA sequence. TheRNA-seq data can be used to validate that a putative crRNA element isactively transcribed in vivo.

Putative crRNA can be tested with their cognate Type I cas genes for theability to carry out programmable DNA targeting, following the guidanceof Example 17.A of the present Specification.

Example 16 Probing for Sites Tolerant of Modification in Cascade GuideRNA Backbones

This Example describes the generation and testing of variousmodifications of Type I guide crRNAs and their suitability for use inconstructing Cascade polynucleotide complexes. The method describedbelow is adapted from Briner, A., et al., Molecular Cell 56(2):333-339(2014).

Modifications can be introduced into the crRNA backbone, and themodified crRNA tested with a cognate Cascade complex to facilitate theidentification of regions or positions in the Type I guide crRNAbackbone amenable to modification.

A crRNA from a Type I CRISPR system (e.g., E. coli Cascade) can beselected for engineering. The crRNA sequence can be modified in silicoto introduce one or more base substitutions, deletions, or insertionsinto nucleic acid sequences in regions selected from one or more of thefollowing regions: nucleic acid sequences 5′ of the spacer (5′ handle),the spacer element, Type I CRISPR repeat stem sequence, or 3′ of theType I CRISPR repeat stem sequence (3′ handle).

Base modification can also be used to introduce mismatches in thehydrogen base-pair interactions of any of the crRNA regions, orbase-pair mutation introducing an alternative hydrogen base-pairinteraction through substitution of two bases, wherein the alternativehydrogen base-pair interaction differs from the original hydrogenbase-pair interaction (e.g., the original hydrogen base-pair interactionis Watson-Crick base pairing and the substitution of the two bases forma reverse Hoogsteen base pairing). Substitution of bases can also beused to introduce hydrogen base-pair interaction within the crRNAbackbone.

Regions of the crRNA can be independently engineered to introducesecondary structure elements into the crRNA backbone. Such secondarystructure elements include, but are not limited to, the following:stem-loop elements, stem elements, pseudo-knots, and ribozymes.Furthermore, the crRNA guide RNA backbone can be modified to deleteportions of the crRNA backbone either through deletion at the 5′ end, 3′end, or internal to the crRNA. Alternative backbone structures can alsobe introduced.

In silico designed crRNA sequences can be provided to a commercialmanufacturer for synthesis.

Modified crRNAs can be evaluated for their ability to support binding byindividual Cascade subunit proteins (i.e., Cas6, Cas5, etc.), or tosupport complete formation of the Cascade protein complex, or to supportformation of the Cascade complex and modification of a double-strandedDNA target sequence through recruitment of a nuclease (e.g., Cas3).crRNA binding to individual Cascade subunit proteins and Cascade proteincomplex assembly can be evaluated by nano-ESI mass spectrometry in amanner similar to Jore, M., et al., Nature Structural & MolecularBiology 18:529-536 (2011). Biochemical characterization of crRNA andCascade protein complex modification of a double-stranded DNA targetsequence through recruitment of a nuclease can be carried out in amanner similar to those described in Examples 6 and 7. Modified crRNAthat are capable of supporting formation of the Cascade complex andmodification of a double-stranded DNA target sequence throughrecruitment of a nuclease can be validated for activity in cells usingthe method described in Example 8.

Example 17 Screening of Cascade Complex Guides Comprising DNA TargetBinding Sequences

This Example illustrates the use of Type I CRISPR proteins and Type Iguide crRNAs of the present invention to modify DNA target sequencespresent in human genomic DNA (gDNA) and to measure the level of cleavageactivity at those sites.

Target sites (DNA target sequences) can be first selected from genomicDNA. Type I guide crRNAs can be designed to target the selectedsequences. Assays (e.g., as described in Example 7) can be performed todetermine the level of DNA target sequence cleavage.

A. Selecting DNA Target Sequences from Genomic DNA

PAM sequences (e.g., ATG) for a Cascade protein complex (e.g., E. coliType I-E Cascade) can be identified within the selected genomic region.

One or more Cascade DNA target sequences (e.g., 32 nucleotides inlength) that are 3′ adjacent to a ATG PAM sequence can be identified.

Criteria for selection of nucleic acid target sequences can include, butare not limited to, the following: homology to other regions in thegenome; percent G-C content; melting temperature; presences ofhomopolymer within the spacer; distance between the two sequences; andother criteria known to one skilled in the art.

A DNA target binding sequence that hybridizes to the Cascade DNA targetsequence can be incorporated into a guide crRNAs. The nucleic acidsequence of a guide crRNA construct is typically provided to andsynthesized by a commercial manufacturer.

A guide crRNA, as described herein, can be used with cognate Type ICascade protein complex to form crRNA/Cascade protein complexes.

B. Determination of Cleavage Percentages and Specificity

In vitro cleavage percentages and specificity (i.e., the amount ofoff-target binding) related to a guide crRNA can be determined, forexample, using the cleavage assays described in Example 7, and comparedas follows:

(1) If only a single DNA target sequences is identified or selected fora guide crRNA, the cleavage percentage and specificity for each of theDNA target sequences can be determined. If so desired, cleavagepercentage and/or specificity can be altered in further experimentsusing methods including, but not limited to, modifying the guide crRNA,or introducing effector proteins/effector protein-binding sequences tomodify the guide crRNA or the Cascade subunit proteins, orligand/ligand-binding moieties to modify the guide crRNA or the Cascadesubunit proteins.

(2) If multiple DNA target sequences are identified or selected forguide crRNAs, the percentage cleavage data and site-specificity dataobtained from the cleavage assays can be compared between different DNAscomprising the target binding sequence to identify the DNA targetsequences having the desired cleavage percentage and specificity.Cleavage percentage data and specificity data provide criteria on whichto base choices for a variety of applications. For example, in somesituations the activity of the guide crRNA may be the most importantfactor. In other situations, the specificity of the cleavage site may berelatively more important than the cleavage percentage. If so desired,cleavage percentage and/or specificity can be altered in furtherexperiments using methods including, but not limited to, modifying theguide crRNA, introducing effector proteins/effector protein-bindingsequences to modify the guide crRNA or the Cascade subunit proteins, orligand/ligand-binding moieties to modify the guide crRNA or the Cascadesubunit proteins.

Alternatively, or in addition to the in vitro analysis, in-cell cleavagepercentages and specificities of guide crRNAs can be obtained using, forexample, the method described in Example 8, and compared as follows:

(1) If only a single DNA target sequences is identified or selected fora guide crRNA, the cleavage percentage and specificity for each of theDNA target sequences can be determined. If so desired, cleavagepercentage and/or specificity can be altered in further experimentsusing methods including, but not limited to, modifying the guide crRNA,or introducing effector proteins/effector protein-binding sequences tomodify the guide crRNA or the Cascade subunit proteins, orligand/ligand-binding moieties to modify the guide crRNA or the Cascadesubunit proteins.

(2) If multiple DNA target sequences are identified or selected forguide crRNAs, the percentage cleavage data and site-specificity dataobtained from the cleavage assays can be compared between different DNAscomprising the target binding sequence to identify the DNA targetsequences having the desired cleavage percentage and specificity.Cleavage percentage data and specificity data provide criteria on whichto base choices for a variety of applications. For example, in somesituations the activity of the guide crRNA may be the most importantfactor. In other situations, the specificity of the cleavage site may berelatively more important than the cleavage percentage. If so desired,cleavage percentage and/or specificity can be altered in furtherexperiments using methods including, but not limited to, modifying theguide crRNA, introducing effector proteins/effector protein-bindingsequences to modify the guide crRNA or the Cascade subunit proteins, orligand/ligand-binding moieties to modify the guide crRNA or the Cascadesubunit proteins.

Example 18 Varying FokI-Cas8 Linker Composition and Interspacer Distancefor Efficient FokI-Cascade Complex Genome Editing

This Example illustrates the design and testing of multiple fusionproteins comprising FokI-Cas8 and linker polypeptides of variouslengths, as well as the effect of varying interspacer distances forefficient genome editing.

A. Production of a Vector Encoding E. coli Type I-E Cascade ComplexComponents Comprising FokI Fusion Proteins to be Transfected into TargetCells

Minimal CRISPR arrays were designed to target a set of loci in the humangenome at or near two different genes: ADAMTSL1 and PCSK9. Interspacerdistances ranged from 14-60 bp, in increments of 2 bp. Four targets weredesigned for each interspacer distance. Targets were flanked by eitherAAG or ATG PAM sequences. Dual guides containing“repeat-spacer-repeat-spacer-repeat” sequences were cloned as describedin Example 9 with SEQ ID NO:454. SEQ ID NO:625 through SEQ ID NO:816provide the sequences for the full set of oligonucleotide sequences usedto generate the minimal CRISPR arrays.

FokI-Cascade RNP subunit protein component-encoding genes were clonedinto vectors comprising: CMV promoters to enable delivery and expressionin mammalian cells; cas genes linked via 2A viral peptide“ribosome-skipping” sequences; a fusion protein comprising FokI and Cas8connected with a 30-aa linker (SEQ ID NO:455 from Example 3). Additionallinker polypeptide sequences of varying length and amino acidcomposition were designed and used to connect FokI to the Cas8 proteinin these vectors. The additional linker polypeptide sequences are listedin Table 38.

TABLE 38 Amino Acid Linker Sequences Linker length SEQ ID NO:(amino acids) Amino acid sequence SEQ ID NO: 817  5 GGGGS SEQ ID NO: 818 8 TGPGAAAR SEQ ID NO: 819 10 GGSGSSGGSG SEQ ID NO: 820 15GGSGSSGGSGSSGGS SEQ ID NO: 821 17 ADPTNRAKGLEAVSVAS SEQ ID NO: 822 20SGSETPGTSESATPESGGSG SEQ ID NO: 433 30 SGSETPGTSESATPESGGSGSSGGSGSSGGSEQ ID NO: 823 40 SGSETPGTSESATPESGGSGSSGGSGSSGGSGS SGGSGSSSEQ ID NO: 824 50 SGSETPGTSESATPESGGSGSSGGSGSSGGSGS SGGSGSSGGSGSSGGSG

B. Transfection of Vectors Encoding FokI-Cascade RNP Complex Components

Transfection conditions were essentially as described in Example 8 withthe following modifications. Prior to nucleofection, 5 μl of plasmidvector solution was transferred to individual wells of a 96-well plate.Each well contained 2.4 μg of plasmid encoding FokI-Cascade RNP complexsubunit protein components and ˜1-2 μg of plasmid encoding the minimalCRISPR array.

C. Deep Sequencing of gDNA from Transfected Cells

Deep sequencing was performed essentially as described in Example 8 withthe following modifications. Instead of primers Y and Z from Table 31 ofExample 8, the target-specific primers were SEQ ID NO:825 to SEQ IDNO:1016.

D. Deep Sequencing Data Analysis

Deep sequencing data analysis was performed essentially as described inExample 8. FIG. 32A and FIG. 32B present the results of the dataanalysis. In FIG. 32A and FIG. 32B, percent genome editing is shown as afunction of FokI-Cas8 linker type and interspacer distance (n=1); greyscale vertical bar to the right is percentage of indels. An initialanalysis of the data showed genome editing was highest with FokI-Cas8linkers of 17 and 20 amino acids (SEQ ID NO:821 and SEQ ID NO:822,respectively) and with interspacer distances of ˜26 bp and ˜30-32 bp.The data was reprocessed and samples with less than a thousand sequencesreads were removed as they may contain inflated editing values due tolow coverage (sites were only retained if all the associated samplescontained >1000 reads). This data, presented in FIG. 32A and FIG. 32B,showed that genome editing was highest with FokI-Cas8 linkers of 17 and20 amino acids (SEQ ID NO:821 and SEQ ID NO:822, respectively) and withinterspacer distances of ˜30-32 bp. Thus, efficient genome editing usingType I CRISPR-Cas complexes comprising FokI-Cas8 fusion proteins wasachieved by varying the interspacer distance and the linker polypeptidelength of the FokI-Cas8 fusion protein. The amino acid composition ofthe linker polypeptides is discussed herein.

Example 19 Identifying Cascade Homologs that Enable High-efficiencyGenome Editing

This Example illustrates the design and testing of multiple homologCascade complexes to evaluate the efficiency of genome editing.

A. Identification of Sites for Testing with Homolog Cascade Complexes

A panel of sites was identified for testing additional homolog Cascadecomplexes. Specifically, minimal CRISPR arrays were designed to target aset of loci in the human genome with 30 bp interspacer distances andthat were flanked by either AAG or ATG PAM sequences. Dual-guidepolynucleotides containing “repeat-spacer-repeat-spacer-repeat”sequences were cloned following the method described in Example 9 withSEQ ID NO:454. The full set of oligonucleotide sequences used togenerate the minimal CRISPR arrays are presented as SEQ ID NO:1017 toSEQ ID NO:1130 (Hsa33F, SEQ ID NO:1017, and Hsa33R, SEQ ID NO:1074,exemplify one pair). A positive control dual-guide targeting the TRAClocus was included (SEQ ID NO:454).

FokI-Cascade RNP subunit protein component-encoding genes were clonedinto vectors comprising: CMV promoters to enable delivery and expressionin mammalian cells; cas genes linked via 2A viral peptide“ribosome-skipping” sequences; a fusion protein comprisng FokI and Cas8connected with a 30-aa linker (SEQ ID NO:455 from Example 3).

B. Transfection of Vectors Encoding FokI-Cascade RNP Complex Components

Transfection conditions were performed essentially as described inExample 8 with the following modifications. Prior to nucleofection, 5 μlof plasmid vector solution was transferred to individual wells of a96-well plate. Each well contained 3 μg of plasmid encoding FokI-CascadeRNP subunit protein components and 0.3 μg of plasmid encoding theminimal CRISPR array.

C. Deep Sequencing of gDNA from Transfected Cells

Deep sequencing was performed essentially as described in Example 8 withthe following modifications. Instead of primers Y and Z from Table 31 ofExample 8, the target-specific primers used in this Example were SEQ IDNO:1131 to SEQ ID NO:1244.

D. Deep Sequencing Data Analysis

Deep sequencing data analysis was performed essentially as described inExample 8. FIG. 33 present the results of the data analysis. In FIG. 33,percent genome editing is plotted against 58 test sites (oligonucleotidesequences used to generate these minimal CRISPR arrays are discussedabove) in addition to target Hsa07 from Example 8 (n=3). As is shown inFIG. 33, editing ranged from ˜6% to below the limit of detection. Fromthese data, a panel of eight sites (Hsa07 as well as targets 1, 3-5, 10,13, and 16 corresponding to the following targets Hsa37, Hsa43, Hsa46,Hsa60, Hsa77, Hsa88, and Hsa126) with AAG PAMs were selected for testinghomolog Cascade complexes for genome editing.

E. Identification of Homolog Cascade Complexes to Test with FokINuclease for Genome Editing

Cas8 protein sequences from different Type I systems were used asqueries for psi-BLASTp to generate phylogenetic trees for homologselection. Specifically, Cas8 from Fusobacterium nucleatum(WP_008798978.1) was used for Type I-B, Cas8 from Bacillus halodurans(WP_010896519.1) was used for Type I-C, Cas8 from E. coli(WP_001050401.1) was used for Type I-E, Cas8 from Pseudomonas aeruginosa(WP_003139224.1) was used for Type I-F, and Cas5 from Shewanellaputrefaciens (WP_011919226.1) was used for Type I-Fv2.

Next, psi-BLASTp was iterated multiple times until thousands of homologswere identified for each Type I system. From this information,phylogenetic trees were built using the interactive Tree of Life onlinesoftware (iTOL, accessible at itol.embl.de/login.cgi). The trees werevisually inspected after auto-collapsing clades using variable branchlengths.

Lists of organisms falling within major clades were then outputted andmanually inspected for selection. In this step, priority was placed onselecting homologs that sampled from different regions of thephylogenetic tree, both for the 12 homologs within the Type I-E as wellas 2-3 representative homologs for Types I-B, I-C, I-F, and I-Fv2. cas8and cas5 candidates, based on the above phylogenetic analysis, wereinputted into NCBI, and the genomic context within the endogenous hostbacterium was visually inspected within NCBI's genome graphics browser.Cascade homologs were selected only if (1) they were found in organismsthat grow at 37° C.; (2) their cas gene operons were intact and had allthe expected Cascade subunit protein encoding genes, a cas3 gene, andintact acquisition genes (i.e., cas1 and cast); (3) their cas geneoperon was flanked by one or more CRISPR arrays; and (4) their CRISPRarrays contained >10 spacers. For some homologs, the CRISPRfinderprogram (crispr.i2bc.paris-saclay.fr/Server/) was used to identifyputative PAM sequences. Based on the above criteria, the 22 homologCascade complexes shown in Table 39 were selected.

TABLE 39 Homolog Cascade Complexes Spacer SEQ ID NO: Cascade homologorganism PAM length Type SEQ ID NO: 1245 Oceanicola sp. HL-35 AAG 32 I-ESEQ ID NO: 1246 Pseudomonas sp. S-6-2 AAG 32 I-E SEQ ID NO: 1247Salmonella enterica subsp. AAG 32 I-E enterica serovar Muenster strainSEQ ID NO: 1248 Atlantibacter hermannii NBRC 105704 AAG 32 I-E SEQ IDNO: 1249 Geothermobacter sp. EPR-M AAG 32 I-E SEQ ID NO: 1250Methylocaldum sp. 14B AAG 32 I-E SEQ ID NO: 1251 Methanocella arvoryzaeMRE50 AAG 32 I-E SEQ ID NO: 1252 Pseudomonas aeruginosa DHS01 AAG 32 I-ESEQ ID NO: 1253 Lachnospiraceae bacterium KH1T2 GAA 35 I-E SEQ ID NO:1254 Klebsiella pneumoniae strain VRCO0172 GAA 33 I-E SEQ ID NO: 1255Streptococcus thermophilus strain ND07 GAA 33 I-E SEQ ID NO: 1256Streptomyces sp. S4 GAA 33 I-E SEQ ID NO: 1257 Campylobacter fetussubsp. TCA 36 I-B testudinum Sp3 SEQ ID NO: 1258 Odoribactersplanchnicus DSM 20712 TCA 36 I-B SEQ ID NO: 1259 Bacillus haloduransC-125 TTC 34 I-C SEQ ID NO: 1260 Desulfovibrio vulgaris RCH1 TTC 34 I-Cplasmid pDEVAL01 SEQ ID NO:1261 Geobacillus thermocatenulatus TTC 35 I-Cstrain KCTC 3921 SEQ ID NO: 1262 Vibrio cholerae strain L15 L15_contig8CC 32 I-F SEQ ID NO: 1263 Pseudomonas aeruginosa UCBPP-PA14 CC 32 I-FSEQ ID NO: 1264 Shewanella putrefaciens CN-32 CC 32 I-Fv2 SEQ ID NO:1265 Acinetobacter sp. 869535 CC 32 I-Fv2 SEQ ID NO: 1266 Vibriocholerae HE48 vcoHE48.contig.11 CC 32 I-Fv2

F. Production of Vectors Encoding FokI-Cascade RNP Components from 22Distinct Species for Transfection into Target Cells

Sequences for each cas gene from each homolog were synthesized as partof a polycistronic construct that included a fusion protein comprisingFokI nuclease and Cas8. For each Type I-E Cascade complex homolog, a setof ˜7-8 guides targeting loci with the appropriate PAM sequences weregenerated. For each Type I-B, I-C, I-F, and I-Fv2 Cascade homolog, a setof ˜2-7 guides targeting loci with appropriate PAM sequences weregenerated. Each Cascade complex homolog system required unique repeatsequences to process their cognate guide (SEQ ID NO:1267 to SEQ IDNO:1288). Dual guides containing “repeat-spacer-repeat-spacer-repeat”sequences were cloned using the method described in Example 9 for SEQ IDNO:454. Oligonucleotides were phosphorylated on the 5′ end and appendedwith overhang sequences to enable cloning into plasmid vectors with theappropriate repeat sequences. The full set of oligonucleotide sequencesused to generate the minimal CRISPR arrays for the 22 Cascade complexhomologs are presented as (SEQ ID NO:1289 to SEQ ID NO:1400).

FokI-Cascade RNP subunit protein component-encoding genes were clonedinto vectors comprising: CMV promoters to enable delivery and expressionin mammalian cells; cas genes linked via 2A viral peptide“ribosome-skipping” sequences; a fusion protein comprising FokI and Cas8connected with a 30-aa linker.

G. Transfection of Plasmids Encoding FokI-Cascade Complex RNPs

Transfection conditions were essentially as described in Example 8 withthe following modifications. Prior to nucleofection, 5 μl of plasmidvector solution was transferred to individual wells of a 96-well plate.Each well contained 1.5 μg of plasmid encoding FokI-Cascade RNP subunitprotein components and ˜0.5-1.5 μg of plasmid encoding the minimalCRISPR array. Experiments were performed in triplicate and includedFokI-Cascade RNP complexes from E. coli (SEQ ID NO:455) targeted toeight sites (Hsa07 from Example 8 and Hsa37, Hsa43, Hsa46, Hsa60, Hsa77,Hsa88, Hsa126 from section D of this Example) as positive controls. Aspreviously described, the following oligonucleotides were used togenerate the minimal CRISPR arrays used with the E. coli positivecontrol: Hsa37 (SEQ ID NO:1019; SEQ ID NO:1076), Hsa43 (SEQ ID NO:1024;SEQ ID NO:1081), Hsa46 (SEQ ID NO:1027; SEQ ID NO:1084), Hsa60 (SEQ IDNO:1037; SEQ ID NO:1094), Hsa77 (SEQ ID NO:1045; SEQ ID NO:1102), Hsa88(SEQ ID NO:1050; SEQ ID NO:1107), Hsa126 (SEQ ID NO:1072; SEQ IDNO:1129).

H. Deep Sequencing of gDNA from Transfected Cells

Deep sequencing was performed essentially as described in Example 8 withthe following modifications. Instead of primers Y and Z from Table 31 ofExample 8, the target-specific primers used in this Example were SEQ IDNO:1401 to SEQ ID NO:1512. For both Type I-E RNP complexes and Type I-B,I-C, I-F, and I-Fv2 RNP complexes, control samples comprising E. coliType I-E Cascade were included for comparison and sequenced withtarget-specific primers corresponding to targets Hsa07 from Example 8and Hsa37, Hsa43, Hsa46, Hsa60, Hsa77, Hsa88, Hsa126 from this Example.More specifically, the following target-specific amplification primerswere used for these targets: Hsa37 (SEQ ID NO:1133; SEQ ID NO:1190),Hsa43 (SEQ ID NO:1138; SEQ ID NO:1195), Hsa46 (SEQ ID NO:1141; SEQ IDNO:1198), Hsa60 (SEQ ID NO:1151; SEQ ID NO:1208), Hsa77 (SEQ ID NO:1159;SEQ ID NO:1216), Hsa88 (SEQ ID NO:1164; SEQ ID NO:1221), Hsa126 (SEQ IDNO:1186; SEQ ID NO:1243).

I. Deep Sequencing Data Analysis

Deep sequencing data analysis was performed essentially as described inExample 8. FIG. 34A and FIG. 34B show results from these experiments.Editing was observed with many of the Type I-E FokI-Cascade homologs(FIG. 34A). The highest editing was observed with the variant fromPseudomonas sp. S-6-2, while other homologs (i.e., Salmonella enterica,Geothermobacter sp. EPR-M, Methanocella arvoryzae MRE50, and S.thermophilus (strain ND07)) showed editing approximately equivalent toE. coli. Editing with FokI-Cascade RNPs derived from Types I-B, I-C,I-F, and I-Fv2 was not observed and therefore may be below the limit ofdetection (FIG. 34B).

Example 20 Varying FokI-Cas8 Linker Length and Interspacer Distances inPseudomonas sp S-6-2 for Efficient Genome Editing

This Example illustrates the design and testing of multiple fusionproteins comprising FokI-Cas8 and linker polypeptides of variouslengths, as well as the effect of varying interspacer distances forefficient genome editing with Pseudomonas sp S-6-2 Type I-E CRISPR-Cassystems.

A. Production of a Vector Encoding FokI-Cascade RNP Components to beTransfected into Target Cells

Minimal CRISPR arrays were designed to target a set of loci in the humangenome. Interspacer distances ranged from 23-34 bp, in increments of 1bp. Eight targets were designed for each of the interspacer distances,and targets were flanked by AAG PAM sequences. Dual guides weregenerated with PCR-based assembly using three oligonucleotides (SEQ IDNO:1513 to SEQ ID NO:1515) and a unique primer encoding a“repeat-spacer-repeat-spacer-repeat” sequence to enable FokI-Cascadetargeting. The full set of unique oligonucleotide sequences to generatethe minimal CRISPR arrays were SEQ ID NO:1516 to SEQ ID NO:1704.PCR-assembled guides were purified and concentrated using SPRIselect®beads (Beckman Coulter, Pasadena, Calif.) essentially according to themanufacturer's instructions.

FokI-Cascade RNP subunit protein component-encoding genes were clonedinto vectors comprising: CMV promoters to enable delivery and expressionin mammalian cells, cas genes linked via 2A “ribosome-skipping”sequences, and FokI attached to Cas8 with a 30-aa linker (SEQ IDNO:1748). Additional linker polypeptide sequences of varying length weredesigned and used to connect FokI to the Cas8 protein to form fusionproteins. The linker polypeptide sequences are listed in Table 40.

TABLE 40 Amino Acid Linker Sequences Linker length (amino acids)Amino acid sequence SEQ ID NO: 17 ADPTNRAKGLEAVSVAS SEQ ID NO: 821 20SGSETPGTSESATPESGGSG SEQ ID NO: 822

B. Transfection of Vectors Encoding FokI-Cascade RNP Complex Components

Transfection conditions were performed essentially as described inExample 8 except for with the following modifications. Prior tonucleofection, 5 μl of plasmid vector solution was transferred toindividual wells of a 96-well plate. Each well contained 5 μg of plasmidencoding FokI-Cascade RNP protein components and ˜0.1-0.5 μg of linearPCR product encoding the minimal CRISPR array.

C. Deep Sequencing of gDNA from Transfected Cells

Deep sequencing was performed essentially as described in Example 8.Instead of primers Y and Z from Table 31 of Example 8, thetarget-specific primers were SEQ ID NO:1705 to SEQ ID NO:1803.

D. Deep Sequencing Data Analysis

Deep sequencing data analysis was performed essentially as described inExample 8. FIG. 35 shows genome editing at 95 sites (n=1). Editingranged from ˜50% (FIG. 35 shows the mean+/−1 standard deviation) tobelow the limit of detection, and was related to the interspacerdistance and linker polypeptide length. The amino acid composition ofthe linker polypeptides is discussed herein. Interspacer distances of˜30-33 bp and linker polypeptide lengths of 17 and 20 amino acidsprovided very efficient editing.

Example 21 Utilizing Cas3-FokI and FokI-Cas8 to Enable FokI-CascadeGenome Editing

This Example illustrates the use of Cas3-FokI and FokI-Cascade to inducedimerization of FokI to generate a double-strand break at a locus in thehuman genome (see e.g., FIG. 17A, FIG. 17B, and FIG. 17C). Morespecifically, this Example details the design and testing of multipleCas3-FokI linker compositions and lengths and FokI-Cas8 linkercompositions and lengths for affecting genome editing efficiency.

A. Production of a Vectors Encoding FokI-Cas3 and FokI-Cascade RNPComponents to be Transfected into Target Cells

Minimal CRISPR arrays are designed to target three distinct sitesflanked by AAG PAMs in the human genome. Sites are selected that werepreviously shown to support interspacer editing with E. coliFokI-Cascade dimers directed by dual-guides and are therefore known tobe permissive for FokI-Cascade binding (e.g., Hsa37, Hsa43, and Hsa46).

The FokI-Cascade systems described in the Examples above used two FokICascade complexes (see e.g., FIG. 16A, FIG. 16B, and FIG. 16C);accordingly, dual-guides comprising a first guide sequence specifying afirst nucleic acid target site and a second guide sequence specifying asecond nucleic acid target site can be used. Because theCas3-FokI-FokI-Cascade system only requires a single PAM, a guidecomprising “repeat-spacer-repeat” should be sufficient to facilitatebinding of the functional Cascade complex to a nucleic acid target site.A dual-guide containing “repeat-spacer-repeat-spacer-repeats” can alsobe used but, typically in this embodiment, the two spacer sequencesdirect binding of the Cascade complex to the same nucleic acid targetsequence; that is, the two spacers can have the same sequence. Theguides are cloned essentially as described in Example 9 with SEQ IDNo:454. The following annealed oligonucleotides are used for generationof the minimal CRISPR arrays: Hsa37 (SEQ ID NO:1019; SEQ ID NO:1076),Hsa43 (SEQ ID NO:1024; SEQ ID NO:1081), and Hsa46 (SEQ ID NO:1027; SEQID NO:1084).

As described in Example 9, FokI-Cascade RNP protein component-encodinggenes are cloned into plasmid vectors containing CMV promoters to enabledelivery and expression in mammalian cells. cas genes are linked via 2A“ribosome-skipping” sequences. Furthermore, FokI is fused to Cas8 with a30-aa linker (SEQ ID NO:455 from Example 3). Additional linkerssequences of varying length and composition are designed and used toconnect FokI to the Cas8 protein. Example of such sequences are listedin Table 41.

Cas3 protein from E. coli is fused with FokI on the C-terminus using a30-aa linker. This fusion is further modified with an NLS sequence onthe N-terminus (SEQ ID NO:1806). Additional linkers sequences of varyinglength and composition are designed and used to connect FokI to the Cas3protein (Table 41 and SEQ ID NO:1804 to SEQ ID NO:1807).

Additional Cas3-FokI fusion constructs are generated wherein thehelicase or nuclease activity of the Cas3 protein is inactivated (SEQ IDNO:1808 to SEQ ID NO:1815). Helicase and nuclease activities areimpaired by making D452A and D75A modifications, respectively, of theCas3 protein (Mulepati, S., et al., J. Biol. Chem. 288(31):22184-22192(2013)).

TABLE 41 Amino Acid Linker Sequences Linker length (amino acids)Amino acid sequence SEQ ID NO:  5 GGGGS SEQ ID NO: 817 10 GGSGSSGGSGSEQ ID NO: 819 17 ADPTNRAKGLEAVSVAS SEQ ID NO: 821 20SGSETPGTSESATPESGGSG SEQ ID NO: 822 40 SGSETPGTSESATPESGGSGSSGGSGSSGGSEQ ID NO: 823 SGSSGGSGSS

B. Transfection of Plasmids Encoding FokI-Cascade Complex RNPs

Transfection conditions are performed as described in Example 8 with thefollowing modifications. Prior to nucleofection, 5 μl of plasmid vectorsolution are transferred to individual wells of a 96-well plate. Eachwell comprises the following three components: 3 μg of a plasmidencoding a set of FokI-Cascade RNP protein components, 3 μg of a plasmidencoding a Cas3-FokI, and 0.5 μg of a plasmid encoding a minimal CRISPRarray. The 96-well plate is set up as a matrix to provide allcombinations of the three components.

C. Deep Sequencing of gDNA from Transfected Cells

Deep sequencing is performed as described in Example 8 with thefollowing modifications. Instead of primers Y and Z from Table 4 ofExample 8, the target-specific primers used in this Example are asfollows: SEQ ID NO:1133 and SEQ ID NO:1190 (Hsa37 target site), SEQ IDNO:1138 and SEQ ID NO:1195 (Hsa43 target site), and SEQ ID NO:1141 andSEQ ID NO:1198 (Hsa46 target site).

D. Deep Sequencing Data Analysis

Deep sequencing data analysis is performed as described in Example 8with the exception that indels ˜1 bp to ˜25 bp upstream of theFokI-Cascade binding site PAM sequence are tallied. In this manner, thecombinations of FokI-Cas8 linker sequences, Cas3-FokI linker sequences,and Cas3 variants that support the most efficient editing can bedetermined.

As is apparent to one of skill in the art, various modification andvariations of the above embodiments can be made without departing fromthe spirit and scope of this invention. Such modifications andvariations are within the scope of this invention.

The invention claimed is:
 1. A composition comprising: a firstengineered Class 1 Type I CRISPR-Cas effector complex comprising, afirst Cas5 subunit protein and a first Cas7 subunit protein, a firstfusion protein comprising a first Cas8 subunit protein and a first FokI,wherein the N-terminus of the first Cas8 subunit protein or theC-terminus of the first Cas8 subunit protein is covalently connected bya first linker polypeptide to the C-terminus or N-terminus of the firstFokI, and wherein the first linker polypeptide has a length of between10 amino acids to 40 amino acids, and a first guide polynucleotidecomprising a first spacer capable of binding a first nucleic acid targetsequence; and a second engineered Class 1 Type I CRISPR-Cas effectorcomplex comprising, a second Cas5 subunit protein and a second Cas7subunit protein, a second fusion protein comprising a second Cas8subunit protein and a second FokI, wherein the N-terminus of the secondCas8 subunit protein or the C-terminus of the second Cas8 subunitprotein is covalently connected by a second linker polypeptide to theC-terminus or N-terminus of the second FokI, and wherein the secondlinker polypeptide has a length of between 10 amino acids to 40 aminoacids, and a second guide polynucleotide comprising a second spacercapable of binding a second nucleic acid target sequence, wherein aprotospacer adjacent motif (PAM) of the second nucleic acid targetsequence and a PAM of the first nucleic acid target sequence have aninterspacer distance between 20 base pairs to 42 base pairs.
 2. Thecomposition of claim 1, wherein the first engineered Class 1 Type ICRISPR-Cas effector complex further comprises a first Cas6 subunitprotein and the second engineered Class 1 Type I CRISPR-Cas effectorcomplex further comprises a second Cas6 subunit protein.
 3. Thecomposition of claim 1, wherein the first linker polypeptide has alength of between 15 amino acids and 30 amino acids.
 4. The compositionof claim 3, wherein the first linker polypeptide has a length of between17 amino acids and 20 amino acids.
 5. The composition of claim 1,wherein the second linker polypeptide has a length of between 15 aminoacids and 30 amino acids.
 6. The composition of claim 5, wherein thesecond linker polypeptide has a length of between 17 amino acids and 20amino acids.
 7. The composition of claim 1, wherein the length of thefirst linker polypeptide and the second linker polypeptide are the same.8. The composition of claim 1, wherein the interspacer distance of thePAM of the second nucleic acid target sequence and the PAM of the firstnucleic acid target sequence is between 22 base pairs to 40 base pairs.9. The composition of claim 8, wherein the interspacer distance of thePAM of the second nucleic acid target sequence and the PAM of the firstnucleic acid target sequence is between 26 base pairs to 36 base pairs.10. The composition of claim 9, wherein the interspacer distance of thePAM of the second nucleic acid target sequence and the PAM of the firstnucleic acid target sequence is between 30 base pairs to 34 base pairs.11. The composition of claim 1, wherein the first FokI and the secondFokI comprise monomeric subunits capable of associating to form ahomodimer.
 12. The composition of claim 1, wherein the first FokI andthe second FokI comprise distinct monomeric subunits capable ofassociating to form a heterodimer.
 13. The composition of claim 1,wherein the N-terminus of the first Cas8 subunit protein is covalentlyconnected by the first linker polypeptide to the C-terminus of the firstFokI.
 14. The composition of claim 1, wherein the C-terminus of thefirst Cas8 subunit protein is covalently connected by the first linkerpolypeptide to the N-terminus of the first FokI.
 15. The composition ofclaim 1, wherein the N-terminus of the second Cas8 subunit protein iscovalently connected by the second linker polypeptide to the C-terminusof the second FokI.
 16. The composition of claim 1, wherein theC-terminus of the second Cas8 subunit protein is covalently connected bythe second linker polypeptide to the N-terminus of the second FokI. 17.The composition of claim 1, wherein the first Cas5 subunit protein andthe second Cas5 subunit protein comprise identical amino acid sequences,the first Cas7 subunit protein and the second Cas7 subunit proteincomprise identical amino acid sequences, and the first Cas8 subunitprotein and the second Cas8 subunit protein comprise identical aminoacid sequences.
 18. The composition of claim 2, wherein the first Cas6subunit protein and the second Cas6 subunit protein comprise identicalamino acid sequences.
 19. The composition of claim 1, wherein the firstguide polynucleotide comprises RNA.
 20. The composition of claim 1,wherein the second guide polynucleotide comprises RNA.